Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_domain_or_region_B
locus xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
beta-globin xxx-xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_M
cluster xxx DNA_domain_or_region_E
depends xxx NE
upon xxx NE
upstream xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
sequences xxx DNA_domain_or_region_E
, , NE
which xxx NE
are xxx NE
collectively xxx NE
termed xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
provided xxx NE
new xxx NE
insights xxx NE
into xxx NE
how xxx NE
the xxx NE
individual xxx NE
genes xxx NE
of xx NE
the xxx NE
cluster xxx NE
are xxx NE
regulated xxx NE
through xxx NE
development xxx NE
. . NE

The Xxx NE
crux xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
is xx NE
how xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
communicates xxx NE
with xxx NE
the xxx NE
gene-proximal xxx-xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_domain_or_region_B
locus xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
beta-globin xxx-xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_M
cluster xxx DNA_domain_or_region_E
depends xxx NE
upon xxx NE
upstream xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
sequences xxx DNA_domain_or_region_E
, , NE
which xxx NE
are xxx NE
collectively xxx NE
termed xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
provided xxx NE
new xxx NE
insights xxx NE
into xxx NE
how xxx NE
the xxx NE
individual xxx NE
genes xxx NE
of xx NE
the xxx NE
cluster xxx NE
are xxx NE
regulated xxx NE
through xxx NE
development xxx NE
. . NE

The Xxx NE
crux xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
is xx NE
how xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
communicates xxx NE
with xxx NE
the xxx NE
gene-proximal xxx-xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
. . NE

Inhibition Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
by xx NE
dehydroepiandrosterone xxx NE
( ( NE
DHEA XXXX NE
) ) NE
and xxx NE
an xx NE
analog xxx NE
of xx NE
DHEA XXXX NE
. . NE

The Xxx NE
initial xxx NE
infection xxx NE
with xxx NE
human xxx Virus_B
immunodeficiency xxx Virus_M
virus xxx Virus_M
type xxx Virus_M
1 d Virus_E
( ( NE
HIV-1 XXX-d Virus
) ) NE
in xx NE
most xxx NE
individuals xxx NE
usually xxx NE
results xxx NE
in xx NE
the xxx NE
establishment xxx NE
of xx NE
a x NE
latent xxx NE
or xx NE
chronic xxx Other_B
infection xxx Other_E
before xxx NE
eventual xxx NE
progression xxx NE
toward xxx NE
acquired xxx Other_B
immunodeficiency xxx Other_M
syndrome xxx Other_E
. . NE

HIV-1 XXX-d Virus
can xxx NE
also xxx NE
establish xxx NE
a x NE
latent xxx NE
or xx NE
persistent xxx NE
infection xxx NE
in xx NE
some xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
that xxx NE
show xxx NE
minimal xxx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

However Xxxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
leading xxx NE
to xx NE
enhanced xxx NE
HIV-1 XXX-d Virus
replication xxx NE
can xxx NE
be xx NE
induced xxx NE
by xx NE
antigens xxx Protein_family_or_group
, , NE
mitogens xxx Other
, , NE
and xxx NE
cytokines xxx Protein_family_or_group
( ( NE
tumor xxx Protein_family_or_group_B
necrosis xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
alpha xxx Protein_family_or_group_E
[ [ NE
TNF-alpha XXX-xxx Protein_molecule
] ] NE
, , NE
interleukin xxx Protein_molecule_B
1 d Protein_molecule_E
, , NE
and xxx NE
interleukin-2 xxx-d Protein_molecule
) ) NE
. . NE

Various Xxxx NE
gene xxx NE
products xxx NE
from xxx NE
other xxx NE
viruses xxx NE
( ( NE
HTLV-1 XXXX-d Virus
, , NE
HSV XXX Virus
, , NE
EBV XXX Virus
, , NE
CMV XXX Virus
, , NE
HBV XXX Virus
, , NE
and xxx NE
HHV-6 XXX-d Virus
) ) NE
can xxx NE
also xxx NE
enhance xxx NE
HIV-1 XXX-d NE
long xxx NE
terminal xxx NE
repeat xxx NE
( ( NE
LTR XXX NE
)-driven )-xxx NE
reporter xxx NE
gene xxx NE
activity xxx NE
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
these xxx NE
observations xxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
proposed xxx NE
that xxx NE
reactivation xxx NE
of xx NE
latent xxx NE
HIV-1 XXX-d Virus
harbored xxx NE
in xx NE
chronically xxx Cell_natural_B
infected xxx Cell_natural_M
T X Cell_natural_M
lymphocytes xxx Cell_natural_E
, , NE
monocytes xxx Cell_natural
, , NE
or xx NE
macrophages xxx Cell_natural
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
AIDS XXXX Other
. . NE

So Xx NE
far xxx NE
, , NE
there xxx NE
are xxx NE
no xx NE
drugs xxx NE
or xx NE
therapy xxx NE
available xxx NE
that xxx NE
can xxx NE
provide xxx NE
protection xxx NE
against xxx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
, , NE
derived xxx NE
from xxx NE
a x NE
human xxx Cell_cultured_B
T X Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
( ( NE
CEM XXX Cell_cultured
) ) NE
, , NE
is xx NE
chronically xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
, , NE
with xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
can xxx NE
be xx NE
converted xxx NE
to xx NE
productive xxx NE
infection xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx Organic_compound_other
( ( NE
TPA XXX Organic_compound_other
) ) NE
, , NE
mitogen xxx Organic_compound_other
or xx NE
cytokines xxx Protein_family_or_group
( ( NE
TNF-alpha XXX-xxx Protein_molecule
) ) NE
, , NE
or xx NE
infection xxx NE
with xxx NE
HSV XXX Virus
. . NE

Therefore Xxxx NE
the xxx NE
ACH-2 XXX-d Cell_cultured
cell xxx NE
line xxx NE
is xx NE
a x NE
good xxx NE
candidate xxx NE
for xxx NE
studying xxx NE
the xxx NE
effects xxx NE
of xx NE
drugs xxx NE
on xx NE
HIV-1 XXX-d Virus
activation xxx NE
. . NE

Previously Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
DHEA XXXX Lipid
and xxx NE
synthetic xxx NE
analogs xxx NE
of xx NE
DHEA XXXX NE
can xxx NE
be xx NE
modest xxx NE
inhibitors xxx NE
of xx NE
HIV-1 XXX-d Other_B
IIIB XXXX Other_M
replication xxx Other_E
in xx NE
phytohemagglutinin xxx NE
-stimulated -xxx NE
peripheral xxx NE
blood xxx NE
lymphocyte xxx NE
cultures xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_domain_or_region_B
locus xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
beta-globin xxx-xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_M
cluster xxx DNA_domain_or_region_E
depends xxx NE
upon xxx NE
upstream xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
sequences xxx DNA_domain_or_region_E
, , NE
which xxx NE
are xxx NE
collectively xxx NE
termed xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
provided xxx NE
new xxx NE
insights xxx NE
into xxx NE
how xxx NE
the xxx NE
individual xxx NE
genes xxx NE
of xx NE
the xxx NE
cluster xxx NE
are xxx NE
regulated xxx NE
through xxx NE
development xxx NE
. . NE

The Xxx NE
crux xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
is xx NE
how xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
communicates xxx NE
with xxx NE
the xxx NE
gene-proximal xxx-xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
. . NE

Inhibition Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
by xx NE
dehydroepiandrosterone xxx NE
( ( NE
DHEA XXXX NE
) ) NE
and xxx NE
an xx NE
analog xxx NE
of xx NE
DHEA XXXX NE
. . NE

The Xxx NE
initial xxx NE
infection xxx NE
with xxx NE
human xxx Virus_B
immunodeficiency xxx Virus_M
virus xxx Virus_M
type xxx Virus_M
1 d Virus_E
( ( NE
HIV-1 XXX-d Virus
) ) NE
in xx NE
most xxx NE
individuals xxx NE
usually xxx NE
results xxx NE
in xx NE
the xxx NE
establishment xxx NE
of xx NE
a x NE
latent xxx NE
or xx NE
chronic xxx Other_B
infection xxx Other_E
before xxx NE
eventual xxx NE
progression xxx NE
toward xxx NE
acquired xxx Other_B
immunodeficiency xxx Other_M
syndrome xxx Other_E
. . NE

HIV-1 XXX-d Virus
can xxx NE
also xxx NE
establish xxx NE
a x NE
latent xxx NE
or xx NE
persistent xxx NE
infection xxx NE
in xx NE
some xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
that xxx NE
show xxx NE
minimal xxx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

However Xxxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
leading xxx NE
to xx NE
enhanced xxx NE
HIV-1 XXX-d Virus
replication xxx NE
can xxx NE
be xx NE
induced xxx NE
by xx NE
antigens xxx Protein_family_or_group
, , NE
mitogens xxx Other
, , NE
and xxx NE
cytokines xxx Protein_family_or_group
( ( NE
tumor xxx Protein_family_or_group_B
necrosis xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
alpha xxx Protein_family_or_group_E
[ [ NE
TNF-alpha XXX-xxx Protein_molecule
] ] NE
, , NE
interleukin xxx Protein_molecule_B
1 d Protein_molecule_E
, , NE
and xxx NE
interleukin-2 xxx-d Protein_molecule
) ) NE
. . NE

Various Xxxx NE
gene xxx NE
products xxx NE
from xxx NE
other xxx NE
viruses xxx NE
( ( NE
HTLV-1 XXXX-d Virus
, , NE
HSV XXX Virus
, , NE
EBV XXX Virus
, , NE
CMV XXX Virus
, , NE
HBV XXX Virus
, , NE
and xxx NE
HHV-6 XXX-d Virus
) ) NE
can xxx NE
also xxx NE
enhance xxx NE
HIV-1 XXX-d NE
long xxx NE
terminal xxx NE
repeat xxx NE
( ( NE
LTR XXX NE
)-driven )-xxx NE
reporter xxx NE
gene xxx NE
activity xxx NE
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
these xxx NE
observations xxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
proposed xxx NE
that xxx NE
reactivation xxx NE
of xx NE
latent xxx NE
HIV-1 XXX-d Virus
harbored xxx NE
in xx NE
chronically xxx Cell_natural_B
infected xxx Cell_natural_M
T X Cell_natural_M
lymphocytes xxx Cell_natural_E
, , NE
monocytes xxx Cell_natural
, , NE
or xx NE
macrophages xxx Cell_natural
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
AIDS XXXX Other
. . NE

So Xx NE
far xxx NE
, , NE
there xxx NE
are xxx NE
no xx NE
drugs xxx NE
or xx NE
therapy xxx NE
available xxx NE
that xxx NE
can xxx NE
provide xxx NE
protection xxx NE
against xxx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
, , NE
derived xxx NE
from xxx NE
a x NE
human xxx Cell_cultured_B
T X Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
( ( NE
CEM XXX Cell_cultured
) ) NE
, , NE
is xx NE
chronically xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
, , NE
with xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
can xxx NE
be xx NE
converted xxx NE
to xx NE
productive xxx NE
infection xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx Organic_compound_other
( ( NE
TPA XXX Organic_compound_other
) ) NE
, , NE
mitogen xxx Organic_compound_other
or xx NE
cytokines xxx Protein_family_or_group
( ( NE
TNF-alpha XXX-xxx Protein_molecule
) ) NE
, , NE
or xx NE
infection xxx NE
with xxx NE
HSV XXX Virus
. . NE

Therefore Xxxx NE
the xxx NE
ACH-2 XXX-d Cell_cultured
cell xxx NE
line xxx NE
is xx NE
a x NE
good xxx NE
candidate xxx NE
for xxx NE
studying xxx NE
the xxx NE
effects xxx NE
of xx NE
drugs xxx NE
on xx NE
HIV-1 XXX-d Virus
activation xxx NE
. . NE

Previously Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
DHEA XXXX Lipid
and xxx NE
synthetic xxx NE
analogs xxx NE
of xx NE
DHEA XXXX NE
can xxx NE
be xx NE
modest xxx NE
inhibitors xxx NE
of xx NE
HIV-1 XXX-d Other_B
IIIB XXXX Other_M
replication xxx Other_E
in xx NE
phytohemagglutinin xxx NE
-stimulated -xxx NE
peripheral xxx NE
blood xxx NE
lymphocyte xxx NE
cultures xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

C/EBP X/XXX Protein_family_or_group_B
activators xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
and xxx NE
proviral xxx NE
induction xxx NE
in xx NE
monocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

Previous Xxxx NE
work xxx NE
has xxx NE
shown xxx NE
that xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
and xxx NE
C/EBP X/XXX Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
activators xxx Protein_family_or_group_E
are xxx NE
necessary xxx NE
for xxx NE
HIV-1 XXX-d Other_B
LTR XXX Other_M
activity xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
role xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
play xxx NE
in xx NE
induction xxx NE
and xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d Virus
. . NE

Ectopic Xxxx NE
expression xxx NE
of xx NE
the xxx NE
dominant xxx NE
negative xxx NE
C/EBP X/XXX NE
protein xxx NE
LIP XXX NE
inhibited xxx NE
HIV-1 XXX-d NE
mRNA xXXX NE
and xxx NE
virus xxx NE
production xxx NE
in xx NE
activated xxx NE
U1 Xd NE
cells xxx NE
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX NE
proteins xxx NE
are xxx NE
required xxx NE
for xxx NE
provirus xxx NE
induction xxx NE
. . NE

U1 Xd Cell_cultured_B
lines xxx Cell_cultured_E
overexpressing xxx NE
C/EBP X/XXX Protein_family_or_group_B
activator xxx Protein_family_or_group_E
NF-IL-6 XX-XX-d Protein_molecule
produced xxx NE
more xxx NE
viral xxx RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
and xxx NE
virus xxx Virus_B
particles xxx Virus_E
following xxx NE
cellular xxx Other_B
activation xxx Other_E
than xxx NE
control xxx Cell_cultured_B
lines xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
are xxx NE
limiting xxx NE
for xxx NE
virus xxx Other_B
transcription xxx Other_E
. . NE

HIV-1 XXX-d Virus
harboring xxx NE
mutations xxx NE
within xxx NE
two xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
were xxx NE
crippled xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
replicate xxx NE
in xx NE
U937 Xddd Cell_cultured_B
promonocytic xxx Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
indicating xxx NE
that xxx NE
these xxx NE
sites xxx NE
are xxx NE
required xxx NE
for xxx NE
replication xxx NE
. . NE

These Xxxx NE
data xxx NE
identify xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
as xx NE
regulators xxx NE
of xx NE
HIV-1 XXX-d Other_B
expression xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_domain_or_region_B
locus xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
beta-globin xxx-xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_M
cluster xxx DNA_domain_or_region_E
depends xxx NE
upon xxx NE
upstream xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
sequences xxx DNA_domain_or_region_E
, , NE
which xxx NE
are xxx NE
collectively xxx NE
termed xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
provided xxx NE
new xxx NE
insights xxx NE
into xxx NE
how xxx NE
the xxx NE
individual xxx NE
genes xxx NE
of xx NE
the xxx NE
cluster xxx NE
are xxx NE
regulated xxx NE
through xxx NE
development xxx NE
. . NE

The Xxx NE
crux xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
is xx NE
how xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
communicates xxx NE
with xxx NE
the xxx NE
gene-proximal xxx-xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
. . NE

Inhibition Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
by xx NE
dehydroepiandrosterone xxx NE
( ( NE
DHEA XXXX NE
) ) NE
and xxx NE
an xx NE
analog xxx NE
of xx NE
DHEA XXXX NE
. . NE

The Xxx NE
initial xxx NE
infection xxx NE
with xxx NE
human xxx Virus_B
immunodeficiency xxx Virus_M
virus xxx Virus_M
type xxx Virus_M
1 d Virus_E
( ( NE
HIV-1 XXX-d Virus
) ) NE
in xx NE
most xxx NE
individuals xxx NE
usually xxx NE
results xxx NE
in xx NE
the xxx NE
establishment xxx NE
of xx NE
a x NE
latent xxx NE
or xx NE
chronic xxx Other_B
infection xxx Other_E
before xxx NE
eventual xxx NE
progression xxx NE
toward xxx NE
acquired xxx Other_B
immunodeficiency xxx Other_M
syndrome xxx Other_E
. . NE

HIV-1 XXX-d Virus
can xxx NE
also xxx NE
establish xxx NE
a x NE
latent xxx NE
or xx NE
persistent xxx NE
infection xxx NE
in xx NE
some xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
that xxx NE
show xxx NE
minimal xxx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

However Xxxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
leading xxx NE
to xx NE
enhanced xxx NE
HIV-1 XXX-d Virus
replication xxx NE
can xxx NE
be xx NE
induced xxx NE
by xx NE
antigens xxx Protein_family_or_group
, , NE
mitogens xxx Other
, , NE
and xxx NE
cytokines xxx Protein_family_or_group
( ( NE
tumor xxx Protein_family_or_group_B
necrosis xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
alpha xxx Protein_family_or_group_E
[ [ NE
TNF-alpha XXX-xxx Protein_molecule
] ] NE
, , NE
interleukin xxx Protein_molecule_B
1 d Protein_molecule_E
, , NE
and xxx NE
interleukin-2 xxx-d Protein_molecule
) ) NE
. . NE

Various Xxxx NE
gene xxx NE
products xxx NE
from xxx NE
other xxx NE
viruses xxx NE
( ( NE
HTLV-1 XXXX-d Virus
, , NE
HSV XXX Virus
, , NE
EBV XXX Virus
, , NE
CMV XXX Virus
, , NE
HBV XXX Virus
, , NE
and xxx NE
HHV-6 XXX-d Virus
) ) NE
can xxx NE
also xxx NE
enhance xxx NE
HIV-1 XXX-d NE
long xxx NE
terminal xxx NE
repeat xxx NE
( ( NE
LTR XXX NE
)-driven )-xxx NE
reporter xxx NE
gene xxx NE
activity xxx NE
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
these xxx NE
observations xxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
proposed xxx NE
that xxx NE
reactivation xxx NE
of xx NE
latent xxx NE
HIV-1 XXX-d Virus
harbored xxx NE
in xx NE
chronically xxx Cell_natural_B
infected xxx Cell_natural_M
T X Cell_natural_M
lymphocytes xxx Cell_natural_E
, , NE
monocytes xxx Cell_natural
, , NE
or xx NE
macrophages xxx Cell_natural
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
AIDS XXXX Other
. . NE

So Xx NE
far xxx NE
, , NE
there xxx NE
are xxx NE
no xx NE
drugs xxx NE
or xx NE
therapy xxx NE
available xxx NE
that xxx NE
can xxx NE
provide xxx NE
protection xxx NE
against xxx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
, , NE
derived xxx NE
from xxx NE
a x NE
human xxx Cell_cultured_B
T X Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
( ( NE
CEM XXX Cell_cultured
) ) NE
, , NE
is xx NE
chronically xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
, , NE
with xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
can xxx NE
be xx NE
converted xxx NE
to xx NE
productive xxx NE
infection xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx Organic_compound_other
( ( NE
TPA XXX Organic_compound_other
) ) NE
, , NE
mitogen xxx Organic_compound_other
or xx NE
cytokines xxx Protein_family_or_group
( ( NE
TNF-alpha XXX-xxx Protein_molecule
) ) NE
, , NE
or xx NE
infection xxx NE
with xxx NE
HSV XXX Virus
. . NE

Therefore Xxxx NE
the xxx NE
ACH-2 XXX-d Cell_cultured
cell xxx NE
line xxx NE
is xx NE
a x NE
good xxx NE
candidate xxx NE
for xxx NE
studying xxx NE
the xxx NE
effects xxx NE
of xx NE
drugs xxx NE
on xx NE
HIV-1 XXX-d Virus
activation xxx NE
. . NE

Previously Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
DHEA XXXX Lipid
and xxx NE
synthetic xxx NE
analogs xxx NE
of xx NE
DHEA XXXX NE
can xxx NE
be xx NE
modest xxx NE
inhibitors xxx NE
of xx NE
HIV-1 XXX-d Other_B
IIIB XXXX Other_M
replication xxx Other_E
in xx NE
phytohemagglutinin xxx NE
-stimulated -xxx NE
peripheral xxx NE
blood xxx NE
lymphocyte xxx NE
cultures xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

C/EBP X/XXX Protein_family_or_group_B
activators xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
and xxx NE
proviral xxx NE
induction xxx NE
in xx NE
monocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

Previous Xxxx NE
work xxx NE
has xxx NE
shown xxx NE
that xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
and xxx NE
C/EBP X/XXX Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
activators xxx Protein_family_or_group_E
are xxx NE
necessary xxx NE
for xxx NE
HIV-1 XXX-d Other_B
LTR XXX Other_M
activity xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
role xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
play xxx NE
in xx NE
induction xxx NE
and xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d Virus
. . NE

Ectopic Xxxx NE
expression xxx NE
of xx NE
the xxx NE
dominant xxx NE
negative xxx NE
C/EBP X/XXX NE
protein xxx NE
LIP XXX NE
inhibited xxx NE
HIV-1 XXX-d NE
mRNA xXXX NE
and xxx NE
virus xxx NE
production xxx NE
in xx NE
activated xxx NE
U1 Xd NE
cells xxx NE
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX NE
proteins xxx NE
are xxx NE
required xxx NE
for xxx NE
provirus xxx NE
induction xxx NE
. . NE

U1 Xd Cell_cultured_B
lines xxx Cell_cultured_E
overexpressing xxx NE
C/EBP X/XXX Protein_family_or_group_B
activator xxx Protein_family_or_group_E
NF-IL-6 XX-XX-d Protein_molecule
produced xxx NE
more xxx NE
viral xxx RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
and xxx NE
virus xxx Virus_B
particles xxx Virus_E
following xxx NE
cellular xxx Other_B
activation xxx Other_E
than xxx NE
control xxx Cell_cultured_B
lines xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
are xxx NE
limiting xxx NE
for xxx NE
virus xxx Other_B
transcription xxx Other_E
. . NE

HIV-1 XXX-d Virus
harboring xxx NE
mutations xxx NE
within xxx NE
two xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
were xxx NE
crippled xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
replicate xxx NE
in xx NE
U937 Xddd Cell_cultured_B
promonocytic xxx Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
indicating xxx NE
that xxx NE
these xxx NE
sites xxx NE
are xxx NE
required xxx NE
for xxx NE
replication xxx NE
. . NE

These Xxxx NE
data xxx NE
identify xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
as xx NE
regulators xxx NE
of xx NE
HIV-1 XXX-d Other_B
expression xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibits xxx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
in xx NE
CD3 XXd NE
-stimulated -xxx NE
human xxx NE
peripheral xxx NE
T X NE
lymphocytes xxx NE
. . NE

IL-10 XX-dd Protein_molecule
markedly xxx NE
reduces xxx NE
nuclear xxx NE
factor xxx NE
(NF)-kappa (XX)-xxx Other_B
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
induced xxx NE
in xx NE
PBMC XXXX NE
by xx NE
stimulation xxx NE
with xxx NE
the xxx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
OKT3 XXXd NE
. . NE

The Xxx NE
inhibition xxx NE
is xx NE
exerted xxx NE
specifically xxx NE
on xx NE
the xxx NE
NF-kappa XX-xxx Other_B
B/Rel X/Xxx Other_M
activation xxx Other_E
induced xxx NE
by xx NE
mAb xXx NE
OKT3 XXXd NE
, , NE
and xxx NE
not xxx NE
that xxx NE
produced xxx NE
by xx NE
PMA XXX NE
. . NE

As Xx NE
judged xxx NE
by xx NE
supershifting xxx NE
the xxx NE
DNA-protein XXX-xxx NE
complexes xxx NE
with xxx NE
Abs Xxx NE
recognizing xxx NE
specific xxx NE
components xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B/Rel X/Xxx NE
protein xxx NE
family xxx NE
, , NE
the xxx NE
p50/p65 xdd/xdd NE
( ( NE
Rel Xxx NE
A X NE
) ) NE
heterodimeric xxx NE
form xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
primarily xxx NE
affected xxx NE
. . NE

The Xxx NE
maximal xxx NE
effect xxx NE
is xx NE
observed xxx NE
at xx NE
the xxx NE
IL-10 XX-dd Other_B
concentration xxx Other_E
of xx NE
20 dd NE
U/ml X/xx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibitory xxx NE
activity xxx NE
is xx NE
exerted xxx NE
on xx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
and xxx NE
is xx NE
mediated xxx NE
by xx NE
monocytes xxx Cell_natural
. . NE

Indeed Xxxx NE
, , NE
monocytes xxx Cell_natural
pretreated xxx NE
with xxx NE
IL-10 XX-dd Protein_molecule
are xxx NE
able xxx NE
so xx NE
inhibit xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
purified xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
stimulated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
. . NE

Soluble Xxxx NE
factors xxx NE
do xx NE
not xxx NE
appear xxx NE
to xx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
mechanism xxx NE
of xx NE
inhibition xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
the xxx NE
up-regulation xx-xxx NE
of xx NE
CD80 XXdd Protein_molecule_B
Ag Xx Protein_molecule_E
, , NE
found xxx NE
on xx NE
monocytes xxx Cell_natural
obtained xxx NE
from xxx NE
PBMC XXXX Cell_natural
incubated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
, , NE
is xx NE
not xxx NE
detected xxx NE
after xxx NE
addition xxx NE
of xx NE
IL-10 XX-dd Protein_molecule
, , NE
and xxx NE
the xxx NE
anti-CD28 xxx-XXdd Protein_family_or_group_B
mAb xXx Protein_family_or_group_E
CLB-CD28/1 XXX-XXdd/d Protein_molecule
restores xxx NE
the xxx NE
NF-kappa XX-xxx Element_B
B/Rel X/Xxx Element_M
nuclear xxx Element_M
activity xxx Element_E
in xx NE
IL-10 XX-dd NE
-inhibited -xxx NE
lymphocytes xxx NE
. . NE

Therefore Xxxx NE
, , NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
inhibition xxx NE
might xxx NE
be xx NE
ascribed xxx NE
to xx NE
a x NE
lack xxx NE
of xx NE
cooperation xxx NE
between xxx NE
accessory xxx NE
cells xxx NE
and xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
, , NE
resulting xxx NE
from xxx NE
down-regulation xxx-xxx NE
of xx NE
a x NE
costimulatory xxx NE
molecule xxx NE
, , NE
such xxx NE
as xx NE
CD80 XXdd Protein_molecule
, , NE
produced xxx NE
by xx NE
IL-10 XX-dd Protein_molecule
on xx NE
activated xxx NE
monocytes xxx Cell_natural
. . NE

Our Xxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
IL-10 XX-dd Protein_molecule
can xxx NE
inhibit xxx NE
the xxx NE
induction xxx NE
of xx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
CD3 XXd NE
-stimulated -xxx NE
T X NE
lymphocytes xxx NE
. . NE

Since Xxxx NE
inappropriate xxx NE
activation xxx NE
of xx NE
kappa xxx DNA_family_or_group_B
B-driven X-xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
has xxx NE
a x NE
physiopathologic xxx NE
role xxx NE
in xx NE
a x NE
number xxx NE
of xx NE
diseases xxx NE
, , NE
such xxx NE
as xx NE
HIV XXX Other_B
infection xxx Other_E
, , NE
our xxx NE
findings xxx NE
support xxx NE
the xxx NE
possibility xxx NE
of xx NE
using xxx NE
this xxx NE
cytokine xxx NE
to xx NE
suppress xxx NE
an xx NE
undesirable xxx NE
activation xxx NE
of xx NE
these xxx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_domain_or_region_B
locus xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
beta-globin xxx-xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_M
cluster xxx DNA_domain_or_region_E
depends xxx NE
upon xxx NE
upstream xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
sequences xxx DNA_domain_or_region_E
, , NE
which xxx NE
are xxx NE
collectively xxx NE
termed xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
provided xxx NE
new xxx NE
insights xxx NE
into xxx NE
how xxx NE
the xxx NE
individual xxx NE
genes xxx NE
of xx NE
the xxx NE
cluster xxx NE
are xxx NE
regulated xxx NE
through xxx NE
development xxx NE
. . NE

The Xxx NE
crux xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
is xx NE
how xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
communicates xxx NE
with xxx NE
the xxx NE
gene-proximal xxx-xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
. . NE

Inhibition Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
by xx NE
dehydroepiandrosterone xxx NE
( ( NE
DHEA XXXX NE
) ) NE
and xxx NE
an xx NE
analog xxx NE
of xx NE
DHEA XXXX NE
. . NE

The Xxx NE
initial xxx NE
infection xxx NE
with xxx NE
human xxx Virus_B
immunodeficiency xxx Virus_M
virus xxx Virus_M
type xxx Virus_M
1 d Virus_E
( ( NE
HIV-1 XXX-d Virus
) ) NE
in xx NE
most xxx NE
individuals xxx NE
usually xxx NE
results xxx NE
in xx NE
the xxx NE
establishment xxx NE
of xx NE
a x NE
latent xxx NE
or xx NE
chronic xxx Other_B
infection xxx Other_E
before xxx NE
eventual xxx NE
progression xxx NE
toward xxx NE
acquired xxx Other_B
immunodeficiency xxx Other_M
syndrome xxx Other_E
. . NE

HIV-1 XXX-d Virus
can xxx NE
also xxx NE
establish xxx NE
a x NE
latent xxx NE
or xx NE
persistent xxx NE
infection xxx NE
in xx NE
some xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
that xxx NE
show xxx NE
minimal xxx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

However Xxxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
leading xxx NE
to xx NE
enhanced xxx NE
HIV-1 XXX-d Virus
replication xxx NE
can xxx NE
be xx NE
induced xxx NE
by xx NE
antigens xxx Protein_family_or_group
, , NE
mitogens xxx Other
, , NE
and xxx NE
cytokines xxx Protein_family_or_group
( ( NE
tumor xxx Protein_family_or_group_B
necrosis xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
alpha xxx Protein_family_or_group_E
[ [ NE
TNF-alpha XXX-xxx Protein_molecule
] ] NE
, , NE
interleukin xxx Protein_molecule_B
1 d Protein_molecule_E
, , NE
and xxx NE
interleukin-2 xxx-d Protein_molecule
) ) NE
. . NE

Various Xxxx NE
gene xxx NE
products xxx NE
from xxx NE
other xxx NE
viruses xxx NE
( ( NE
HTLV-1 XXXX-d Virus
, , NE
HSV XXX Virus
, , NE
EBV XXX Virus
, , NE
CMV XXX Virus
, , NE
HBV XXX Virus
, , NE
and xxx NE
HHV-6 XXX-d Virus
) ) NE
can xxx NE
also xxx NE
enhance xxx NE
HIV-1 XXX-d NE
long xxx NE
terminal xxx NE
repeat xxx NE
( ( NE
LTR XXX NE
)-driven )-xxx NE
reporter xxx NE
gene xxx NE
activity xxx NE
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
these xxx NE
observations xxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
proposed xxx NE
that xxx NE
reactivation xxx NE
of xx NE
latent xxx NE
HIV-1 XXX-d Virus
harbored xxx NE
in xx NE
chronically xxx Cell_natural_B
infected xxx Cell_natural_M
T X Cell_natural_M
lymphocytes xxx Cell_natural_E
, , NE
monocytes xxx Cell_natural
, , NE
or xx NE
macrophages xxx Cell_natural
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
AIDS XXXX Other
. . NE

So Xx NE
far xxx NE
, , NE
there xxx NE
are xxx NE
no xx NE
drugs xxx NE
or xx NE
therapy xxx NE
available xxx NE
that xxx NE
can xxx NE
provide xxx NE
protection xxx NE
against xxx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
, , NE
derived xxx NE
from xxx NE
a x NE
human xxx Cell_cultured_B
T X Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
( ( NE
CEM XXX Cell_cultured
) ) NE
, , NE
is xx NE
chronically xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
, , NE
with xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
can xxx NE
be xx NE
converted xxx NE
to xx NE
productive xxx NE
infection xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx Organic_compound_other
( ( NE
TPA XXX Organic_compound_other
) ) NE
, , NE
mitogen xxx Organic_compound_other
or xx NE
cytokines xxx Protein_family_or_group
( ( NE
TNF-alpha XXX-xxx Protein_molecule
) ) NE
, , NE
or xx NE
infection xxx NE
with xxx NE
HSV XXX Virus
. . NE

Therefore Xxxx NE
the xxx NE
ACH-2 XXX-d Cell_cultured
cell xxx NE
line xxx NE
is xx NE
a x NE
good xxx NE
candidate xxx NE
for xxx NE
studying xxx NE
the xxx NE
effects xxx NE
of xx NE
drugs xxx NE
on xx NE
HIV-1 XXX-d Virus
activation xxx NE
. . NE

Previously Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
DHEA XXXX Lipid
and xxx NE
synthetic xxx NE
analogs xxx NE
of xx NE
DHEA XXXX NE
can xxx NE
be xx NE
modest xxx NE
inhibitors xxx NE
of xx NE
HIV-1 XXX-d Other_B
IIIB XXXX Other_M
replication xxx Other_E
in xx NE
phytohemagglutinin xxx NE
-stimulated -xxx NE
peripheral xxx NE
blood xxx NE
lymphocyte xxx NE
cultures xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

C/EBP X/XXX Protein_family_or_group_B
activators xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
and xxx NE
proviral xxx NE
induction xxx NE
in xx NE
monocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

Previous Xxxx NE
work xxx NE
has xxx NE
shown xxx NE
that xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
and xxx NE
C/EBP X/XXX Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
activators xxx Protein_family_or_group_E
are xxx NE
necessary xxx NE
for xxx NE
HIV-1 XXX-d Other_B
LTR XXX Other_M
activity xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
role xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
play xxx NE
in xx NE
induction xxx NE
and xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d Virus
. . NE

Ectopic Xxxx NE
expression xxx NE
of xx NE
the xxx NE
dominant xxx NE
negative xxx NE
C/EBP X/XXX NE
protein xxx NE
LIP XXX NE
inhibited xxx NE
HIV-1 XXX-d NE
mRNA xXXX NE
and xxx NE
virus xxx NE
production xxx NE
in xx NE
activated xxx NE
U1 Xd NE
cells xxx NE
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX NE
proteins xxx NE
are xxx NE
required xxx NE
for xxx NE
provirus xxx NE
induction xxx NE
. . NE

U1 Xd Cell_cultured_B
lines xxx Cell_cultured_E
overexpressing xxx NE
C/EBP X/XXX Protein_family_or_group_B
activator xxx Protein_family_or_group_E
NF-IL-6 XX-XX-d Protein_molecule
produced xxx NE
more xxx NE
viral xxx RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
and xxx NE
virus xxx Virus_B
particles xxx Virus_E
following xxx NE
cellular xxx Other_B
activation xxx Other_E
than xxx NE
control xxx Cell_cultured_B
lines xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
are xxx NE
limiting xxx NE
for xxx NE
virus xxx Other_B
transcription xxx Other_E
. . NE

HIV-1 XXX-d Virus
harboring xxx NE
mutations xxx NE
within xxx NE
two xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
were xxx NE
crippled xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
replicate xxx NE
in xx NE
U937 Xddd Cell_cultured_B
promonocytic xxx Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
indicating xxx NE
that xxx NE
these xxx NE
sites xxx NE
are xxx NE
required xxx NE
for xxx NE
replication xxx NE
. . NE

These Xxxx NE
data xxx NE
identify xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
as xx NE
regulators xxx NE
of xx NE
HIV-1 XXX-d Other_B
expression xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibits xxx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
in xx NE
CD3 XXd NE
-stimulated -xxx NE
human xxx NE
peripheral xxx NE
T X NE
lymphocytes xxx NE
. . NE

IL-10 XX-dd Protein_molecule
markedly xxx NE
reduces xxx NE
nuclear xxx NE
factor xxx NE
(NF)-kappa (XX)-xxx Other_B
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
induced xxx NE
in xx NE
PBMC XXXX NE
by xx NE
stimulation xxx NE
with xxx NE
the xxx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
OKT3 XXXd NE
. . NE

The Xxx NE
inhibition xxx NE
is xx NE
exerted xxx NE
specifically xxx NE
on xx NE
the xxx NE
NF-kappa XX-xxx Other_B
B/Rel X/Xxx Other_M
activation xxx Other_E
induced xxx NE
by xx NE
mAb xXx NE
OKT3 XXXd NE
, , NE
and xxx NE
not xxx NE
that xxx NE
produced xxx NE
by xx NE
PMA XXX NE
. . NE

As Xx NE
judged xxx NE
by xx NE
supershifting xxx NE
the xxx NE
DNA-protein XXX-xxx NE
complexes xxx NE
with xxx NE
Abs Xxx NE
recognizing xxx NE
specific xxx NE
components xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B/Rel X/Xxx NE
protein xxx NE
family xxx NE
, , NE
the xxx NE
p50/p65 xdd/xdd NE
( ( NE
Rel Xxx NE
A X NE
) ) NE
heterodimeric xxx NE
form xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
primarily xxx NE
affected xxx NE
. . NE

The Xxx NE
maximal xxx NE
effect xxx NE
is xx NE
observed xxx NE
at xx NE
the xxx NE
IL-10 XX-dd Other_B
concentration xxx Other_E
of xx NE
20 dd NE
U/ml X/xx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibitory xxx NE
activity xxx NE
is xx NE
exerted xxx NE
on xx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
and xxx NE
is xx NE
mediated xxx NE
by xx NE
monocytes xxx Cell_natural
. . NE

Indeed Xxxx NE
, , NE
monocytes xxx Cell_natural
pretreated xxx NE
with xxx NE
IL-10 XX-dd Protein_molecule
are xxx NE
able xxx NE
so xx NE
inhibit xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
purified xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
stimulated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
. . NE

Soluble Xxxx NE
factors xxx NE
do xx NE
not xxx NE
appear xxx NE
to xx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
mechanism xxx NE
of xx NE
inhibition xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
the xxx NE
up-regulation xx-xxx NE
of xx NE
CD80 XXdd Protein_molecule_B
Ag Xx Protein_molecule_E
, , NE
found xxx NE
on xx NE
monocytes xxx Cell_natural
obtained xxx NE
from xxx NE
PBMC XXXX Cell_natural
incubated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
, , NE
is xx NE
not xxx NE
detected xxx NE
after xxx NE
addition xxx NE
of xx NE
IL-10 XX-dd Protein_molecule
, , NE
and xxx NE
the xxx NE
anti-CD28 xxx-XXdd Protein_family_or_group_B
mAb xXx Protein_family_or_group_E
CLB-CD28/1 XXX-XXdd/d Protein_molecule
restores xxx NE
the xxx NE
NF-kappa XX-xxx Element_B
B/Rel X/Xxx Element_M
nuclear xxx Element_M
activity xxx Element_E
in xx NE
IL-10 XX-dd NE
-inhibited -xxx NE
lymphocytes xxx NE
. . NE

Therefore Xxxx NE
, , NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
inhibition xxx NE
might xxx NE
be xx NE
ascribed xxx NE
to xx NE
a x NE
lack xxx NE
of xx NE
cooperation xxx NE
between xxx NE
accessory xxx NE
cells xxx NE
and xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
, , NE
resulting xxx NE
from xxx NE
down-regulation xxx-xxx NE
of xx NE
a x NE
costimulatory xxx NE
molecule xxx NE
, , NE
such xxx NE
as xx NE
CD80 XXdd Protein_molecule
, , NE
produced xxx NE
by xx NE
IL-10 XX-dd Protein_molecule
on xx NE
activated xxx NE
monocytes xxx Cell_natural
. . NE

Our Xxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
IL-10 XX-dd Protein_molecule
can xxx NE
inhibit xxx NE
the xxx NE
induction xxx NE
of xx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
CD3 XXd NE
-stimulated -xxx NE
T X NE
lymphocytes xxx NE
. . NE

Since Xxxx NE
inappropriate xxx NE
activation xxx NE
of xx NE
kappa xxx DNA_family_or_group_B
B-driven X-xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
has xxx NE
a x NE
physiopathologic xxx NE
role xxx NE
in xx NE
a x NE
number xxx NE
of xx NE
diseases xxx NE
, , NE
such xxx NE
as xx NE
HIV XXX Other_B
infection xxx Other_E
, , NE
our xxx NE
findings xxx NE
support xxx NE
the xxx NE
possibility xxx NE
of xx NE
using xxx NE
this xxx NE
cytokine xxx NE
to xx NE
suppress xxx NE
an xx NE
undesirable xxx NE
activation xxx NE
of xx NE
these xxx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
. . NE

Multiple Xxxx NE
prolactin xxx NE
-responsive -xxx NE
elements xxx NE
mediate xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
expression xxx NE
of xx NE
the xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
gene xxx NE
. . NE

The Xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
( ( NE
IRF-1 XXX-d NE
) ) NE
gene xxx NE
is xx NE
both xxx NE
an xx NE
immediate-early xxx-xxx NE
G1 Xd NE
phase xxx NE
gene xxx NE
and xxx NE
an xx NE
S X NE
phase xxx NE
gene xxx NE
inducible xxx NE
by xx NE
PRL XXX NE
in xx NE
rat xxx NE
Nb2 Xxd NE
T X NE
lymphocytes xxx NE
. . NE

To Xx NE
understand xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
PRL XXX Protein_molecule
regulates xxx NE
the xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
IRF-1 XXX-d Protein_molecule
, , NE
we xx NE
cloned xxx NE
the xxx NE
rat xxx DNA_domain_or_region_B
IRF-1 XXX-d DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
and xxx NE
functionally xxx NE
characterized xxx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
. . NE

Upon Xxxx NE
transfection xxx NE
into xxx NE
Nb2 Xxd Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
1.7 d.d NE
kilobases xxx NE
(kb) (xx) NE
of xx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
DNA XXX NE
linked xxx NE
to xx NE
a x NE
chloramphenicol xxx NE
acetyl xxx NE
transferase xxx NE
( ( NE
CAT XXX NE
) ) NE
reporter xxx NE
gene xxx NE
mediated xxx NE
a x NE
30-fold dd-xxx NE
induction xxx NE
of xx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
in xx NE
response xxx NE
to xx NE
24 dd NE
h x NE
of xx NE
PRL XXX NE
stimulation xxx NE
. . NE

Deletion Xxxx NE
mutants xxx NE
containing xxx NE
1.3 d.d NE
, , NE
0.6 d.d NE
, , NE
and xxx NE
0.2 d.d NE
kb xx NE
5'-flanking d'-xxx NE
DNA XXX NE
were xxx NE
incrementally xxx NE
less xxx NE
transcriptionally xxx NE
active xxx NE
, , NE
although xxx NE
0.2 d.d NE
kb xx NE
still xxx NE
mediated xxx NE
a x NE
12-fold dd-xxx NE
induction xxx NE
by xx NE
PRL XXX NE
. . NE

The Xxx NE
sequence xxx NE
between xxx NE
-1.7 -d.d NE
and xxx NE
-0.2 -d.d NE
kb xx NE
linked xxx NE
to xx NE
a x NE
heterologous xxx NE
thymidine xxx NE
kinase xxx NE
promoter xxx NE
failed xxx NE
to xx NE
respond xxx NE
to xx NE
PRL XXX Protein_molecule
stimulation xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
activity xxx NE
of xx NE
upstream xxx DNA_family_or_group_B
PRL XXX DNA_family_or_group_M
response xxx DNA_family_or_group_M
elements xxx DNA_family_or_group_E
may xxx NE
require xxx NE
an xx NE
interaction xxx NE
with xxx NE
promoter-proximal xxx-xxx NE
elements xxx NE
. . NE

By Xx NE
assaying xxx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
across xxx NE
a x NE
24-h dd-x NE
PRL XXX NE
induction xxx NE
time xxx NE
course xxx NE
, , NE
we xx NE
were xxx NE
able xxx NE
to xx NE
assign xxx NE
G1 Xd NE
vs xx NE
. . NE
S X NE
phase xxx NE
PRL XXX NE
responses xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
gene xxx NE
to xx NE
different xxx NE
regions xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
and xxx NE
promoter xxx NE
DNA XXX NE
. . NE

The Xxx NE
0.2-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
induced xxx NE
by xx NE
PRL XXX NE
stimulation xxx NE
during xxx NE
the xxx NE
G1 Xd NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
1.7-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
inducible xxx NE
by xx NE
PRL XXX Protein_molecule
during xxx NE
both xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

Hence Xxxx NE
, , NE
the xxx NE
PRL XXX Protein_molecule
-induced -xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
appears xxx NE
to xx NE
be xx NE
controlled xxx NE
by xx NE
separate xxx NE
PRL XXX NE
-responsive -xxx NE
elements xxx NE
: : NE
elements xxx NE
in xx NE
the xxx NE
first xxx NE
0.2 d.d NE
kb xx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
region xxx NE
act xxx NE
during xxx NE
early xxx NE
activation xxx NE
, , NE
and xxx NE
elements xxx NE
between xxx NE
0.2 d.d NE
and xxx NE
1.7 d.d NE
kb xx NE
act xxx NE
in xx NE
concert xxx NE
with xxx NE
the xxx NE
proximal xxx NE
0.2-kb d.d-xx NE
region xxx NE
during xxx NE
S X NE
phase xxx NE
progression xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_domain_or_region_B
locus xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
beta-globin xxx-xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_M
cluster xxx DNA_domain_or_region_E
depends xxx NE
upon xxx NE
upstream xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
sequences xxx DNA_domain_or_region_E
, , NE
which xxx NE
are xxx NE
collectively xxx NE
termed xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
provided xxx NE
new xxx NE
insights xxx NE
into xxx NE
how xxx NE
the xxx NE
individual xxx NE
genes xxx NE
of xx NE
the xxx NE
cluster xxx NE
are xxx NE
regulated xxx NE
through xxx NE
development xxx NE
. . NE

The Xxx NE
crux xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
is xx NE
how xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
communicates xxx NE
with xxx NE
the xxx NE
gene-proximal xxx-xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
. . NE

Inhibition Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
by xx NE
dehydroepiandrosterone xxx NE
( ( NE
DHEA XXXX NE
) ) NE
and xxx NE
an xx NE
analog xxx NE
of xx NE
DHEA XXXX NE
. . NE

The Xxx NE
initial xxx NE
infection xxx NE
with xxx NE
human xxx Virus_B
immunodeficiency xxx Virus_M
virus xxx Virus_M
type xxx Virus_M
1 d Virus_E
( ( NE
HIV-1 XXX-d Virus
) ) NE
in xx NE
most xxx NE
individuals xxx NE
usually xxx NE
results xxx NE
in xx NE
the xxx NE
establishment xxx NE
of xx NE
a x NE
latent xxx NE
or xx NE
chronic xxx Other_B
infection xxx Other_E
before xxx NE
eventual xxx NE
progression xxx NE
toward xxx NE
acquired xxx Other_B
immunodeficiency xxx Other_M
syndrome xxx Other_E
. . NE

HIV-1 XXX-d Virus
can xxx NE
also xxx NE
establish xxx NE
a x NE
latent xxx NE
or xx NE
persistent xxx NE
infection xxx NE
in xx NE
some xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
that xxx NE
show xxx NE
minimal xxx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

However Xxxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
leading xxx NE
to xx NE
enhanced xxx NE
HIV-1 XXX-d Virus
replication xxx NE
can xxx NE
be xx NE
induced xxx NE
by xx NE
antigens xxx Protein_family_or_group
, , NE
mitogens xxx Other
, , NE
and xxx NE
cytokines xxx Protein_family_or_group
( ( NE
tumor xxx Protein_family_or_group_B
necrosis xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
alpha xxx Protein_family_or_group_E
[ [ NE
TNF-alpha XXX-xxx Protein_molecule
] ] NE
, , NE
interleukin xxx Protein_molecule_B
1 d Protein_molecule_E
, , NE
and xxx NE
interleukin-2 xxx-d Protein_molecule
) ) NE
. . NE

Various Xxxx NE
gene xxx NE
products xxx NE
from xxx NE
other xxx NE
viruses xxx NE
( ( NE
HTLV-1 XXXX-d Virus
, , NE
HSV XXX Virus
, , NE
EBV XXX Virus
, , NE
CMV XXX Virus
, , NE
HBV XXX Virus
, , NE
and xxx NE
HHV-6 XXX-d Virus
) ) NE
can xxx NE
also xxx NE
enhance xxx NE
HIV-1 XXX-d NE
long xxx NE
terminal xxx NE
repeat xxx NE
( ( NE
LTR XXX NE
)-driven )-xxx NE
reporter xxx NE
gene xxx NE
activity xxx NE
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
these xxx NE
observations xxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
proposed xxx NE
that xxx NE
reactivation xxx NE
of xx NE
latent xxx NE
HIV-1 XXX-d Virus
harbored xxx NE
in xx NE
chronically xxx Cell_natural_B
infected xxx Cell_natural_M
T X Cell_natural_M
lymphocytes xxx Cell_natural_E
, , NE
monocytes xxx Cell_natural
, , NE
or xx NE
macrophages xxx Cell_natural
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
AIDS XXXX Other
. . NE

So Xx NE
far xxx NE
, , NE
there xxx NE
are xxx NE
no xx NE
drugs xxx NE
or xx NE
therapy xxx NE
available xxx NE
that xxx NE
can xxx NE
provide xxx NE
protection xxx NE
against xxx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
, , NE
derived xxx NE
from xxx NE
a x NE
human xxx Cell_cultured_B
T X Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
( ( NE
CEM XXX Cell_cultured
) ) NE
, , NE
is xx NE
chronically xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
, , NE
with xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
can xxx NE
be xx NE
converted xxx NE
to xx NE
productive xxx NE
infection xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx Organic_compound_other
( ( NE
TPA XXX Organic_compound_other
) ) NE
, , NE
mitogen xxx Organic_compound_other
or xx NE
cytokines xxx Protein_family_or_group
( ( NE
TNF-alpha XXX-xxx Protein_molecule
) ) NE
, , NE
or xx NE
infection xxx NE
with xxx NE
HSV XXX Virus
. . NE

Therefore Xxxx NE
the xxx NE
ACH-2 XXX-d Cell_cultured
cell xxx NE
line xxx NE
is xx NE
a x NE
good xxx NE
candidate xxx NE
for xxx NE
studying xxx NE
the xxx NE
effects xxx NE
of xx NE
drugs xxx NE
on xx NE
HIV-1 XXX-d Virus
activation xxx NE
. . NE

Previously Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
DHEA XXXX Lipid
and xxx NE
synthetic xxx NE
analogs xxx NE
of xx NE
DHEA XXXX NE
can xxx NE
be xx NE
modest xxx NE
inhibitors xxx NE
of xx NE
HIV-1 XXX-d Other_B
IIIB XXXX Other_M
replication xxx Other_E
in xx NE
phytohemagglutinin xxx NE
-stimulated -xxx NE
peripheral xxx NE
blood xxx NE
lymphocyte xxx NE
cultures xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

C/EBP X/XXX Protein_family_or_group_B
activators xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
and xxx NE
proviral xxx NE
induction xxx NE
in xx NE
monocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

Previous Xxxx NE
work xxx NE
has xxx NE
shown xxx NE
that xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
and xxx NE
C/EBP X/XXX Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
activators xxx Protein_family_or_group_E
are xxx NE
necessary xxx NE
for xxx NE
HIV-1 XXX-d Other_B
LTR XXX Other_M
activity xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
role xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
play xxx NE
in xx NE
induction xxx NE
and xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d Virus
. . NE

Ectopic Xxxx NE
expression xxx NE
of xx NE
the xxx NE
dominant xxx NE
negative xxx NE
C/EBP X/XXX NE
protein xxx NE
LIP XXX NE
inhibited xxx NE
HIV-1 XXX-d NE
mRNA xXXX NE
and xxx NE
virus xxx NE
production xxx NE
in xx NE
activated xxx NE
U1 Xd NE
cells xxx NE
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX NE
proteins xxx NE
are xxx NE
required xxx NE
for xxx NE
provirus xxx NE
induction xxx NE
. . NE

U1 Xd Cell_cultured_B
lines xxx Cell_cultured_E
overexpressing xxx NE
C/EBP X/XXX Protein_family_or_group_B
activator xxx Protein_family_or_group_E
NF-IL-6 XX-XX-d Protein_molecule
produced xxx NE
more xxx NE
viral xxx RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
and xxx NE
virus xxx Virus_B
particles xxx Virus_E
following xxx NE
cellular xxx Other_B
activation xxx Other_E
than xxx NE
control xxx Cell_cultured_B
lines xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
are xxx NE
limiting xxx NE
for xxx NE
virus xxx Other_B
transcription xxx Other_E
. . NE

HIV-1 XXX-d Virus
harboring xxx NE
mutations xxx NE
within xxx NE
two xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
were xxx NE
crippled xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
replicate xxx NE
in xx NE
U937 Xddd Cell_cultured_B
promonocytic xxx Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
indicating xxx NE
that xxx NE
these xxx NE
sites xxx NE
are xxx NE
required xxx NE
for xxx NE
replication xxx NE
. . NE

These Xxxx NE
data xxx NE
identify xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
as xx NE
regulators xxx NE
of xx NE
HIV-1 XXX-d Other_B
expression xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibits xxx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
in xx NE
CD3 XXd NE
-stimulated -xxx NE
human xxx NE
peripheral xxx NE
T X NE
lymphocytes xxx NE
. . NE

IL-10 XX-dd Protein_molecule
markedly xxx NE
reduces xxx NE
nuclear xxx NE
factor xxx NE
(NF)-kappa (XX)-xxx Other_B
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
induced xxx NE
in xx NE
PBMC XXXX NE
by xx NE
stimulation xxx NE
with xxx NE
the xxx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
OKT3 XXXd NE
. . NE

The Xxx NE
inhibition xxx NE
is xx NE
exerted xxx NE
specifically xxx NE
on xx NE
the xxx NE
NF-kappa XX-xxx Other_B
B/Rel X/Xxx Other_M
activation xxx Other_E
induced xxx NE
by xx NE
mAb xXx NE
OKT3 XXXd NE
, , NE
and xxx NE
not xxx NE
that xxx NE
produced xxx NE
by xx NE
PMA XXX NE
. . NE

As Xx NE
judged xxx NE
by xx NE
supershifting xxx NE
the xxx NE
DNA-protein XXX-xxx NE
complexes xxx NE
with xxx NE
Abs Xxx NE
recognizing xxx NE
specific xxx NE
components xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B/Rel X/Xxx NE
protein xxx NE
family xxx NE
, , NE
the xxx NE
p50/p65 xdd/xdd NE
( ( NE
Rel Xxx NE
A X NE
) ) NE
heterodimeric xxx NE
form xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
primarily xxx NE
affected xxx NE
. . NE

The Xxx NE
maximal xxx NE
effect xxx NE
is xx NE
observed xxx NE
at xx NE
the xxx NE
IL-10 XX-dd Other_B
concentration xxx Other_E
of xx NE
20 dd NE
U/ml X/xx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibitory xxx NE
activity xxx NE
is xx NE
exerted xxx NE
on xx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
and xxx NE
is xx NE
mediated xxx NE
by xx NE
monocytes xxx Cell_natural
. . NE

Indeed Xxxx NE
, , NE
monocytes xxx Cell_natural
pretreated xxx NE
with xxx NE
IL-10 XX-dd Protein_molecule
are xxx NE
able xxx NE
so xx NE
inhibit xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
purified xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
stimulated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
. . NE

Soluble Xxxx NE
factors xxx NE
do xx NE
not xxx NE
appear xxx NE
to xx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
mechanism xxx NE
of xx NE
inhibition xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
the xxx NE
up-regulation xx-xxx NE
of xx NE
CD80 XXdd Protein_molecule_B
Ag Xx Protein_molecule_E
, , NE
found xxx NE
on xx NE
monocytes xxx Cell_natural
obtained xxx NE
from xxx NE
PBMC XXXX Cell_natural
incubated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
, , NE
is xx NE
not xxx NE
detected xxx NE
after xxx NE
addition xxx NE
of xx NE
IL-10 XX-dd Protein_molecule
, , NE
and xxx NE
the xxx NE
anti-CD28 xxx-XXdd Protein_family_or_group_B
mAb xXx Protein_family_or_group_E
CLB-CD28/1 XXX-XXdd/d Protein_molecule
restores xxx NE
the xxx NE
NF-kappa XX-xxx Element_B
B/Rel X/Xxx Element_M
nuclear xxx Element_M
activity xxx Element_E
in xx NE
IL-10 XX-dd NE
-inhibited -xxx NE
lymphocytes xxx NE
. . NE

Therefore Xxxx NE
, , NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
inhibition xxx NE
might xxx NE
be xx NE
ascribed xxx NE
to xx NE
a x NE
lack xxx NE
of xx NE
cooperation xxx NE
between xxx NE
accessory xxx NE
cells xxx NE
and xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
, , NE
resulting xxx NE
from xxx NE
down-regulation xxx-xxx NE
of xx NE
a x NE
costimulatory xxx NE
molecule xxx NE
, , NE
such xxx NE
as xx NE
CD80 XXdd Protein_molecule
, , NE
produced xxx NE
by xx NE
IL-10 XX-dd Protein_molecule
on xx NE
activated xxx NE
monocytes xxx Cell_natural
. . NE

Our Xxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
IL-10 XX-dd Protein_molecule
can xxx NE
inhibit xxx NE
the xxx NE
induction xxx NE
of xx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
CD3 XXd NE
-stimulated -xxx NE
T X NE
lymphocytes xxx NE
. . NE

Since Xxxx NE
inappropriate xxx NE
activation xxx NE
of xx NE
kappa xxx DNA_family_or_group_B
B-driven X-xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
has xxx NE
a x NE
physiopathologic xxx NE
role xxx NE
in xx NE
a x NE
number xxx NE
of xx NE
diseases xxx NE
, , NE
such xxx NE
as xx NE
HIV XXX Other_B
infection xxx Other_E
, , NE
our xxx NE
findings xxx NE
support xxx NE
the xxx NE
possibility xxx NE
of xx NE
using xxx NE
this xxx NE
cytokine xxx NE
to xx NE
suppress xxx NE
an xx NE
undesirable xxx NE
activation xxx NE
of xx NE
these xxx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
. . NE

Multiple Xxxx NE
prolactin xxx NE
-responsive -xxx NE
elements xxx NE
mediate xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
expression xxx NE
of xx NE
the xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
gene xxx NE
. . NE

The Xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
( ( NE
IRF-1 XXX-d NE
) ) NE
gene xxx NE
is xx NE
both xxx NE
an xx NE
immediate-early xxx-xxx NE
G1 Xd NE
phase xxx NE
gene xxx NE
and xxx NE
an xx NE
S X NE
phase xxx NE
gene xxx NE
inducible xxx NE
by xx NE
PRL XXX NE
in xx NE
rat xxx NE
Nb2 Xxd NE
T X NE
lymphocytes xxx NE
. . NE

To Xx NE
understand xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
PRL XXX Protein_molecule
regulates xxx NE
the xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
IRF-1 XXX-d Protein_molecule
, , NE
we xx NE
cloned xxx NE
the xxx NE
rat xxx DNA_domain_or_region_B
IRF-1 XXX-d DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
and xxx NE
functionally xxx NE
characterized xxx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
. . NE

Upon Xxxx NE
transfection xxx NE
into xxx NE
Nb2 Xxd Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
1.7 d.d NE
kilobases xxx NE
(kb) (xx) NE
of xx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
DNA XXX NE
linked xxx NE
to xx NE
a x NE
chloramphenicol xxx NE
acetyl xxx NE
transferase xxx NE
( ( NE
CAT XXX NE
) ) NE
reporter xxx NE
gene xxx NE
mediated xxx NE
a x NE
30-fold dd-xxx NE
induction xxx NE
of xx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
in xx NE
response xxx NE
to xx NE
24 dd NE
h x NE
of xx NE
PRL XXX NE
stimulation xxx NE
. . NE

Deletion Xxxx NE
mutants xxx NE
containing xxx NE
1.3 d.d NE
, , NE
0.6 d.d NE
, , NE
and xxx NE
0.2 d.d NE
kb xx NE
5'-flanking d'-xxx NE
DNA XXX NE
were xxx NE
incrementally xxx NE
less xxx NE
transcriptionally xxx NE
active xxx NE
, , NE
although xxx NE
0.2 d.d NE
kb xx NE
still xxx NE
mediated xxx NE
a x NE
12-fold dd-xxx NE
induction xxx NE
by xx NE
PRL XXX NE
. . NE

The Xxx NE
sequence xxx NE
between xxx NE
-1.7 -d.d NE
and xxx NE
-0.2 -d.d NE
kb xx NE
linked xxx NE
to xx NE
a x NE
heterologous xxx NE
thymidine xxx NE
kinase xxx NE
promoter xxx NE
failed xxx NE
to xx NE
respond xxx NE
to xx NE
PRL XXX Protein_molecule
stimulation xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
activity xxx NE
of xx NE
upstream xxx DNA_family_or_group_B
PRL XXX DNA_family_or_group_M
response xxx DNA_family_or_group_M
elements xxx DNA_family_or_group_E
may xxx NE
require xxx NE
an xx NE
interaction xxx NE
with xxx NE
promoter-proximal xxx-xxx NE
elements xxx NE
. . NE

By Xx NE
assaying xxx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
across xxx NE
a x NE
24-h dd-x NE
PRL XXX NE
induction xxx NE
time xxx NE
course xxx NE
, , NE
we xx NE
were xxx NE
able xxx NE
to xx NE
assign xxx NE
G1 Xd NE
vs xx NE
. . NE
S X NE
phase xxx NE
PRL XXX NE
responses xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
gene xxx NE
to xx NE
different xxx NE
regions xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
and xxx NE
promoter xxx NE
DNA XXX NE
. . NE

The Xxx NE
0.2-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
induced xxx NE
by xx NE
PRL XXX NE
stimulation xxx NE
during xxx NE
the xxx NE
G1 Xd NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
1.7-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
inducible xxx NE
by xx NE
PRL XXX Protein_molecule
during xxx NE
both xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

Hence Xxxx NE
, , NE
the xxx NE
PRL XXX Protein_molecule
-induced -xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
appears xxx NE
to xx NE
be xx NE
controlled xxx NE
by xx NE
separate xxx NE
PRL XXX NE
-responsive -xxx NE
elements xxx NE
: : NE
elements xxx NE
in xx NE
the xxx NE
first xxx NE
0.2 d.d NE
kb xx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
region xxx NE
act xxx NE
during xxx NE
early xxx NE
activation xxx NE
, , NE
and xxx NE
elements xxx NE
between xxx NE
0.2 d.d NE
and xxx NE
1.7 d.d NE
kb xx NE
act xxx NE
in xx NE
concert xxx NE
with xxx NE
the xxx NE
proximal xxx NE
0.2-kb d.d-xx NE
region xxx NE
during xxx NE
S X NE
phase xxx NE
progression xxx NE
. . NE

Triggering Xxxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
CR1 XXd Protein_molecule
( ( NE
CD35 XXdd Protein_molecule
) ) NE
and xxx NE
CR3 XXd Protein_molecule
( ( NE
CD11b/CD18 XXddx/XXdd Protein_molecule
) ) NE
induces xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50/p65 xdd/xdd Protein_molecule
) ) NE
in xx NE
human xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
enhances xxx NE
viral xxx Other_B
replication xxx Other_E
in xx NE
HIV XXX NE
-infected -xxx NE
monocytic xxx NE
cells xxx NE
. . NE

Monocyte Xxxx NE
/ / NE
macrophages xxx NE
may xxx NE
harbor xxx NE
HIV XXX NE
in xx NE
a x NE
nonproductive xxx NE
fashion xxx NE
for xxx NE
prolonged xxx NE
periods xxx NE
of xx NE
time xxx NE
. . NE

Viral Xxxx Other_B
gene xxx Other_M
expression xxx Other_E
may xxx NE
be xx NE
reactivated xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
LPS XXX Lipid
or xx NE
cytokines xxx Protein_family_or_group
such xxx NE
as xx NE
TNF-alpha XXX-xxx Protein_molecule
in xx NE
vitro xxx NE
. . NE

The Xxx NE
effect xxx NE
of xx NE
LPS XXX Lipid
and xxx NE
TNF-alpha XXX-xxx Protein_molecule
is xx NE
mediated xxx NE
by xx NE
their xxx NE
ability xxx NE
to xx NE
induce xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
the xxx NE
DNA-binding XXX-xxx Protein_family_or_group_B
heterodimer xxx Protein_family_or_group_E
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50/p65 xdd/xdd Protein_molecule
) ) NE
, , NE
which xxx NE
binds xxx NE
to xx NE
a x NE
specific xxx NE
sequence xxx NE
in xx NE
the xxx NE
HIV-long XXX-xxx DNA_domain_or_region_B
terminal xxx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
. . NE

The Xxx NE
present xxx NE
study xxx NE
demonstrates xxx NE
that xxx NE
triggering xxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
CR1 XXd Protein_molecule
( ( NE
CD35 XXdd Protein_molecule
) ) NE
and xxx NE
CR3 XXd Protein_molecule
( ( NE
CD11b/CD18 XXddx/XXdd Protein_molecule
) ) NE
enhances xxx NE
viral xxx Other_B
replication xxx Other_E
in xx NE
HIV XXX NE
-infected -xxx NE
human xxx NE
monocytic xxx NE
cells xxx NE
. . NE

Monocytic Xxxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
and xxx NE
normal xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx NE
were xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
in xx NE
vitro xxx NE
and xxx NE
cultured xxx NE
in xx NE
the xxx NE
presence xxx NE
or xx NE
absence xxx NE
of xx NE
F(ab')2 X(xx')d Protein_molecule_B
fragments xxx Protein_molecule_E
of xx NE
monoclonal xxx NE
anti- xxx- NE
CR1 XXd NE
or xx NE
anti- xxx- NE
CR3 XXd NE
Abs Xxx NE
or xx NE
with xxx NE
C3 Xd NE
fragments xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
induces xxx NE
a x NE
two- xxx- NE
to xx NE
fourfold xxx NE
increase xxx NE
in xx NE
the xxx NE
amount xxx NE
of xx NE
cell-associated xxx-xxx NE
and xxx NE
released xxx NE
p24 xdd Protein_molecule_B
Ag Xx Protein_molecule_E
in xx NE
cell xxx Cell_cultured_B
cultures xxx Cell_cultured_E
that xxx NE
was xxx NE
equivalent xxx NE
to xx NE
that xxx NE
observed xxx NE
in xx NE
control xxx Cell_cultured_B
cultures xxx Cell_cultured_E
triggered xxx NE
with xxx NE
LPS XXX Lipid
. . NE

We Xx NE
further xxx NE
observed xxx NE
that xxx NE
stimulation xxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
induces xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
in xx NE
infected xxx Cell_natural_B
cells xxx Cell_natural_E
. . NE

Translocation Xxxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
was xxx NE
also xxx NE
observed xxx NE
following xxx NE
stimulation xxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
of xx NE
uninfected xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx NE
from xxx NE
HIV-seronegative XXX-xxx NE
donors xxx NE
. . NE

The Xxx NE
amount xxx NE
of xx NE
protein xxx NE
translocated xxx NE
was xxx NE
similar xxx NE
to xx NE
that xxx NE
observed xxx NE
when xxx NE
cells xxx NE
were xxx NE
stimulated xxx NE
with xxx NE
rhTNF-alpha xxXXX-xxx Protein_molecule
. . NE

TNF-alpha XXX-xxx Protein_molecule
did xxx NE
not xxx NE
mediate xxx NE
the xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
induced xxx NE
by xx NE
triggering xxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
observations xxx NE
suggest xxx NE
that xxx NE
HIV XXX Other_B
gene xxx Other_M
expression xxx Other_E
may xxx NE
be xx NE
activated xxx NE
in xx NE
infected xxx Cell_natural_B
monocytes xxx Cell_natural_E
through xxx NE
interaction xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
complement-opsonized xxx-xxx Protein_family_or_group_B
particles xxx Protein_family_or_group_E
and xxx NE
that xxx NE
enhanced xxx NE
viral xxx Other_B
replication xxx Other_E
is xx NE
associated xxx NE
with xxx NE
C3 Xd Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
-mediated -xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_M
complex xxx Protein_complex_E
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_domain_or_region_B
locus xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
beta-globin xxx-xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_M
cluster xxx DNA_domain_or_region_E
depends xxx NE
upon xxx NE
upstream xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
sequences xxx DNA_domain_or_region_E
, , NE
which xxx NE
are xxx NE
collectively xxx NE
termed xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
provided xxx NE
new xxx NE
insights xxx NE
into xxx NE
how xxx NE
the xxx NE
individual xxx NE
genes xxx NE
of xx NE
the xxx NE
cluster xxx NE
are xxx NE
regulated xxx NE
through xxx NE
development xxx NE
. . NE

The Xxx NE
crux xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
is xx NE
how xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
communicates xxx NE
with xxx NE
the xxx NE
gene-proximal xxx-xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
. . NE

Inhibition Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
by xx NE
dehydroepiandrosterone xxx NE
( ( NE
DHEA XXXX NE
) ) NE
and xxx NE
an xx NE
analog xxx NE
of xx NE
DHEA XXXX NE
. . NE

The Xxx NE
initial xxx NE
infection xxx NE
with xxx NE
human xxx Virus_B
immunodeficiency xxx Virus_M
virus xxx Virus_M
type xxx Virus_M
1 d Virus_E
( ( NE
HIV-1 XXX-d Virus
) ) NE
in xx NE
most xxx NE
individuals xxx NE
usually xxx NE
results xxx NE
in xx NE
the xxx NE
establishment xxx NE
of xx NE
a x NE
latent xxx NE
or xx NE
chronic xxx Other_B
infection xxx Other_E
before xxx NE
eventual xxx NE
progression xxx NE
toward xxx NE
acquired xxx Other_B
immunodeficiency xxx Other_M
syndrome xxx Other_E
. . NE

HIV-1 XXX-d Virus
can xxx NE
also xxx NE
establish xxx NE
a x NE
latent xxx NE
or xx NE
persistent xxx NE
infection xxx NE
in xx NE
some xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
that xxx NE
show xxx NE
minimal xxx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

However Xxxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
leading xxx NE
to xx NE
enhanced xxx NE
HIV-1 XXX-d Virus
replication xxx NE
can xxx NE
be xx NE
induced xxx NE
by xx NE
antigens xxx Protein_family_or_group
, , NE
mitogens xxx Other
, , NE
and xxx NE
cytokines xxx Protein_family_or_group
( ( NE
tumor xxx Protein_family_or_group_B
necrosis xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
alpha xxx Protein_family_or_group_E
[ [ NE
TNF-alpha XXX-xxx Protein_molecule
] ] NE
, , NE
interleukin xxx Protein_molecule_B
1 d Protein_molecule_E
, , NE
and xxx NE
interleukin-2 xxx-d Protein_molecule
) ) NE
. . NE

Various Xxxx NE
gene xxx NE
products xxx NE
from xxx NE
other xxx NE
viruses xxx NE
( ( NE
HTLV-1 XXXX-d Virus
, , NE
HSV XXX Virus
, , NE
EBV XXX Virus
, , NE
CMV XXX Virus
, , NE
HBV XXX Virus
, , NE
and xxx NE
HHV-6 XXX-d Virus
) ) NE
can xxx NE
also xxx NE
enhance xxx NE
HIV-1 XXX-d NE
long xxx NE
terminal xxx NE
repeat xxx NE
( ( NE
LTR XXX NE
)-driven )-xxx NE
reporter xxx NE
gene xxx NE
activity xxx NE
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
these xxx NE
observations xxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
proposed xxx NE
that xxx NE
reactivation xxx NE
of xx NE
latent xxx NE
HIV-1 XXX-d Virus
harbored xxx NE
in xx NE
chronically xxx Cell_natural_B
infected xxx Cell_natural_M
T X Cell_natural_M
lymphocytes xxx Cell_natural_E
, , NE
monocytes xxx Cell_natural
, , NE
or xx NE
macrophages xxx Cell_natural
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
AIDS XXXX Other
. . NE

So Xx NE
far xxx NE
, , NE
there xxx NE
are xxx NE
no xx NE
drugs xxx NE
or xx NE
therapy xxx NE
available xxx NE
that xxx NE
can xxx NE
provide xxx NE
protection xxx NE
against xxx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
, , NE
derived xxx NE
from xxx NE
a x NE
human xxx Cell_cultured_B
T X Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
( ( NE
CEM XXX Cell_cultured
) ) NE
, , NE
is xx NE
chronically xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
, , NE
with xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
can xxx NE
be xx NE
converted xxx NE
to xx NE
productive xxx NE
infection xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx Organic_compound_other
( ( NE
TPA XXX Organic_compound_other
) ) NE
, , NE
mitogen xxx Organic_compound_other
or xx NE
cytokines xxx Protein_family_or_group
( ( NE
TNF-alpha XXX-xxx Protein_molecule
) ) NE
, , NE
or xx NE
infection xxx NE
with xxx NE
HSV XXX Virus
. . NE

Therefore Xxxx NE
the xxx NE
ACH-2 XXX-d Cell_cultured
cell xxx NE
line xxx NE
is xx NE
a x NE
good xxx NE
candidate xxx NE
for xxx NE
studying xxx NE
the xxx NE
effects xxx NE
of xx NE
drugs xxx NE
on xx NE
HIV-1 XXX-d Virus
activation xxx NE
. . NE

Previously Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
DHEA XXXX Lipid
and xxx NE
synthetic xxx NE
analogs xxx NE
of xx NE
DHEA XXXX NE
can xxx NE
be xx NE
modest xxx NE
inhibitors xxx NE
of xx NE
HIV-1 XXX-d Other_B
IIIB XXXX Other_M
replication xxx Other_E
in xx NE
phytohemagglutinin xxx NE
-stimulated -xxx NE
peripheral xxx NE
blood xxx NE
lymphocyte xxx NE
cultures xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

C/EBP X/XXX Protein_family_or_group_B
activators xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
and xxx NE
proviral xxx NE
induction xxx NE
in xx NE
monocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

Previous Xxxx NE
work xxx NE
has xxx NE
shown xxx NE
that xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
and xxx NE
C/EBP X/XXX Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
activators xxx Protein_family_or_group_E
are xxx NE
necessary xxx NE
for xxx NE
HIV-1 XXX-d Other_B
LTR XXX Other_M
activity xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
role xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
play xxx NE
in xx NE
induction xxx NE
and xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d Virus
. . NE

Ectopic Xxxx NE
expression xxx NE
of xx NE
the xxx NE
dominant xxx NE
negative xxx NE
C/EBP X/XXX NE
protein xxx NE
LIP XXX NE
inhibited xxx NE
HIV-1 XXX-d NE
mRNA xXXX NE
and xxx NE
virus xxx NE
production xxx NE
in xx NE
activated xxx NE
U1 Xd NE
cells xxx NE
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX NE
proteins xxx NE
are xxx NE
required xxx NE
for xxx NE
provirus xxx NE
induction xxx NE
. . NE

U1 Xd Cell_cultured_B
lines xxx Cell_cultured_E
overexpressing xxx NE
C/EBP X/XXX Protein_family_or_group_B
activator xxx Protein_family_or_group_E
NF-IL-6 XX-XX-d Protein_molecule
produced xxx NE
more xxx NE
viral xxx RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
and xxx NE
virus xxx Virus_B
particles xxx Virus_E
following xxx NE
cellular xxx Other_B
activation xxx Other_E
than xxx NE
control xxx Cell_cultured_B
lines xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
are xxx NE
limiting xxx NE
for xxx NE
virus xxx Other_B
transcription xxx Other_E
. . NE

HIV-1 XXX-d Virus
harboring xxx NE
mutations xxx NE
within xxx NE
two xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
were xxx NE
crippled xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
replicate xxx NE
in xx NE
U937 Xddd Cell_cultured_B
promonocytic xxx Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
indicating xxx NE
that xxx NE
these xxx NE
sites xxx NE
are xxx NE
required xxx NE
for xxx NE
replication xxx NE
. . NE

These Xxxx NE
data xxx NE
identify xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
as xx NE
regulators xxx NE
of xx NE
HIV-1 XXX-d Other_B
expression xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibits xxx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
in xx NE
CD3 XXd NE
-stimulated -xxx NE
human xxx NE
peripheral xxx NE
T X NE
lymphocytes xxx NE
. . NE

IL-10 XX-dd Protein_molecule
markedly xxx NE
reduces xxx NE
nuclear xxx NE
factor xxx NE
(NF)-kappa (XX)-xxx Other_B
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
induced xxx NE
in xx NE
PBMC XXXX NE
by xx NE
stimulation xxx NE
with xxx NE
the xxx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
OKT3 XXXd NE
. . NE

The Xxx NE
inhibition xxx NE
is xx NE
exerted xxx NE
specifically xxx NE
on xx NE
the xxx NE
NF-kappa XX-xxx Other_B
B/Rel X/Xxx Other_M
activation xxx Other_E
induced xxx NE
by xx NE
mAb xXx NE
OKT3 XXXd NE
, , NE
and xxx NE
not xxx NE
that xxx NE
produced xxx NE
by xx NE
PMA XXX NE
. . NE

As Xx NE
judged xxx NE
by xx NE
supershifting xxx NE
the xxx NE
DNA-protein XXX-xxx NE
complexes xxx NE
with xxx NE
Abs Xxx NE
recognizing xxx NE
specific xxx NE
components xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B/Rel X/Xxx NE
protein xxx NE
family xxx NE
, , NE
the xxx NE
p50/p65 xdd/xdd NE
( ( NE
Rel Xxx NE
A X NE
) ) NE
heterodimeric xxx NE
form xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
primarily xxx NE
affected xxx NE
. . NE

The Xxx NE
maximal xxx NE
effect xxx NE
is xx NE
observed xxx NE
at xx NE
the xxx NE
IL-10 XX-dd Other_B
concentration xxx Other_E
of xx NE
20 dd NE
U/ml X/xx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibitory xxx NE
activity xxx NE
is xx NE
exerted xxx NE
on xx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
and xxx NE
is xx NE
mediated xxx NE
by xx NE
monocytes xxx Cell_natural
. . NE

Indeed Xxxx NE
, , NE
monocytes xxx Cell_natural
pretreated xxx NE
with xxx NE
IL-10 XX-dd Protein_molecule
are xxx NE
able xxx NE
so xx NE
inhibit xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
purified xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
stimulated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
. . NE

Soluble Xxxx NE
factors xxx NE
do xx NE
not xxx NE
appear xxx NE
to xx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
mechanism xxx NE
of xx NE
inhibition xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
the xxx NE
up-regulation xx-xxx NE
of xx NE
CD80 XXdd Protein_molecule_B
Ag Xx Protein_molecule_E
, , NE
found xxx NE
on xx NE
monocytes xxx Cell_natural
obtained xxx NE
from xxx NE
PBMC XXXX Cell_natural
incubated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
, , NE
is xx NE
not xxx NE
detected xxx NE
after xxx NE
addition xxx NE
of xx NE
IL-10 XX-dd Protein_molecule
, , NE
and xxx NE
the xxx NE
anti-CD28 xxx-XXdd Protein_family_or_group_B
mAb xXx Protein_family_or_group_E
CLB-CD28/1 XXX-XXdd/d Protein_molecule
restores xxx NE
the xxx NE
NF-kappa XX-xxx Element_B
B/Rel X/Xxx Element_M
nuclear xxx Element_M
activity xxx Element_E
in xx NE
IL-10 XX-dd NE
-inhibited -xxx NE
lymphocytes xxx NE
. . NE

Therefore Xxxx NE
, , NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
inhibition xxx NE
might xxx NE
be xx NE
ascribed xxx NE
to xx NE
a x NE
lack xxx NE
of xx NE
cooperation xxx NE
between xxx NE
accessory xxx NE
cells xxx NE
and xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
, , NE
resulting xxx NE
from xxx NE
down-regulation xxx-xxx NE
of xx NE
a x NE
costimulatory xxx NE
molecule xxx NE
, , NE
such xxx NE
as xx NE
CD80 XXdd Protein_molecule
, , NE
produced xxx NE
by xx NE
IL-10 XX-dd Protein_molecule
on xx NE
activated xxx NE
monocytes xxx Cell_natural
. . NE

Our Xxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
IL-10 XX-dd Protein_molecule
can xxx NE
inhibit xxx NE
the xxx NE
induction xxx NE
of xx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
CD3 XXd NE
-stimulated -xxx NE
T X NE
lymphocytes xxx NE
. . NE

Since Xxxx NE
inappropriate xxx NE
activation xxx NE
of xx NE
kappa xxx DNA_family_or_group_B
B-driven X-xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
has xxx NE
a x NE
physiopathologic xxx NE
role xxx NE
in xx NE
a x NE
number xxx NE
of xx NE
diseases xxx NE
, , NE
such xxx NE
as xx NE
HIV XXX Other_B
infection xxx Other_E
, , NE
our xxx NE
findings xxx NE
support xxx NE
the xxx NE
possibility xxx NE
of xx NE
using xxx NE
this xxx NE
cytokine xxx NE
to xx NE
suppress xxx NE
an xx NE
undesirable xxx NE
activation xxx NE
of xx NE
these xxx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
. . NE

Multiple Xxxx NE
prolactin xxx NE
-responsive -xxx NE
elements xxx NE
mediate xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
expression xxx NE
of xx NE
the xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
gene xxx NE
. . NE

The Xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
( ( NE
IRF-1 XXX-d NE
) ) NE
gene xxx NE
is xx NE
both xxx NE
an xx NE
immediate-early xxx-xxx NE
G1 Xd NE
phase xxx NE
gene xxx NE
and xxx NE
an xx NE
S X NE
phase xxx NE
gene xxx NE
inducible xxx NE
by xx NE
PRL XXX NE
in xx NE
rat xxx NE
Nb2 Xxd NE
T X NE
lymphocytes xxx NE
. . NE

To Xx NE
understand xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
PRL XXX Protein_molecule
regulates xxx NE
the xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
IRF-1 XXX-d Protein_molecule
, , NE
we xx NE
cloned xxx NE
the xxx NE
rat xxx DNA_domain_or_region_B
IRF-1 XXX-d DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
and xxx NE
functionally xxx NE
characterized xxx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
. . NE

Upon Xxxx NE
transfection xxx NE
into xxx NE
Nb2 Xxd Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
1.7 d.d NE
kilobases xxx NE
(kb) (xx) NE
of xx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
DNA XXX NE
linked xxx NE
to xx NE
a x NE
chloramphenicol xxx NE
acetyl xxx NE
transferase xxx NE
( ( NE
CAT XXX NE
) ) NE
reporter xxx NE
gene xxx NE
mediated xxx NE
a x NE
30-fold dd-xxx NE
induction xxx NE
of xx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
in xx NE
response xxx NE
to xx NE
24 dd NE
h x NE
of xx NE
PRL XXX NE
stimulation xxx NE
. . NE

Deletion Xxxx NE
mutants xxx NE
containing xxx NE
1.3 d.d NE
, , NE
0.6 d.d NE
, , NE
and xxx NE
0.2 d.d NE
kb xx NE
5'-flanking d'-xxx NE
DNA XXX NE
were xxx NE
incrementally xxx NE
less xxx NE
transcriptionally xxx NE
active xxx NE
, , NE
although xxx NE
0.2 d.d NE
kb xx NE
still xxx NE
mediated xxx NE
a x NE
12-fold dd-xxx NE
induction xxx NE
by xx NE
PRL XXX NE
. . NE

The Xxx NE
sequence xxx NE
between xxx NE
-1.7 -d.d NE
and xxx NE
-0.2 -d.d NE
kb xx NE
linked xxx NE
to xx NE
a x NE
heterologous xxx NE
thymidine xxx NE
kinase xxx NE
promoter xxx NE
failed xxx NE
to xx NE
respond xxx NE
to xx NE
PRL XXX Protein_molecule
stimulation xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
activity xxx NE
of xx NE
upstream xxx DNA_family_or_group_B
PRL XXX DNA_family_or_group_M
response xxx DNA_family_or_group_M
elements xxx DNA_family_or_group_E
may xxx NE
require xxx NE
an xx NE
interaction xxx NE
with xxx NE
promoter-proximal xxx-xxx NE
elements xxx NE
. . NE

By Xx NE
assaying xxx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
across xxx NE
a x NE
24-h dd-x NE
PRL XXX NE
induction xxx NE
time xxx NE
course xxx NE
, , NE
we xx NE
were xxx NE
able xxx NE
to xx NE
assign xxx NE
G1 Xd NE
vs xx NE
. . NE
S X NE
phase xxx NE
PRL XXX NE
responses xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
gene xxx NE
to xx NE
different xxx NE
regions xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
and xxx NE
promoter xxx NE
DNA XXX NE
. . NE

The Xxx NE
0.2-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
induced xxx NE
by xx NE
PRL XXX NE
stimulation xxx NE
during xxx NE
the xxx NE
G1 Xd NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
1.7-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
inducible xxx NE
by xx NE
PRL XXX Protein_molecule
during xxx NE
both xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

Hence Xxxx NE
, , NE
the xxx NE
PRL XXX Protein_molecule
-induced -xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
appears xxx NE
to xx NE
be xx NE
controlled xxx NE
by xx NE
separate xxx NE
PRL XXX NE
-responsive -xxx NE
elements xxx NE
: : NE
elements xxx NE
in xx NE
the xxx NE
first xxx NE
0.2 d.d NE
kb xx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
region xxx NE
act xxx NE
during xxx NE
early xxx NE
activation xxx NE
, , NE
and xxx NE
elements xxx NE
between xxx NE
0.2 d.d NE
and xxx NE
1.7 d.d NE
kb xx NE
act xxx NE
in xx NE
concert xxx NE
with xxx NE
the xxx NE
proximal xxx NE
0.2-kb d.d-xx NE
region xxx NE
during xxx NE
S X NE
phase xxx NE
progression xxx NE
. . NE

Triggering Xxxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
CR1 XXd Protein_molecule
( ( NE
CD35 XXdd Protein_molecule
) ) NE
and xxx NE
CR3 XXd Protein_molecule
( ( NE
CD11b/CD18 XXddx/XXdd Protein_molecule
) ) NE
induces xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50/p65 xdd/xdd Protein_molecule
) ) NE
in xx NE
human xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
enhances xxx NE
viral xxx Other_B
replication xxx Other_E
in xx NE
HIV XXX NE
-infected -xxx NE
monocytic xxx NE
cells xxx NE
. . NE

Monocyte Xxxx NE
/ / NE
macrophages xxx NE
may xxx NE
harbor xxx NE
HIV XXX NE
in xx NE
a x NE
nonproductive xxx NE
fashion xxx NE
for xxx NE
prolonged xxx NE
periods xxx NE
of xx NE
time xxx NE
. . NE

Viral Xxxx Other_B
gene xxx Other_M
expression xxx Other_E
may xxx NE
be xx NE
reactivated xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
LPS XXX Lipid
or xx NE
cytokines xxx Protein_family_or_group
such xxx NE
as xx NE
TNF-alpha XXX-xxx Protein_molecule
in xx NE
vitro xxx NE
. . NE

The Xxx NE
effect xxx NE
of xx NE
LPS XXX Lipid
and xxx NE
TNF-alpha XXX-xxx Protein_molecule
is xx NE
mediated xxx NE
by xx NE
their xxx NE
ability xxx NE
to xx NE
induce xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
the xxx NE
DNA-binding XXX-xxx Protein_family_or_group_B
heterodimer xxx Protein_family_or_group_E
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50/p65 xdd/xdd Protein_molecule
) ) NE
, , NE
which xxx NE
binds xxx NE
to xx NE
a x NE
specific xxx NE
sequence xxx NE
in xx NE
the xxx NE
HIV-long XXX-xxx DNA_domain_or_region_B
terminal xxx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
. . NE

The Xxx NE
present xxx NE
study xxx NE
demonstrates xxx NE
that xxx NE
triggering xxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
CR1 XXd Protein_molecule
( ( NE
CD35 XXdd Protein_molecule
) ) NE
and xxx NE
CR3 XXd Protein_molecule
( ( NE
CD11b/CD18 XXddx/XXdd Protein_molecule
) ) NE
enhances xxx NE
viral xxx Other_B
replication xxx Other_E
in xx NE
HIV XXX NE
-infected -xxx NE
human xxx NE
monocytic xxx NE
cells xxx NE
. . NE

Monocytic Xxxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
and xxx NE
normal xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx NE
were xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
in xx NE
vitro xxx NE
and xxx NE
cultured xxx NE
in xx NE
the xxx NE
presence xxx NE
or xx NE
absence xxx NE
of xx NE
F(ab')2 X(xx')d Protein_molecule_B
fragments xxx Protein_molecule_E
of xx NE
monoclonal xxx NE
anti- xxx- NE
CR1 XXd NE
or xx NE
anti- xxx- NE
CR3 XXd NE
Abs Xxx NE
or xx NE
with xxx NE
C3 Xd NE
fragments xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
induces xxx NE
a x NE
two- xxx- NE
to xx NE
fourfold xxx NE
increase xxx NE
in xx NE
the xxx NE
amount xxx NE
of xx NE
cell-associated xxx-xxx NE
and xxx NE
released xxx NE
p24 xdd Protein_molecule_B
Ag Xx Protein_molecule_E
in xx NE
cell xxx Cell_cultured_B
cultures xxx Cell_cultured_E
that xxx NE
was xxx NE
equivalent xxx NE
to xx NE
that xxx NE
observed xxx NE
in xx NE
control xxx Cell_cultured_B
cultures xxx Cell_cultured_E
triggered xxx NE
with xxx NE
LPS XXX Lipid
. . NE

We Xx NE
further xxx NE
observed xxx NE
that xxx NE
stimulation xxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
induces xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
in xx NE
infected xxx Cell_natural_B
cells xxx Cell_natural_E
. . NE

Translocation Xxxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
was xxx NE
also xxx NE
observed xxx NE
following xxx NE
stimulation xxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
of xx NE
uninfected xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx NE
from xxx NE
HIV-seronegative XXX-xxx NE
donors xxx NE
. . NE

The Xxx NE
amount xxx NE
of xx NE
protein xxx NE
translocated xxx NE
was xxx NE
similar xxx NE
to xx NE
that xxx NE
observed xxx NE
when xxx NE
cells xxx NE
were xxx NE
stimulated xxx NE
with xxx NE
rhTNF-alpha xxXXX-xxx Protein_molecule
. . NE

TNF-alpha XXX-xxx Protein_molecule
did xxx NE
not xxx NE
mediate xxx NE
the xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
induced xxx NE
by xx NE
triggering xxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
observations xxx NE
suggest xxx NE
that xxx NE
HIV XXX Other_B
gene xxx Other_M
expression xxx Other_E
may xxx NE
be xx NE
activated xxx NE
in xx NE
infected xxx Cell_natural_B
monocytes xxx Cell_natural_E
through xxx NE
interaction xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
complement-opsonized xxx-xxx Protein_family_or_group_B
particles xxx Protein_family_or_group_E
and xxx NE
that xxx NE
enhanced xxx NE
viral xxx Other_B
replication xxx Other_E
is xx NE
associated xxx NE
with xxx NE
C3 Xd Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
-mediated -xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_M
complex xxx Protein_complex_E
. . NE

Genes Xxxx NE
encoding xxx NE
general xxx Protein_family_or_group_B
initiation xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
for xxx NE
RNA XXX Protein_molecule_B
polymerase xxx Protein_molecule_M
II XX Protein_molecule_E
transcription xxx NE
are xxx NE
dispersed xxx NE
in xx NE
the xxx NE
human xxx DNA_family_or_group_B
genome xxx DNA_family_or_group_E
. . NE

General Xxxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
accurate xxx NE
initiation xxx NE
of xx NE
transcription xxx NE
by xx NE
RNA XXX NE
polymerase xxx NE
II XX NE
. . NE

Human Xxxx DNA_family_or_group_B
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
subunits xxx NE
of xx NE
these xxx NE
factors xxx NE
have xxx NE
been xxx NE
cloned xxx NE
and xxx NE
sequenced xxx NE
. . NE

Using Xxxx NE
fluorescence xxx Other_B
in xx Other_M
situ xxx Other_M
hybridization xxx Other_E
( ( NE
FISH XXXX Other
) ) NE
, , NE
we xx NE
show xxx NE
here xxx NE
that xxx NE
the xxx NE
genes xxx DNA_family_or_group
encoding xxx NE
the xxx NE
TATA-box XXXX-xxx Protein_family_or_group_B
binding xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
( ( NE
TBP XXX Protein_family_or_group
) ) NE
, , NE
TFIIB XXXXX Protein_molecule
, , NE
TFIIE XXXXX Protein_molecule_B
alpha xxx Protein_molecule_E
, , NE
TFIIE XXXXX Protein_molecule_B
beta xxx Protein_molecule_E
, , NE
RAP30 XXXdd Protein_molecule
, , NE
RAP74 XXXdd Protein_molecule
and xxx NE
the xxx NE
62 dd Protein_molecule_B
kDa xXx Protein_molecule_M
subunit xxx Protein_molecule_E
, , NE
of xx NE
TFIIH XXXXX Protein_molecule
are xxx NE
located xxx NE
at xx NE
the xxx NE
human xxx NE
chromosomal xxx NE
bands xxx NE
6q26-27 dxdd-dd NE
, , NE
1p21-22 dxdd-dd NE
, , NE
3q21-24 dxdd-dd NE
, , NE
8p12 dxdd NE
, , NE
13q14 ddxdd NE
, , NE
19p13.3 ddxdd.d NE
and xxx NE
11p14-15.1 ddxdd-dd.d NE
, , NE
respectively xxx NE
. . NE

This Xxxx NE
dispersed xxx NE
localization xxx NE
of xx NE
a x NE
group xxx NE
of xx NE
functionally xxx NE
related xxx NE
gene xxx NE
provides xxx NE
insights xxx NE
into xxx NE
the xxx NE
molecular xxx Other_B
mechanism xxx Other_E
of xx NE
human xxx Other_B
genome xxx Other_M
evolution xxx Other_E
and xxx NE
their xxx NE
possible xxx NE
involvement xxx NE
in xx NE
human xxx NE
diseases xxx NE
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_domain_or_region_B
locus xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
beta-globin xxx-xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_M
cluster xxx DNA_domain_or_region_E
depends xxx NE
upon xxx NE
upstream xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
sequences xxx DNA_domain_or_region_E
, , NE
which xxx NE
are xxx NE
collectively xxx NE
termed xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
provided xxx NE
new xxx NE
insights xxx NE
into xxx NE
how xxx NE
the xxx NE
individual xxx NE
genes xxx NE
of xx NE
the xxx NE
cluster xxx NE
are xxx NE
regulated xxx NE
through xxx NE
development xxx NE
. . NE

The Xxx NE
crux xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
is xx NE
how xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
communicates xxx NE
with xxx NE
the xxx NE
gene-proximal xxx-xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
. . NE

Inhibition Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
by xx NE
dehydroepiandrosterone xxx NE
( ( NE
DHEA XXXX NE
) ) NE
and xxx NE
an xx NE
analog xxx NE
of xx NE
DHEA XXXX NE
. . NE

The Xxx NE
initial xxx NE
infection xxx NE
with xxx NE
human xxx Virus_B
immunodeficiency xxx Virus_M
virus xxx Virus_M
type xxx Virus_M
1 d Virus_E
( ( NE
HIV-1 XXX-d Virus
) ) NE
in xx NE
most xxx NE
individuals xxx NE
usually xxx NE
results xxx NE
in xx NE
the xxx NE
establishment xxx NE
of xx NE
a x NE
latent xxx NE
or xx NE
chronic xxx Other_B
infection xxx Other_E
before xxx NE
eventual xxx NE
progression xxx NE
toward xxx NE
acquired xxx Other_B
immunodeficiency xxx Other_M
syndrome xxx Other_E
. . NE

HIV-1 XXX-d Virus
can xxx NE
also xxx NE
establish xxx NE
a x NE
latent xxx NE
or xx NE
persistent xxx NE
infection xxx NE
in xx NE
some xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
that xxx NE
show xxx NE
minimal xxx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

However Xxxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
leading xxx NE
to xx NE
enhanced xxx NE
HIV-1 XXX-d Virus
replication xxx NE
can xxx NE
be xx NE
induced xxx NE
by xx NE
antigens xxx Protein_family_or_group
, , NE
mitogens xxx Other
, , NE
and xxx NE
cytokines xxx Protein_family_or_group
( ( NE
tumor xxx Protein_family_or_group_B
necrosis xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
alpha xxx Protein_family_or_group_E
[ [ NE
TNF-alpha XXX-xxx Protein_molecule
] ] NE
, , NE
interleukin xxx Protein_molecule_B
1 d Protein_molecule_E
, , NE
and xxx NE
interleukin-2 xxx-d Protein_molecule
) ) NE
. . NE

Various Xxxx NE
gene xxx NE
products xxx NE
from xxx NE
other xxx NE
viruses xxx NE
( ( NE
HTLV-1 XXXX-d Virus
, , NE
HSV XXX Virus
, , NE
EBV XXX Virus
, , NE
CMV XXX Virus
, , NE
HBV XXX Virus
, , NE
and xxx NE
HHV-6 XXX-d Virus
) ) NE
can xxx NE
also xxx NE
enhance xxx NE
HIV-1 XXX-d NE
long xxx NE
terminal xxx NE
repeat xxx NE
( ( NE
LTR XXX NE
)-driven )-xxx NE
reporter xxx NE
gene xxx NE
activity xxx NE
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
these xxx NE
observations xxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
proposed xxx NE
that xxx NE
reactivation xxx NE
of xx NE
latent xxx NE
HIV-1 XXX-d Virus
harbored xxx NE
in xx NE
chronically xxx Cell_natural_B
infected xxx Cell_natural_M
T X Cell_natural_M
lymphocytes xxx Cell_natural_E
, , NE
monocytes xxx Cell_natural
, , NE
or xx NE
macrophages xxx Cell_natural
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
AIDS XXXX Other
. . NE

So Xx NE
far xxx NE
, , NE
there xxx NE
are xxx NE
no xx NE
drugs xxx NE
or xx NE
therapy xxx NE
available xxx NE
that xxx NE
can xxx NE
provide xxx NE
protection xxx NE
against xxx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
, , NE
derived xxx NE
from xxx NE
a x NE
human xxx Cell_cultured_B
T X Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
( ( NE
CEM XXX Cell_cultured
) ) NE
, , NE
is xx NE
chronically xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
, , NE
with xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
can xxx NE
be xx NE
converted xxx NE
to xx NE
productive xxx NE
infection xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx Organic_compound_other
( ( NE
TPA XXX Organic_compound_other
) ) NE
, , NE
mitogen xxx Organic_compound_other
or xx NE
cytokines xxx Protein_family_or_group
( ( NE
TNF-alpha XXX-xxx Protein_molecule
) ) NE
, , NE
or xx NE
infection xxx NE
with xxx NE
HSV XXX Virus
. . NE

Therefore Xxxx NE
the xxx NE
ACH-2 XXX-d Cell_cultured
cell xxx NE
line xxx NE
is xx NE
a x NE
good xxx NE
candidate xxx NE
for xxx NE
studying xxx NE
the xxx NE
effects xxx NE
of xx NE
drugs xxx NE
on xx NE
HIV-1 XXX-d Virus
activation xxx NE
. . NE

Previously Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
DHEA XXXX Lipid
and xxx NE
synthetic xxx NE
analogs xxx NE
of xx NE
DHEA XXXX NE
can xxx NE
be xx NE
modest xxx NE
inhibitors xxx NE
of xx NE
HIV-1 XXX-d Other_B
IIIB XXXX Other_M
replication xxx Other_E
in xx NE
phytohemagglutinin xxx NE
-stimulated -xxx NE
peripheral xxx NE
blood xxx NE
lymphocyte xxx NE
cultures xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

C/EBP X/XXX Protein_family_or_group_B
activators xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
and xxx NE
proviral xxx NE
induction xxx NE
in xx NE
monocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

Previous Xxxx NE
work xxx NE
has xxx NE
shown xxx NE
that xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
and xxx NE
C/EBP X/XXX Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
activators xxx Protein_family_or_group_E
are xxx NE
necessary xxx NE
for xxx NE
HIV-1 XXX-d Other_B
LTR XXX Other_M
activity xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
role xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
play xxx NE
in xx NE
induction xxx NE
and xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d Virus
. . NE

Ectopic Xxxx NE
expression xxx NE
of xx NE
the xxx NE
dominant xxx NE
negative xxx NE
C/EBP X/XXX NE
protein xxx NE
LIP XXX NE
inhibited xxx NE
HIV-1 XXX-d NE
mRNA xXXX NE
and xxx NE
virus xxx NE
production xxx NE
in xx NE
activated xxx NE
U1 Xd NE
cells xxx NE
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX NE
proteins xxx NE
are xxx NE
required xxx NE
for xxx NE
provirus xxx NE
induction xxx NE
. . NE

U1 Xd Cell_cultured_B
lines xxx Cell_cultured_E
overexpressing xxx NE
C/EBP X/XXX Protein_family_or_group_B
activator xxx Protein_family_or_group_E
NF-IL-6 XX-XX-d Protein_molecule
produced xxx NE
more xxx NE
viral xxx RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
and xxx NE
virus xxx Virus_B
particles xxx Virus_E
following xxx NE
cellular xxx Other_B
activation xxx Other_E
than xxx NE
control xxx Cell_cultured_B
lines xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
are xxx NE
limiting xxx NE
for xxx NE
virus xxx Other_B
transcription xxx Other_E
. . NE

HIV-1 XXX-d Virus
harboring xxx NE
mutations xxx NE
within xxx NE
two xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
were xxx NE
crippled xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
replicate xxx NE
in xx NE
U937 Xddd Cell_cultured_B
promonocytic xxx Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
indicating xxx NE
that xxx NE
these xxx NE
sites xxx NE
are xxx NE
required xxx NE
for xxx NE
replication xxx NE
. . NE

These Xxxx NE
data xxx NE
identify xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
as xx NE
regulators xxx NE
of xx NE
HIV-1 XXX-d Other_B
expression xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibits xxx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
in xx NE
CD3 XXd NE
-stimulated -xxx NE
human xxx NE
peripheral xxx NE
T X NE
lymphocytes xxx NE
. . NE

IL-10 XX-dd Protein_molecule
markedly xxx NE
reduces xxx NE
nuclear xxx NE
factor xxx NE
(NF)-kappa (XX)-xxx Other_B
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
induced xxx NE
in xx NE
PBMC XXXX NE
by xx NE
stimulation xxx NE
with xxx NE
the xxx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
OKT3 XXXd NE
. . NE

The Xxx NE
inhibition xxx NE
is xx NE
exerted xxx NE
specifically xxx NE
on xx NE
the xxx NE
NF-kappa XX-xxx Other_B
B/Rel X/Xxx Other_M
activation xxx Other_E
induced xxx NE
by xx NE
mAb xXx NE
OKT3 XXXd NE
, , NE
and xxx NE
not xxx NE
that xxx NE
produced xxx NE
by xx NE
PMA XXX NE
. . NE

As Xx NE
judged xxx NE
by xx NE
supershifting xxx NE
the xxx NE
DNA-protein XXX-xxx NE
complexes xxx NE
with xxx NE
Abs Xxx NE
recognizing xxx NE
specific xxx NE
components xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B/Rel X/Xxx NE
protein xxx NE
family xxx NE
, , NE
the xxx NE
p50/p65 xdd/xdd NE
( ( NE
Rel Xxx NE
A X NE
) ) NE
heterodimeric xxx NE
form xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
primarily xxx NE
affected xxx NE
. . NE

The Xxx NE
maximal xxx NE
effect xxx NE
is xx NE
observed xxx NE
at xx NE
the xxx NE
IL-10 XX-dd Other_B
concentration xxx Other_E
of xx NE
20 dd NE
U/ml X/xx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibitory xxx NE
activity xxx NE
is xx NE
exerted xxx NE
on xx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
and xxx NE
is xx NE
mediated xxx NE
by xx NE
monocytes xxx Cell_natural
. . NE

Indeed Xxxx NE
, , NE
monocytes xxx Cell_natural
pretreated xxx NE
with xxx NE
IL-10 XX-dd Protein_molecule
are xxx NE
able xxx NE
so xx NE
inhibit xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
purified xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
stimulated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
. . NE

Soluble Xxxx NE
factors xxx NE
do xx NE
not xxx NE
appear xxx NE
to xx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
mechanism xxx NE
of xx NE
inhibition xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
the xxx NE
up-regulation xx-xxx NE
of xx NE
CD80 XXdd Protein_molecule_B
Ag Xx Protein_molecule_E
, , NE
found xxx NE
on xx NE
monocytes xxx Cell_natural
obtained xxx NE
from xxx NE
PBMC XXXX Cell_natural
incubated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
, , NE
is xx NE
not xxx NE
detected xxx NE
after xxx NE
addition xxx NE
of xx NE
IL-10 XX-dd Protein_molecule
, , NE
and xxx NE
the xxx NE
anti-CD28 xxx-XXdd Protein_family_or_group_B
mAb xXx Protein_family_or_group_E
CLB-CD28/1 XXX-XXdd/d Protein_molecule
restores xxx NE
the xxx NE
NF-kappa XX-xxx Element_B
B/Rel X/Xxx Element_M
nuclear xxx Element_M
activity xxx Element_E
in xx NE
IL-10 XX-dd NE
-inhibited -xxx NE
lymphocytes xxx NE
. . NE

Therefore Xxxx NE
, , NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
inhibition xxx NE
might xxx NE
be xx NE
ascribed xxx NE
to xx NE
a x NE
lack xxx NE
of xx NE
cooperation xxx NE
between xxx NE
accessory xxx NE
cells xxx NE
and xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
, , NE
resulting xxx NE
from xxx NE
down-regulation xxx-xxx NE
of xx NE
a x NE
costimulatory xxx NE
molecule xxx NE
, , NE
such xxx NE
as xx NE
CD80 XXdd Protein_molecule
, , NE
produced xxx NE
by xx NE
IL-10 XX-dd Protein_molecule
on xx NE
activated xxx NE
monocytes xxx Cell_natural
. . NE

Our Xxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
IL-10 XX-dd Protein_molecule
can xxx NE
inhibit xxx NE
the xxx NE
induction xxx NE
of xx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
CD3 XXd NE
-stimulated -xxx NE
T X NE
lymphocytes xxx NE
. . NE

Since Xxxx NE
inappropriate xxx NE
activation xxx NE
of xx NE
kappa xxx DNA_family_or_group_B
B-driven X-xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
has xxx NE
a x NE
physiopathologic xxx NE
role xxx NE
in xx NE
a x NE
number xxx NE
of xx NE
diseases xxx NE
, , NE
such xxx NE
as xx NE
HIV XXX Other_B
infection xxx Other_E
, , NE
our xxx NE
findings xxx NE
support xxx NE
the xxx NE
possibility xxx NE
of xx NE
using xxx NE
this xxx NE
cytokine xxx NE
to xx NE
suppress xxx NE
an xx NE
undesirable xxx NE
activation xxx NE
of xx NE
these xxx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
. . NE

Multiple Xxxx NE
prolactin xxx NE
-responsive -xxx NE
elements xxx NE
mediate xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
expression xxx NE
of xx NE
the xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
gene xxx NE
. . NE

The Xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
( ( NE
IRF-1 XXX-d NE
) ) NE
gene xxx NE
is xx NE
both xxx NE
an xx NE
immediate-early xxx-xxx NE
G1 Xd NE
phase xxx NE
gene xxx NE
and xxx NE
an xx NE
S X NE
phase xxx NE
gene xxx NE
inducible xxx NE
by xx NE
PRL XXX NE
in xx NE
rat xxx NE
Nb2 Xxd NE
T X NE
lymphocytes xxx NE
. . NE

To Xx NE
understand xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
PRL XXX Protein_molecule
regulates xxx NE
the xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
IRF-1 XXX-d Protein_molecule
, , NE
we xx NE
cloned xxx NE
the xxx NE
rat xxx DNA_domain_or_region_B
IRF-1 XXX-d DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
and xxx NE
functionally xxx NE
characterized xxx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
. . NE

Upon Xxxx NE
transfection xxx NE
into xxx NE
Nb2 Xxd Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
1.7 d.d NE
kilobases xxx NE
(kb) (xx) NE
of xx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
DNA XXX NE
linked xxx NE
to xx NE
a x NE
chloramphenicol xxx NE
acetyl xxx NE
transferase xxx NE
( ( NE
CAT XXX NE
) ) NE
reporter xxx NE
gene xxx NE
mediated xxx NE
a x NE
30-fold dd-xxx NE
induction xxx NE
of xx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
in xx NE
response xxx NE
to xx NE
24 dd NE
h x NE
of xx NE
PRL XXX NE
stimulation xxx NE
. . NE

Deletion Xxxx NE
mutants xxx NE
containing xxx NE
1.3 d.d NE
, , NE
0.6 d.d NE
, , NE
and xxx NE
0.2 d.d NE
kb xx NE
5'-flanking d'-xxx NE
DNA XXX NE
were xxx NE
incrementally xxx NE
less xxx NE
transcriptionally xxx NE
active xxx NE
, , NE
although xxx NE
0.2 d.d NE
kb xx NE
still xxx NE
mediated xxx NE
a x NE
12-fold dd-xxx NE
induction xxx NE
by xx NE
PRL XXX NE
. . NE

The Xxx NE
sequence xxx NE
between xxx NE
-1.7 -d.d NE
and xxx NE
-0.2 -d.d NE
kb xx NE
linked xxx NE
to xx NE
a x NE
heterologous xxx NE
thymidine xxx NE
kinase xxx NE
promoter xxx NE
failed xxx NE
to xx NE
respond xxx NE
to xx NE
PRL XXX Protein_molecule
stimulation xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
activity xxx NE
of xx NE
upstream xxx DNA_family_or_group_B
PRL XXX DNA_family_or_group_M
response xxx DNA_family_or_group_M
elements xxx DNA_family_or_group_E
may xxx NE
require xxx NE
an xx NE
interaction xxx NE
with xxx NE
promoter-proximal xxx-xxx NE
elements xxx NE
. . NE

By Xx NE
assaying xxx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
across xxx NE
a x NE
24-h dd-x NE
PRL XXX NE
induction xxx NE
time xxx NE
course xxx NE
, , NE
we xx NE
were xxx NE
able xxx NE
to xx NE
assign xxx NE
G1 Xd NE
vs xx NE
. . NE
S X NE
phase xxx NE
PRL XXX NE
responses xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
gene xxx NE
to xx NE
different xxx NE
regions xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
and xxx NE
promoter xxx NE
DNA XXX NE
. . NE

The Xxx NE
0.2-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
induced xxx NE
by xx NE
PRL XXX NE
stimulation xxx NE
during xxx NE
the xxx NE
G1 Xd NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
1.7-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
inducible xxx NE
by xx NE
PRL XXX Protein_molecule
during xxx NE
both xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

Hence Xxxx NE
, , NE
the xxx NE
PRL XXX Protein_molecule
-induced -xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
appears xxx NE
to xx NE
be xx NE
controlled xxx NE
by xx NE
separate xxx NE
PRL XXX NE
-responsive -xxx NE
elements xxx NE
: : NE
elements xxx NE
in xx NE
the xxx NE
first xxx NE
0.2 d.d NE
kb xx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
region xxx NE
act xxx NE
during xxx NE
early xxx NE
activation xxx NE
, , NE
and xxx NE
elements xxx NE
between xxx NE
0.2 d.d NE
and xxx NE
1.7 d.d NE
kb xx NE
act xxx NE
in xx NE
concert xxx NE
with xxx NE
the xxx NE
proximal xxx NE
0.2-kb d.d-xx NE
region xxx NE
during xxx NE
S X NE
phase xxx NE
progression xxx NE
. . NE

Triggering Xxxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
CR1 XXd Protein_molecule
( ( NE
CD35 XXdd Protein_molecule
) ) NE
and xxx NE
CR3 XXd Protein_molecule
( ( NE
CD11b/CD18 XXddx/XXdd Protein_molecule
) ) NE
induces xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50/p65 xdd/xdd Protein_molecule
) ) NE
in xx NE
human xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
enhances xxx NE
viral xxx Other_B
replication xxx Other_E
in xx NE
HIV XXX NE
-infected -xxx NE
monocytic xxx NE
cells xxx NE
. . NE

Monocyte Xxxx NE
/ / NE
macrophages xxx NE
may xxx NE
harbor xxx NE
HIV XXX NE
in xx NE
a x NE
nonproductive xxx NE
fashion xxx NE
for xxx NE
prolonged xxx NE
periods xxx NE
of xx NE
time xxx NE
. . NE

Viral Xxxx Other_B
gene xxx Other_M
expression xxx Other_E
may xxx NE
be xx NE
reactivated xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
LPS XXX Lipid
or xx NE
cytokines xxx Protein_family_or_group
such xxx NE
as xx NE
TNF-alpha XXX-xxx Protein_molecule
in xx NE
vitro xxx NE
. . NE

The Xxx NE
effect xxx NE
of xx NE
LPS XXX Lipid
and xxx NE
TNF-alpha XXX-xxx Protein_molecule
is xx NE
mediated xxx NE
by xx NE
their xxx NE
ability xxx NE
to xx NE
induce xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
the xxx NE
DNA-binding XXX-xxx Protein_family_or_group_B
heterodimer xxx Protein_family_or_group_E
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50/p65 xdd/xdd Protein_molecule
) ) NE
, , NE
which xxx NE
binds xxx NE
to xx NE
a x NE
specific xxx NE
sequence xxx NE
in xx NE
the xxx NE
HIV-long XXX-xxx DNA_domain_or_region_B
terminal xxx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
. . NE

The Xxx NE
present xxx NE
study xxx NE
demonstrates xxx NE
that xxx NE
triggering xxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
CR1 XXd Protein_molecule
( ( NE
CD35 XXdd Protein_molecule
) ) NE
and xxx NE
CR3 XXd Protein_molecule
( ( NE
CD11b/CD18 XXddx/XXdd Protein_molecule
) ) NE
enhances xxx NE
viral xxx Other_B
replication xxx Other_E
in xx NE
HIV XXX NE
-infected -xxx NE
human xxx NE
monocytic xxx NE
cells xxx NE
. . NE

Monocytic Xxxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
and xxx NE
normal xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx NE
were xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
in xx NE
vitro xxx NE
and xxx NE
cultured xxx NE
in xx NE
the xxx NE
presence xxx NE
or xx NE
absence xxx NE
of xx NE
F(ab')2 X(xx')d Protein_molecule_B
fragments xxx Protein_molecule_E
of xx NE
monoclonal xxx NE
anti- xxx- NE
CR1 XXd NE
or xx NE
anti- xxx- NE
CR3 XXd NE
Abs Xxx NE
or xx NE
with xxx NE
C3 Xd NE
fragments xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
induces xxx NE
a x NE
two- xxx- NE
to xx NE
fourfold xxx NE
increase xxx NE
in xx NE
the xxx NE
amount xxx NE
of xx NE
cell-associated xxx-xxx NE
and xxx NE
released xxx NE
p24 xdd Protein_molecule_B
Ag Xx Protein_molecule_E
in xx NE
cell xxx Cell_cultured_B
cultures xxx Cell_cultured_E
that xxx NE
was xxx NE
equivalent xxx NE
to xx NE
that xxx NE
observed xxx NE
in xx NE
control xxx Cell_cultured_B
cultures xxx Cell_cultured_E
triggered xxx NE
with xxx NE
LPS XXX Lipid
. . NE

We Xx NE
further xxx NE
observed xxx NE
that xxx NE
stimulation xxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
induces xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
in xx NE
infected xxx Cell_natural_B
cells xxx Cell_natural_E
. . NE

Translocation Xxxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
was xxx NE
also xxx NE
observed xxx NE
following xxx NE
stimulation xxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
of xx NE
uninfected xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx NE
from xxx NE
HIV-seronegative XXX-xxx NE
donors xxx NE
. . NE

The Xxx NE
amount xxx NE
of xx NE
protein xxx NE
translocated xxx NE
was xxx NE
similar xxx NE
to xx NE
that xxx NE
observed xxx NE
when xxx NE
cells xxx NE
were xxx NE
stimulated xxx NE
with xxx NE
rhTNF-alpha xxXXX-xxx Protein_molecule
. . NE

TNF-alpha XXX-xxx Protein_molecule
did xxx NE
not xxx NE
mediate xxx NE
the xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
induced xxx NE
by xx NE
triggering xxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
observations xxx NE
suggest xxx NE
that xxx NE
HIV XXX Other_B
gene xxx Other_M
expression xxx Other_E
may xxx NE
be xx NE
activated xxx NE
in xx NE
infected xxx Cell_natural_B
monocytes xxx Cell_natural_E
through xxx NE
interaction xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
complement-opsonized xxx-xxx Protein_family_or_group_B
particles xxx Protein_family_or_group_E
and xxx NE
that xxx NE
enhanced xxx NE
viral xxx Other_B
replication xxx Other_E
is xx NE
associated xxx NE
with xxx NE
C3 Xd Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
-mediated -xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_M
complex xxx Protein_complex_E
. . NE

Genes Xxxx NE
encoding xxx NE
general xxx Protein_family_or_group_B
initiation xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
for xxx NE
RNA XXX Protein_molecule_B
polymerase xxx Protein_molecule_M
II XX Protein_molecule_E
transcription xxx NE
are xxx NE
dispersed xxx NE
in xx NE
the xxx NE
human xxx DNA_family_or_group_B
genome xxx DNA_family_or_group_E
. . NE

General Xxxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
accurate xxx NE
initiation xxx NE
of xx NE
transcription xxx NE
by xx NE
RNA XXX NE
polymerase xxx NE
II XX NE
. . NE

Human Xxxx DNA_family_or_group_B
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
subunits xxx NE
of xx NE
these xxx NE
factors xxx NE
have xxx NE
been xxx NE
cloned xxx NE
and xxx NE
sequenced xxx NE
. . NE

Using Xxxx NE
fluorescence xxx Other_B
in xx Other_M
situ xxx Other_M
hybridization xxx Other_E
( ( NE
FISH XXXX Other
) ) NE
, , NE
we xx NE
show xxx NE
here xxx NE
that xxx NE
the xxx NE
genes xxx DNA_family_or_group
encoding xxx NE
the xxx NE
TATA-box XXXX-xxx Protein_family_or_group_B
binding xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
( ( NE
TBP XXX Protein_family_or_group
) ) NE
, , NE
TFIIB XXXXX Protein_molecule
, , NE
TFIIE XXXXX Protein_molecule_B
alpha xxx Protein_molecule_E
, , NE
TFIIE XXXXX Protein_molecule_B
beta xxx Protein_molecule_E
, , NE
RAP30 XXXdd Protein_molecule
, , NE
RAP74 XXXdd Protein_molecule
and xxx NE
the xxx NE
62 dd Protein_molecule_B
kDa xXx Protein_molecule_M
subunit xxx Protein_molecule_E
, , NE
of xx NE
TFIIH XXXXX Protein_molecule
are xxx NE
located xxx NE
at xx NE
the xxx NE
human xxx NE
chromosomal xxx NE
bands xxx NE
6q26-27 dxdd-dd NE
, , NE
1p21-22 dxdd-dd NE
, , NE
3q21-24 dxdd-dd NE
, , NE
8p12 dxdd NE
, , NE
13q14 ddxdd NE
, , NE
19p13.3 ddxdd.d NE
and xxx NE
11p14-15.1 ddxdd-dd.d NE
, , NE
respectively xxx NE
. . NE

This Xxxx NE
dispersed xxx NE
localization xxx NE
of xx NE
a x NE
group xxx NE
of xx NE
functionally xxx NE
related xxx NE
gene xxx NE
provides xxx NE
insights xxx NE
into xxx NE
the xxx NE
molecular xxx Other_B
mechanism xxx Other_E
of xx NE
human xxx Other_B
genome xxx Other_M
evolution xxx Other_E
and xxx NE
their xxx NE
possible xxx NE
involvement xxx NE
in xx NE
human xxx NE
diseases xxx NE
. . NE

Cell Xxxx Cell_natural_B
type xxx Cell_natural_M
specificity xxx Cell_natural_E
and xxx NE
activation xxx NE
requirements xxx NE
for xxx NE
NFAT-1 XXXX-d Protein_molecule
( ( NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
of xx NE
activated xxx Cell_natural_B
T-cells X-xxx Cell_natural_E
) ) NE
transcriptional xxx NE
activity xxx NE
determined xxx NE
by xx NE
a x NE
new xxx NE
method xxx NE
using xxx NE
transgenic xxx Multicellular_organism_genetically_modified_B
mice xxx Multicellular_organism_genetically_modified_E
to xx NE
assay xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
an xx NE
individual xxx NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
. . NE

Nuclear Xxxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
of xx NE
activated xxx Cell_natural_B
T-cells X-xxx Cell_natural_E
( ( NE
NFAT-1 XXXX-d Protein_molecule
) ) NE
is xx NE
a x NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
which xxx NE
is xx NE
considered xxx NE
to xx NE
be xx NE
an xx NE
important xxx NE
regulator xxx NE
in xx NE
early xxx NE
T-cell X-xxx Other_B
activation xxx Other_E
. . NE

We Xx NE
have xxx NE
developed xxx NE
a x NE
system xxx NE
to xx NE
monitor xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
NFAT-1 XXXX-d Protein_molecule
at xx NE
the xxx NE
single xxx Cell_natural_B
cell xxx Cell_natural_M
level xxx Cell_natural_E
in xx NE
whole xxx Multicellular_organism_natural_B
animals xxx Multicellular_organism_natural_E
. . NE

The Xxx NE
system xxx NE
is xx NE
based xxx NE
on xx NE
the xxx NE
use xxx NE
of xx NE
an xx NE
oligomerized xxx Polynucleotide_B
NFAT-1 XXXX-d Polynucleotide_M
binding xxx Polynucleotide_M
motif xxx Polynucleotide_E
that xxx NE
directs xxx NE
transcription xxx NE
of xx NE
SV40 XXdd NE
T-antigen X-xxx NE
in xx NE
transgenic xxx NE
mice xxx NE
. . NE

This Xxxx NE
report xxx NE
represents xxx NE
the xxx NE
first xxx NE
demonstration xxx NE
that xxx NE
a x NE
multimerized xxx Polynucleotide_B
short xxx Polynucleotide_M
binding xxx Polynucleotide_M
motif xxx Polynucleotide_E
can xxx NE
function xxx NE
appropriately xxx NE
in xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
mice xxx Multicellular_organism_genetically_modified_E
. . NE

NFAT-1 XXXX-d Protein_molecule
activity xxx NE
had xxx NE
previously xxx NE
been xxx NE
thought xxx NE
to xx NE
be xx NE
confined xxx NE
to xx NE
activated xxx Cell_natural_B
T-lymphocytes X-xxx Cell_natural_E
upon xxx NE
release xxx NE
of xx NE
intracellular xxx NE
calcium xxx NE
. . NE

By Xx NE
targeting xxx NE
NFAT-1 XXXX-d Protein_molecule
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
mice xxx Multicellular_organism_genetically_modified_E
we xx NE
discovered xxx NE
new xxx NE
sites xxx NE
of xx NE
NFAT-1 XXXX-d Other_B
activity xxx Other_E
. . NE

Besides Xxxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
NFAT-1 XXXX-d Other_B
activity xxx Other_E
could xxx NE
also xxx NE
be xx NE
induced xxx NE
in xx NE
T-lymphocyte X-xxx NE
-depleted -xxx NE
spleen xxx NE
cells xxx NE
and xxx NE
purified xxx NE
B-lymphocytes X-xxx NE
and xxx NE
requires xxx NE
agents xxx NE
that xxx NE
both xxx NE
release xxx NE
intracellular xxx NE
calcium xxx NE
and xxx NE
activate xxx NE
protein xxx NE
kinase xxx NE
C X NE
. . NE

A X NE
difference xxx NE
in xx NE
the xxx NE
time xxx NE
course xxx NE
of xx NE
appearance xxx NE
of xx NE
NFAT-1 XXXX-d Other_B
activity xxx Other_E
between xxx NE
T-lymphocytes X-xxx NE
and xxx NE
non-T-lymphocytes xxx-X-xxx NE
was xxx NE
revealed xxx NE
. . NE

Constitutive Xxxx Other_B
expression xxx Other_E
was xxx NE
observed xxx NE
in xx NE
a x NE
small xxx NE
population xxx NE
of xx NE
cells xxx NE
in xx NE
the xxx NE
dermis xxx Tissue_natural
and xxx NE
some xxx NE
mice xxx NE
have xxx NE
developed xxx NE
skin xxx Tissue_natural_B
lesions xxx Tissue_natural_E
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
tissue xxx NE
pattern xxx NE
of xx NE
expression xxx NE
of xx NE
the xxx NE
NFAT-1 XXXX-d Protein_molecule
activity xxx NE
resembles xxx NE
the xxx NE
expression xxx NE
pattern xxx NE
described xxx NE
for xxx NE
HIV-LTR/tat XXX-XXX/xxx Multicellular_organism_natural_B
transgenic xxx Multicellular_organism_natural_M
mice xxx Multicellular_organism_natural_E
(Vogel (Xxxx NE
, , NE
J. X. NE
, , NE
Hinrichs Xxxx NE
, , NE
S X NE
. . NE
H. X. NE
, , NE
Reynolds Xxxx NE
, , NE
R X NE
. . NE
K. X. NE
, , NE
Luciw Xxxx NE
, , NE
P X NE
. . NE
A. X. NE
, , NE
and xxx NE
Jay Xxx NE
, , NE
G X NE
. . NE
(1988) (dddd) NE
Nature Xxxx NE
335 ddd NE
, , NE
606-611) ddd-ddd) NE
. . NE

This Xxxx NE
similarity xxx NE
in xx NE
expression xxx NE
and xxx NE
the xxx NE
fact xxx NE
that xxx NE
NFAT-1 XXXX-d Protein_molecule
has xxx NE
been xxx NE
shown xxx NE
to xx NE
bind xxx NE
functional xxx NE
sequences xxx NE
in xx NE
HIV-LTR XXX-XXX NE
suggest xxx NE
a x NE
role xxx NE
for xxx NE
NFAT-1 XXXX-d Protein_molecule
in xx NE
dermal xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
HIV-LTR XXX-XXX DNA_domain_or_region
. . NE

Transcription Xxxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
activates xxx NE
gene xxx NE
expression xxx NE
of xx NE
HTLV-I XXXX-X NE
. . NE

The Xxx NE
HTLV-I XXXX-X DNA_domain_or_region_B
LTR XXX DNA_domain_or_region_E
contains xxx NE
three xxx NE
conserved xxx NE
regulatory xxx DNA_domain_or_region_B
elements xxx DNA_domain_or_region_E
known xxx NE
as xx NE
21 dd DNA_domain_or_region_B
base xxx DNA_domain_or_region_M
pair xxx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
which xxx NE
are xxx NE
required xxx NE
for xxx NE
stimulation xxx NE
of xx NE
gene xxx Other_B
expression xxx Other_E
by xx NE
the xxx NE
transactivator xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
tax xxx Protein_molecule
. . NE

Mutagenesis Xxxx Other
indicates xxx NE
that xxx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
can xxx NE
be xx NE
subdivided xxx NE
into xxx NE
three xxx NE
motifs xxx NE
, , NE
A X DNA_substructure
, , NE
B X DNA_substructure
and xxx NE
C X DNA_substructure
, , NE
each xxx NE
of xx NE
which xxx NE
influences xxx NE
the xxx NE
level xxx NE
of xx NE
tax xxx Other_B
activation xxx Other_E
. . NE

The Xxx NE
A X DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
has xxx NE
strong xxx NE
homology xxx NE
with xxx NE
previously xxx NE
described xxx NE
binding xxx DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
for xxx NE
the xxx NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
AP-2 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
was xxx NE
present xxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
and xxx NE
that xxx NE
cellular xxx NE
factors xxx NE
from xxx NE
both xxx NE
non-transformed xxx-xxx NE
and xxx NE
transformed xxx NE
T-lymphocytes X-xxx Cell_natural
specifically xxx NE
bound xxx NE
to xx NE
the xxx NE
consensus xxx NE
motif xxx NE
for xxx NE
AP-2 XX-d NE
in xx NE
each xxx NE
21 dd NE
bp xx NE
. . NE

To Xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
AP-2 XX-d Protein_molecule
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X Other_B
LTR XXX Other_M
gene xxx Other_M
expression xxx Other_E
, , NE
we xx NE
used xxx NE
an xx NE
AP-2 XX-d NE
cDNA xXXX NE
in xx NE
DNA XXX NE
binding xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assays xxx NE
. . NE

Gel Xxx Other_B
retardation xxx Other_E
and xxx NE
methylation xxx Other_B
interference xxx Other_E
studies xxx NE
revealed xxx NE
that xxx NE
bacterially xxx Protein_molecule_B
produced xxx Protein_molecule_M
AP-2 XX-d Protein_molecule_E
bound xxx NE
specifically xxx NE
and xxx NE
with xxx NE
high xxx NE
affinity xxx NE
to xx NE
all xxx NE
three xxx NE
21 dd NE
bp xx NE
repeats xxx NE
, , NE
and xxx NE
that xxx NE
it xx NE
required xxx NE
the xxx NE
core xxx NE
sequence xxx NE
AGGC XXXX NE
for xxx NE
specific xxx NE
binding xxx NE
. . NE

Binding Xxxx NE
of xx NE
AP-2 XX-d Protein_molecule
prevented xxx NE
the xxx NE
subsequent xxx NE
binding xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX Protein_family_or_group_B
family xxx Protein_family_or_group_E
to xx NE
an xx NE
adjacent xxx NE
regulatory xxx NE
motif xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeat xxx NE
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
AP-2 XX-d DNA_molecule_B
expression xxx DNA_molecule_M
construct xxx DNA_molecule_E
into xxx NE
T-lymphocytes X-xxx NE
activated xxx NE
gene xxx NE
expression xxx NE
from xxx NE
the xxx NE
HTLV-I XXXX-X NE
LTR XXX NE
. . NE

At Xx NE
least xxx NE
two xxx NE
21 dd DNA_domain_or_region_B
bp xx DNA_domain_or_region_M
repeats xxx DNA_domain_or_region_E
were xxx NE
required xxx NE
for xxx NE
high xxx NE
levels xxx NE
of xx NE
AP-2 XX-d Protein_molecule
activation xxx NE
and xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
AP-2 XX-d NE
consensus xxx NE
binding xxx NE
sequences xxx NE
in xx NE
the xxx NE
21 dd NE
bp xx NE
repeats xxx NE
eliminate xxx NE
this xxx NE
activation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Peripheral Xxxx Cell_natural_B
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
isolated xxx NE
from xxx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
show xxx NE
increased xxx NE
activation xxx NE
of xx NE
the xxx NE
oxidative-stress xxx-xxx Protein_family_or_group_B
sensitive xxx Protein_family_or_group_M
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
. . NE

Increased Xxxx NE
oxidative xxx Other_B
stress xxx Other_E
and xxx NE
subsequent xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX Protein_complex
has xxx NE
been xxx NE
linked xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
late xxx NE
diabetic xxx Other_B
complications xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
oxidative xxx Other_B
stress xxx Other_E
dependent xxx NE
NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
evident xxx NE
in xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
we xx NE
used xxx NE
an xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assay Xxxx Other_E
based xxx NE
semiquantitative xxx NE
detection xxx NE
system xxx NE
which xxx NE
enabled xxx NE
us xx NE
to xx NE
determine xxx NE
NF-kappaB XX-xxxX Other_B
activation xxx Other_E
in xx NE
ex xx NE
vivo xxx NE
isolated xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
. . NE

We Xx NE
examined xxx NE
33 dd NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
(Type (Xxxx NE
I X NE
and xxx NE
Type Xxxx NE
II) XX) NE
. . NE

Patients Xxxx NE
with xxx NE
diabetic xxx Other_B
nephropathy xxx Other_E
showed xxx NE
higher xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
Electrophoretic Xxxx Other_B
Mobility Xxxx Other_M
Shift Xxxx Other_M
Assays Xxxx Other_E
and xxx NE
stronger xxx NE
immunohistological xxx NE
staining xxx NE
for xxx NE
activated xxx NE
NF-kappaBp65 XX-xxxXxdd Protein_molecule
than xxx NE
patients xxx Multicellular_organism_natural
without xxx NE
renal xxx Other_B
complications xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
albuminuria xxx Other
(r (x NE
= = NE
0.316) d.ddd) NE
and xxx NE
with xxx NE
thrombomodulin xxx Other_B
plasma xxx Other_M
concentrations xxx Other_E
(r (x NE
= = NE
0.33) d.dd) NE
, , NE
indicative xxx NE
for xxx NE
albuminuria xxx NE
associated xxx NE
endothelial xxx NE
dysfunction xxx NE
. . NE

In Xx NE
a x NE
3 d NE
day xxx NE
intervention xxx NE
study xxx NE
in xx NE
which xxx NE
600 ddd NE
mg xx NE
of xx NE
the xxx NE
antioxidant xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
per xxx NE
day xxx NE
were xxx NE
given xxx NE
to xx NE
nine xxx NE
patients xxx NE
with xxx NE
diabetic xxx NE
nephropathy xxx NE
oxidative xxx Other_B
stress xxx Other_E
in xx NE
plasma xxx NE
samples xxx NE
was xxx NE
decreased xxx NE
by xx NE
48% dd% NE
and xxx NE
NF-kappaB XX-xxxX Protein_complex
binding xxx NE
activity xxx NE
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
by xx NE
38% dd% NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NF-kappaB XX-xxxX Protein_complex
in xx NE
ex xx NE
vivo xxx NE
isolated xxx Cell_natural_B
peripheral xxx Cell_natural_M
blood xxx Cell_natural_M
mononuclear xxx Cell_natural_M
cells xxx Cell_natural_E
of xx NE
patients xxx Multicellular_organism_natural
with xxx NE
diabetes xxx Other_B
mellitus xxx Other_E
correlates xxx NE
with xxx NE
the xxx NE
degree xxx NE
of xx NE
diabetic xxx Other_B
nephropathy xxx Other_E
. . NE

NF-kappaB XX-xxxX Protein_complex
activation xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
oxidative xxx Other_B
stress xxx Other_E
since xxx NE
thioctic xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
alpha-lipoic xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
) ) NE
reduced xxx NE
NF-kappaB XX-xxxX Other_B
binding xxx Other_M
activity xxx Other_E
. . NE

The Xxx NE
human xxx Other_B
toll xxx Other_M
signaling xxx Other_M
pathway xxx Other_E
: : NE
divergence xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
kappaB xxxX Protein_complex_E
and xxx NE
JNK XXX NE
/SAPK /XXXX NE
activation xxx NE
upstream xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor-associated xxx-xxx NE
factor xxx NE
6 d NE
( ( NE
TRAF6 XXXXd NE
) ) NE
. . NE

The Xxx NE
human xxx NE
homologue xxx NE
of xx NE
Drosophila Xxxx Protein_molecule_B
Toll Xxxx Protein_molecule_E
( ( NE
hToll xXxxx Protein_molecule
) ) NE
is xx NE
a x NE
recently xxx NE
cloned xxx NE
receptor xxx NE
of xx NE
the xxx NE
interleukin xxx NE
1 d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
) ) NE
superfamily xxx NE
, , NE
and xxx NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
adaptive xxx NE
immunity xxx NE
. . NE

Signaling Xxxx NE
by xx NE
hToll xXxxx Protein_molecule
is xx NE
shown xxx NE
to xx NE
occur xxx NE
through xxx NE
sequential xxx NE
recruitment xxx NE
of xx NE
the xxx NE
adapter xxx Protein_family_or_group_B
molecule xxx Protein_family_or_group_E
MyD88 XxXdd Protein_molecule
and xxx NE
the xxx NE
IL-1R-associated XX-dX-xxx Protein_molecule_B
kinase xxx Protein_molecule_E
. . NE

Tumor Xxxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor xxx Protein_molecule_M
receptor-activated xxx-xxx Protein_molecule_M
factor xxx Protein_molecule_M
6 d Protein_molecule_E
( ( NE
TRAF6 XXXXd Protein_molecule
) ) NE
and xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
)-inducing )-xxx NE
kinase xxx NE
( ( NE
NIK XXX NE
) ) NE
are xxx NE
both xxx NE
involved xxx NE
in xx NE
subsequent xxx NE
steps xxx NE
of xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Conversely Xxxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
version xxx NE
of xx NE
TRAF6 XXXXd NE
failed xxx NE
to xx NE
block xxx NE
hToll xXxxx Protein_molecule
-induced -xxx NE
activation xxx NE
of xx NE
stress-activated xxx-xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_M
kinase/c-Jun xxx/x-Xxx Protein_family_or_group_M
NH2-terminal XXd-xxx Protein_family_or_group_M
kinases xxx Protein_family_or_group_E
, , NE
thus xxx NE
suggesting xxx NE
an xx NE
early xxx NE
divergence xxx NE
of xx NE
the xxx NE
two xxx NE
pathways xxx NE
. . NE

Various Xxxx NE
modes xxx NE
of xx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
protein xxx NE
-mediated -xxx NE
regulation xxx NE
of xx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
transcriptionally xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
regions xxx DNA_domain_or_region_E
of xx NE
the xxx NE
lymphomagenic xxx NE
Akv Xxx NE
and xxx NE
SL3-3 XXd-d NE
murine xxx NE
leukemia xxx NE
retroviruses xxx NE
( ( NE
MLVs XXXx NE
) ) NE
contain xxx NE
two xxx NE
types xxx NE
of xx NE
E-box X-xxx NE
consensus xxx NE
motifs xxx NE
, , NE
CAGATG XXXXXX NE
. . NE

One Xxx NE
type xxx NE
, , NE
EA/S XX/X DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
the xxx NE
upstream xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
, , NE
and xxx NE
the xxx NE
other xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
, , NE
is xx NE
located xxx NE
in xx NE
a x NE
tandem xxx DNA_domain_or_region_B
repeat xxx DNA_domain_or_region_E
with xxx NE
enhancer xxx NE
properties xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
requirements xxx NE
of xx NE
the xxx NE
individual xxx NE
E-boxes X-xxx NE
in xx NE
MLV XXX NE
transcriptional xxx NE
regulation xxx NE
. . NE

In Xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
only xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
-binding -xxx NE
protein xxx NE
complexes xxx NE
included xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
proteins xxx NE
. . NE

Ectopic Xxxx NE
ALF1 XXXd Protein_complex
and xxx NE
E2A XdX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
required xxx NE
intact xxx NE
E(gre) X(xxx) DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
for xxx NE
mediating xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

ALF1 XXXd Other_B
transactivated xxx Other_M
transcription xxx Other_E
of xx NE
Akv Xxx NE
MLV XXX NE
through xxx NE
the xxx NE
two xxx NE
E(gre) X(xxx) NE
motifs xxx NE
equally xxx NE
, , NE
whereas xxx NE
E2A XdX NE
protein xxx NE
required xxx NE
the xxx NE
promoter-proximal xxx-xxx NE
E(gre) X(xxx) NE
motif xxx NE
. . NE

In Xx NE
T- X- NE
and xxx NE
B- X- NE
cell xxx NE
lines xxx NE
, , NE
the xxx NE
E(gre) X(xxx) NE
motifs xxx NE
were xxx NE
of xx NE
major xxx NE
importance xxx NE
for xxx NE
Akv Xxx NE
MLV XXX NE
transcriptional xxx NE
activity xxx NE
, , NE
while xxx NE
the xxx NE
EA/S XX/X NE
motif xxx NE
had xxx NE
some xxx NE
effect xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
neither xxx NE
E(gre) X(xxx) DNA_domain_or_region
nor xxx NE
EA/S XX/X DNA_domain_or_region_B
motifs xxx DNA_domain_or_region_E
contributed xxx NE
pronouncedly xxx NE
to xx NE
Akv Xxx NE
MLV XXX NE
transcription xxx NE
in xx NE
NIH XXX NE
3T3 dXd NE
cells xxx NE
lacking xxx NE
DNA XXX NE
-binding -xxx NE
ALF1 XXXd NE
or xx NE
HEB XXX NE
and xxx NE
E2A XdX NE
proteins xxx NE
. . NE

The Xxx NE
Id1 Xxd NE
protein xxx NE
was xxx NE
found xxx NE
to xx NE
repress xxx NE
ALF1 XXXd Other_B
activity xxx Other_E
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Moreover Xxxx NE
, , NE
ectopic xxx Protein_molecule_B
Id1 Xxd Protein_molecule_E
repressed xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
but xxx NE
not xxx NE
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
E(gre)-directed X(xxx)-xxx Other_B
MLV XXX Other_M
transcription xxx Other_M
but xxx Other_M
not xxx Other_M
EA/S-directed XX/X-xxx Other_M
MLV XXX Other_M
transcription xxx Other_E
in xx NE
lymphoid xxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
. . NE

In Xx NE
conclusion xxx NE
, , NE
E(gre) X(xxx) DNA_domain_or_region
motifs xxx NE
and xxx NE
interacting xxx NE
basic xxx Protein_family_or_group_B
helix-loop-helix xxx-xxx-xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
are xxx NE
important xxx NE
determinants xxx NE
for xxx NE
MLV XXX Other_B
transcriptional xxx Other_M
activity xxx Other_E
in xx NE
lymphocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
is xx NE
responsible xxx NE
for xxx NE
its xxx NE
B X NE
cell xxx NE
-specific -xxx NE
activity xxx NE
and xxx NE
binds xxx NE
to xx NE
a x NE
B X NE
cell xxx NE
110-kDa ddd-xXx NE
nuclear xxx NE
protein xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
as xx NE
well xxx NE
as xx NE
the xxx NE
use xxx NE
of xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
animals xxx Multicellular_organism_genetically_modified_E
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
A-MYB X-XXX Protein_molecule
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
plays xxx NE
central xxx NE
and xxx NE
specific xxx NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
mature xxx Other_B
B X Other_M
cell xxx Other_M
proliferation xxx Other_E
and/or xxx/xx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
is xx NE
highly xxx NE
expressed xxx NE
in xx NE
Burkitt's Xxxx'x Cell_cultured_B
lymphoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
and xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
disease xxx NE
. . NE

We Xx NE
have xxx NE
therefore xxx NE
investigated xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
A-MYB X-XXX Protein_molecule
and xxx NE
its xxx NE
regulation xxx NE
in xx NE
several xxx NE
human xxx Cell_cultured_B
lymphoid xxx Cell_cultured_M
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
using xxx NE
co-transfection xx-xxx NE
assays xxx NE
and xxx NE
show xxx NE
that xxx NE
A-MYB X-XXX Protein_molecule
is xx NE
transcriptionally xxx NE
active xxx NE
in xx NE
all xxx NE
the xxx NE
B X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
studied xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

In Xx NE
particular xxx NE
the xxx NE
best xxx NE
responder xxx Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
was xxx NE
the xxx NE
Burkitt's Xxxx'x Cell_cultured_B
cell xxx Cell_cultured_M
line xxx Cell_cultured_M
Namalwa Xxxx Cell_cultured_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
A-MYB X-XXX Protein_molecule
in xx NE
B X NE
and xxx NE
not xxx NE
T X NE
cells xxx NE
was xxx NE
observed xxx NE
when xxx NE
either xxx NE
an xx NE
artificial xxx NE
construct xxx NE
or xx NE
the xxx NE
c-MYC x-XXX NE
promoter xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
reporter xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
functional xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
responsible xxx NE
for xxx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
transactivation xxx Other
, , NE
and xxx NE
negative xxx Other_B
regulation xxx Other_E
, , NE
previously xxx NE
characterized xxx NE
in xx NE
a x NE
fibroblast xxx NE
context xxx NE
, , NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
similar xxx NE
activity xxx NE
in xx NE
B X Cell_natural_B
cells xxx Cell_natural_E
. . NE

The Xxx NE
region xxx NE
of xx NE
A-MYB X-XXX NE
responsible xxx NE
for xxx NE
the xxx NE
B X Other_B
cell xxx Other_M
specific xxx Other_M
activity xxx Other_E
was xxx NE
defined xxx NE
to xx NE
be xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
218 ddd Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
containing xxx NE
the xxx NE
DNA XXX Protein_domain_or_region_B
binding xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

Finally Xxxx NE
, , NE
a x NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
all xxx NE
the xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
T X NE
, , NE
cell xxx NE
lines xxx NE
that xxx NE
specifically xxx NE
binds xxx NE
to xx NE
this xxx NE
A-MYB X-XXX NE
N-terminal X-xxx NE
domain xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
this xxx NE
110-kDa ddd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
may xxx NE
be xx NE
a x NE
functionally xxx NE
important xxx NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
co-activator xx-xxx Protein_family_or_group_E
of xx NE
A-MYB X-XXX Protein_molecule
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
is xx NE
mediated xxx NE
through xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid xxx Protein_family_or_group_B
lineage-determining xxx-xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
Ikaros Xxxx Protein_molecule
and xxx NE
Aiolos Xxxx Protein_molecule
can xxx NE
function xxx NE
as xx NE
strong xxx Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
repressors xxx Protein_family_or_group_E
. . NE

This Xxxx NE
function xxx NE
is xx NE
mediated xxx NE
through xxx NE
two xxx NE
repression xxx Protein_family_or_group_B
domains xxx Protein_family_or_group_E
and xxx NE
is xx NE
dependent xxx NE
upon xxx NE
the xxx NE
promoter xxx DNA_domain_or_region_B
context xxx DNA_domain_or_region_E
and xxx NE
cell xxx Cell_natural_B
type xxx Cell_natural_E
. . NE

Repression Xxxx NE
by xx NE
Ikaros Xxxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
correlates xxx NE
with xxx NE
hypo-acetylation xxx-xxx NE
of xx NE
core xxx NE
histones xxx NE
at xx NE
promoter xxx NE
sites xxx NE
and xxx NE
is xx NE
relieved xxx NE
by xx NE
histone xxx NE
deacetylase xxx NE
inhibitors xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
Ikaros Xxxx Protein_molecule
and xxx NE
its xxx NE
repression xxx Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
can xxx NE
interact xxx NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
with xxx NE
the xxx NE
mSin3 xXxxd NE
family xxx NE
of xx NE
co-repressors xx-xxx NE
which xxx NE
bind xxx NE
to xx NE
histone xxx Protein_family_or_group_B
deacetylases xxx Protein_family_or_group_E
. . NE

Based Xxxx NE
on xx NE
these xxx NE
and xxx NE
our xxx NE
recent xxx NE
findings xxx NE
of xx NE
associations xxx NE
between xxx NE
Ikaros Xxxx Protein_molecule
and xxx NE
Mi-2-HDAC Xx-d-XXXX Protein_molecule
, , NE
we xx NE
propose xxx NE
that xxx NE
Ikaros Xxxx Protein_family_or_group_B
family xxx Protein_family_or_group_M
members xxx Protein_family_or_group_E
modulate xxx NE
gene xxx NE
expression xxx NE
during xxx NE
lymphocyte xxx NE
development xxx NE
by xx NE
recruiting xxx NE
distinct xxx NE
histone xxx NE
deacetylase xxx NE
complexes xxx NE
to xx NE
specific xxx NE
promoters xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophil xxx Cell_natural
interleukin-8 xxx-d Other_B
production xxx Other_E
by xx NE
eosinophil xxx NE
granule xxx NE
major xxx NE
basic xxx NE
protein xxx NE
. . NE

We Xx NE
evaluated xxx NE
the xxx NE
ability xxx NE
of xx NE
eosinophil xxx Protein_molecule_B
granule xxx Protein_molecule_M
major xxx Protein_molecule_M
basic xxx Protein_molecule_M
protein xxx Protein_molecule_E
( ( NE
MBP XXX Protein_molecule
) ) NE
to xx NE
stimulate xxx NE
interleukin xxx Other_B
(IL)-8 (XX)-d Other_M
production xxx Other_E
by xx NE
neutrophils xxx NE
. . NE

MBP XXX Protein_molecule
over xxx NE
the xxx NE
concentration xxx NE
range xxx NE
of xx NE
0.1 d.d NE
to xx NE
10 dd NE
microM xxxX NE
stimulated xxx NE
the xxx NE
release xxx NE
of xx NE
up xx NE
to xx NE
approximately xxx NE
8 d NE
ng/ml xx/xx NE
IL-8 XX-d Protein_molecule
. . NE

Incubation Xxxx NE
with xxx NE
2 d NE
microM xxxX NE
MBP XXX Protein_molecule
showed xxx NE
that xxx NE
, , NE
after xxx NE
a x NE
1 d NE
h x NE
lag xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
IL-8 XX-d Protein_molecule
release xxx NE
increased xxx NE
with xxx NE
time xxx NE
for xxx NE
approximately xxx NE
10 dd NE
h x NE
. . NE

At Xx NE
the xxx NE
2 d NE
microM xxxX NE
concentration xxx NE
, , NE
eosinophil xxx Protein_molecule_B
cationic xxx Protein_molecule_M
protein xxx Protein_molecule_E
, , NE
eosinophil-derived xxx-xxx Organic_compound_other_B
neurotoxin xxx Organic_compound_other_E
, , NE
and xxx NE
eosinophil xxx Protein_molecule_B
peroxidase xxx Protein_molecule_E
did xxx NE
not xxx NE
stimulate xxx NE
significant xxx NE
levels xxx NE
of xx NE
IL-8 XX-d Other_B
production xxx Other_E
. . NE

MBP XXX Protein_molecule
stimulated xxx NE
2-fold d-xxx NE
increases xxx NE
in xx NE
IL-8 XX-d RNA_molecule_B
messenger xxx RNA_molecule_M
RNA XXX RNA_molecule_E
( ( NE
mRNA xXXX NE
) ) NE
after xxx NE
1 d NE
and xxx NE
3 d NE
h x NE
of xx NE
incubation xxx NE
, , NE
which xxx NE
were xxx NE
blocked xxx NE
by xx NE
pretreatment xxx NE
with xxx NE
actinomycin xxx NE
D X NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
did xxx NE
not xxx NE
produce xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
nuclear xxx Protein_complex_B
factor xxx Protein_complex_M
(NF)-kappaB (XX)-xxxX Protein_complex_E
or xx NE
activator xxx Protein_molecule_B
protein-1 xxx-d Protein_molecule_E
. . NE

No Xx NE
NF-IL-6 XX-XX-d Other_B
binding xxx Other_M
activity xxx Other_E
was xxx NE
detected xxx NE
in xx NE
the xxx NE
same xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
stimulation xxx NE
with xxx NE
MBP XXX Protein_molecule
prolonged xxx NE
the xxx NE
stability xxx NE
of xx NE
IL-8 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
. . NE

MBP XXX Protein_molecule
also xxx NE
induced xxx NE
transient xxx NE
increases xxx NE
in xx NE
mRNA xXXX RNA_family_or_group
for xxx NE
macrophage xxx Protein_molecule_B
inflammatory xxx Protein_molecule_M
protein xxx Protein_molecule_M
(MIP)-1alpha (XXX)-dxxx Protein_molecule_E
and xxx NE
MIP-1beta XXX-dxxx Protein_molecule
, , NE
but xxx NE
did xxx NE
not xxx NE
stimulate xxx NE
the xxx NE
release xxx NE
of xx NE
either xxx NE
chemokine xxx Protein_family_or_group
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
MBP XXX Protein_molecule
is xx NE
selective xxx NE
among xxx NE
the xxx NE
eosinophil xxx Protein_family_or_group_B
granule xxx Protein_family_or_group_M
proteins xxx Protein_family_or_group_E
as xx NE
a x NE
stimulus xxx NE
for xxx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
and xxx NE
, , NE
further xxx NE
, , NE
that xxx NE
stimulation xxx NE
of xx NE
neutrophil xxx Other_B
IL-8 XX-d Other_M
release xxx Other_E
by xx NE
MBP XXX NE
involves xxx NE
both xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
regulation xxx NE
. . NE

We Xx NE
postulate xxx NE
that xxx NE
MBP XXX NE
-induced -xxx NE
release xxx NE
of xx NE
IL-8 XX-d NE
by xx NE
neutrophils xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
pathophysiology xxx NE
of xx NE
acute xxx NE
asthma xxx NE
and xxx NE
other xxx NE
inflammatory xxx NE
lung xxx NE
diseases xxx NE
. . NE

IFN-gamma XXX-xxx Protein_molecule
priming xxx NE
of xx NE
monocytes xxx Cell_natural
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx Other_B
expression xxx Other_E
in xx NE
monocytes xxx NE
/ / NE
macrophages xxx NE
by xx NE
bacterial xxx NE
endotoxin xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX Lipid
responses xxx NE
by xx NE
interferon xxx Protein_molecule_B
gamma xxx Protein_molecule_E
( ( NE
IFN-gamma XXX-xxx Protein_molecule
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx Protein_molecule
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX Other_B
mRNA xXXX Other_M
accumulation xxx Other_E
. . NE

IFN-gamma XXX-xxx Other_B
pre-treatment xxx-xxx Other_E
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx Other
, , NE
and xxx NE
the xxx NE
primed xxx Other_B
state xxx Other_E
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx Protein_molecule
or xx NE
GM-CSF XX-XXX Protein_molecule
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX Protein_molecule
. . NE

Primed Xxxx NE
monocytes xxx Cell_natural
transcribed xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx NE
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx Other_B
rate xxx Other_E
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B X Other_M
activity xxx Other_E
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx NE
NF-kappa XX-xxx NE
B X NE
oligonucleotide xxx NE
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
induced xxx NE
in xx NE
primed xxx NE
cells xxx NE
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX Other_B
stability xxx Other_E
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx NE
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx Organic_compound_other_B
inhibitor xxx Organic_compound_other_M
H-89 X-dd Organic_compound_other_E
. . NE

H-89 X-dd Organic_compound_other
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Two Xxx NE
distinct xxx NE
pathways xxx NE
of xx NE
interleukin-5 xxx-d Other_B
synthesis xxx Other_E
in xx NE
allergen-specific xxx-xxx NE
human xxx NE
T-cell X-xxx NE
clones xxx NE
are xxx NE
suppressed xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx Lipid
( ( NE
GC XX Lipid
) ) NE
have xxx NE
long xxx NE
been xxx NE
used xxx NE
as xx NE
the xxx NE
most xxx NE
effective xxx NE
agents xxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx Other_B
diseases xxx Other_E
accompanied xxx NE
by xx NE
eosinophilia xxx Other
such xxx NE
as xx NE
chronic xxx Other_B
asthma xxx Other_E
and xxx NE
atopic xxx Other_B
dermatitis xxx Other_E
. . NE

The Xxx NE
development xxx NE
of xx NE
chronic xxx Other_B
eosinophilic xxx Other_M
inflammation xxx Other_E
is xx NE
dependent xxx NE
on xx NE
interleukin-5 xxx-d Protein_molecule
( ( NE
IL-5 XX-d Protein_molecule
) ) NE
, , NE
a x NE
selective xxx Protein_family_or_group_B
eosinophil-activating xxx-xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_E
, , NE
produced xxx NE
by xx NE
helper xxx Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

To Xx NE
delineate xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
human xxx Other_B
IL-5 XX-d Other_M
synthesis xxx Other_E
, , NE
we xx NE
established xxx NE
allergen-specific xxx-xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
from xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

GC XX Lipid
efficiently xxx NE
suppressed xxx NE
IL-5 XX-d Other_B
synthesis xxx Other_E
of xx NE
T-cell X-xxx NE
clones xxx NE
activated xxx NE
via xxx NE
either xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
or xx NE
IL-2 XX-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
. . NE

Induction Xxxx NE
of xx NE
IL-5 XX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
upon xxx NE
TCR XXX NE
and xxx NE
IL-2R XX-dX NE
stimulation xxx NE
was xxx NE
totally xxx NE
inhibited xxx NE
by xx NE
dexamethasone xxx NE
. . NE

Human Xxxx NE
IL-5 XX-d NE
promoter/enhancer-luciferase xxx/xxx-xxx NE
gene xxx NE
construct xxx NE
transfected xxx NE
to xx NE
T-cell X-xxx Cell_cultured_B
clones xxx Cell_cultured_E
was xxx NE
transcribed xxx NE
on xx NE
either xxx NE
TCR XXX Protein_family_or_group
or xx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
and xxx NE
was xxx NE
clearly xxx NE
downregulated xxx NE
by xx NE
dexamethasone xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
approximately xxx NE
500-bp ddd-xx NE
human xxx NE
IL-5 XX-d NE
gene xxx NE
segment xxx NE
located xxx NE
5' d' NE
upstream xxx NE
of xx NE
the xxx NE
coding xxx NE
region xxx NE
contains xxx NE
activation xxx NE
-inducible -xxx NE
enhancer xxx NE
elements xxx NE
responsible xxx NE
for xxx NE
the xxx NE
regulation xxx NE
by xx NE
GC XX NE
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assay xxx Other_M
analysis xxx Other_E
suggested xxx NE
that xxx NE
AP-1 XX-d Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
are xxx NE
among xxx NE
the xxx NE
possible xxx NE
targets xxx NE
of xx NE
GC XX Other_B
actions xxx Other_E
on xx NE
TCR XXX NE
-stimulated -xxx NE
T X NE
cells xxx NE
. . NE

NF-AT XX-XX Protein_molecule
and xxx NE
NF-kappaB XX-xxxX Protein_complex
were xxx NE
not xxx NE
significantly xxx NE
induced xxx NE
by xx NE
IL-2 XX-d Other_B
stimulation xxx Other_E
. . NE

Our Xxx NE
results xxx NE
showing xxx NE
that xxx NE
GC XX Lipid
suppressed xxx NE
IL-5 XX-d Protein_molecule
production xxx NE
by xx NE
human xxx Cell_natural_B
CD4+ XXd+ Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
by xx NE
two xxx NE
distinct xxx NE
stimuli xxx NE
, , NE
TCR XXX Protein_family_or_group
and xxx NE
IL-2R XX-dX Other_B
stimulation xxx Other_E
, , NE
underscore xxx NE
the xxx NE
efficacy xxx NE
of xx NE
GC XX NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
allergic xxx NE
diseases xxx NE
via xxx NE
suppression xxx NE
of xx NE
T-cell X-xxx NE
IL-5 XX-d NE
synthesis xxx NE
. . NE

Differential Xxxx NE
expression xxx NE
and xxx NE
phosphorylation xxx Other
of xx NE
CTCF XXXX Protein_molecule
, , NE
a x NE
c-myc x-xxx NE
transcriptional xxx NE
regulator xxx NE
, , NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
cells xxx NE
. . NE

CTCF XXXX Protein_molecule
is xx NE
a x NE
transcriptional xxx NE
repressor xxx NE
of xx NE
the xxx NE
c-myc x-xxx NE
gene xxx NE
. . NE

Although Xxxx NE
CTCF XXXX Protein_molecule
has xxx NE
been xxx NE
characterized xxx NE
in xx NE
some xxx NE
detail xxx NE
, , NE
there xxx NE
is xx NE
very xxx NE
little xxx NE
information xxx NE
about xxx NE
the xxx NE
regulation xxx NE
of xx NE
CTCF XXXX Other_B
activity xxx Other_E
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
phosphorylation xxx NE
during xxx NE
induced xxx NE
differentiation xxx NE
of xx NE
human xxx NE
myeloid xxx NE
leukemia xxx NE
cells xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
: : NE
(i) (x) NE
both xxx NE
CTCF XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
and xxx NE
protein xxx NE
are xxx NE
down-regulated xxx-xxx NE
during xxx NE
terminal xxx NE
differentiation xxx NE
in xx NE
most xxx NE
cell xxx NE
lines xxx NE
tested xxx NE
; ; NE
(ii) (xx) NE
CTCF XXXX NE
down-regulation xxx-xxx NE
is xx NE
retarded xxx NE
and xxx NE
less xxx NE
pronounced xxx NE
than xxx NE
that xxx NE
of xx NE
c-myc x-xxx NE
; ; NE
(iii) (xxx) NE
CTCF XXXX NE
protein xxx NE
is xx NE
differentially xxx NE
phosphorylated xxx NE
and xxx NE
the xxx NE
phosphorylation xxx NE
profiles xxx NE
depend xxx NE
on xx NE
the xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

We Xx NE
concluded xxx NE
that xxx NE
CTCF XXXX Other_B
expression xxx Other_E
and xxx NE
activity xxx NE
is xx NE
controlled xxx NE
at xx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
levels xxx NE
. . NE

Role Xxxx NE
of xx NE
IKK1 XXXd Protein_molecule
and xxx NE
IKK2 XXXd Protein_molecule
in xx NE
lipopolysaccharide xxx Other_B
signaling xxx Other_E
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
. . NE

Mononuclear Xxxx Cell_natural_B
phagocytes xxx Cell_natural_E
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
immune xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Bacterial Xxxx Lipid_B
lipopolysaccharide xxx Lipid_E
( ( NE
LPS XXX Lipid
) ) NE
induces xxx NE
monocytes xxx Cell_natural
to xx NE
express xxx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
by xx NE
activating xxx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
family xxx Protein_family_or_group_E
. . NE

Recently Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
the xxx NE
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
tumor xxx Other_B
necrosis xxx Other_M
factor xxx Other_M
signaling xxx Other_M
pathway xxx Other_M
and xxx Other_M
interleukin xxx Other_M
1 d Other_M
signaling xxx Other_M
pathway xxx Other_E
IKK1 XXXd NE
and xxx NE
IKK2 XXXd Protein_molecule
. . NE

Phosphorylation Xxxx NE
of xx NE
the xxx NE
IkappaB XxxxX Protein_family_or_group_B
cytoplasmic xxx Protein_family_or_group_M
inhibitors xxx Protein_family_or_group_E
, , NE
IkappaBalpha XxxxXxxx NE
, , NE
IkappaBbeta XxxxXxxx NE
, , NE
and xxx NE
IkappaBepsilon XxxxXxxx NE
, , NE
by xx NE
these xxx NE
kinases xxx NE
triggers xxx NE
proteolytic xxx NE
degradation xxx NE
and xxx NE
the xxx NE
release xxx NE
of xx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
proteins xxx NE
into xxx NE
the xxx NE
nucleus xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
the xxx NE
IKKs XXXx NE
in xx NE
LPS XXX Lipid
signaling xxx NE
has xxx NE
not xxx NE
been xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
LPS XXX Lipid
induces xxx NE
IKK XXX Other_B
activity xxx Other_E
in xx NE
human xxx NE
monocytes xxx NE
and xxx NE
THP-1 XXX-d NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
activation xxx NE
of xx NE
kinase xxx Other_B
activity xxx Other_E
in xx NE
monocytic xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
relatively xxx NE
slow xxx NE
with xxx NE
maximal xxx NE
activity xxx NE
observed xxx NE
at xx NE
60 dd NE
min xxx NE
, , NE
which xxx NE
coincides xxx NE
with xxx NE
the xxx NE
degradation xxx NE
of xx NE
IkappaBs XxxxXx Protein_family_or_group
and xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappaB XX-xxxX Protein_complex
. . NE

In Xx NE
transfection xxx NE
experiments xxx NE
, , NE
overexpression xxx NE
of xx NE
wild xxx NE
type xxx NE
IKK1 XXXd Protein_molecule
, , NE
a x NE
dominant xxx Protein_molecule_B
negative xxx Protein_molecule_M
mutant xxx Protein_molecule_M
IKK1 XXXd Protein_molecule_E
( ( NE
K44M XddX NE
) ) NE
, , NE
or xx NE
wild xxx NE
type xxx NE
IKK2 XXXd NE
did xxx NE
not xxx NE
affect xxx NE
LPS XXX NE
-induced -xxx NE
kappaB xxxX NE
-dependent -xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
dominant xxx NE
negative xxx NE
mutant xxx NE
of xx NE
IKK2 XXXd Protein_molecule
inhibited xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX Protein_molecule
-dependent -xxx NE
transcription xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx Other_B
manner xxx Other_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LPS XXX Lipid
induction xxx NE
of xx NE
kappaB xxxX NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx Cell_natural_B
monocytic xxx Cell_natural_M
cells xxx Cell_natural_E
requires xxx NE
activation xxx NE
of xx NE
IKK2 XXXd NE
. . NE

OBF-1 XXX-d Protein_molecule
, , NE
a x NE
novel xxx Protein_family_or_group_B
B X Protein_family_or_group_M
cell-specific xxx-xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx Other_B
promoter xxx Other_M
activity xxx Other_E
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx NE
proteins xxx NE
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
, , NE
other xxx NE
B X Protein_family_or_group_B
cell xxx Protein_family_or_group_M
components xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted xxx-xxx NE
, , NE
octamer xxx NE
site xxx NE
-mediated -xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_family_or_group_B
cell-derived xxx-xxx DNA_family_or_group_M
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
Oct-binding Xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_M
1 d Protein_molecule_E
( ( NE
OBF-1 XXX-d Protein_molecule
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d Protein_molecule
and xxx NE
Oct-2 Xxx-d Protein_molecule
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d Protein_molecule
has xxx NE
no xx NE
intrinsic xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX Protein_domain_or_region_B
domains xxx Protein_domain_or_region_E
of xx NE
Oct-1 Xxx-d Protein_domain_or_region
and xxx NE
Oct-2 Xxx-d Protein_domain_or_region
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d Protein_domain_or_region
and xxx NE
Oct-6 Xxx-d Protein_domain_or_region
. . NE

The Xxx NE
OBF-1 XXX-d RNA_molecule_B
mRNA xXXX RNA_molecule_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X NE
cells xxx NE
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d Protein_molecule
in xx NE
HeLa XxXx Cell_cultured_B
cells xxx Cell_cultured_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d Protein_molecule
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X Protein_family_or_group_B
cell-specific xxx-xxx Protein_family_or_group_M
transcriptional xxx Protein_family_or_group_M
coactivator xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
. . NE

Differential Xxxx NE
utilization xxx NE
of xx NE
Janus Xxxx NE
kinase xxx NE
-signal -xxx NE
transducer xxx NE
activator xxx NE
of xx NE
transcription xxx NE
signaling xxx NE
pathways xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
human xxx NE
natural xxx NE
killer xxx NE
cells xxx NE
by xx NE
IL-2 XX-d NE
, , NE
IL-12 XX-dd NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
. . NE

IL-2 XX-d NE
- - NE
, , NE
IL-12 XX-dd NE
- - NE
, , NE
and xxx NE
IFN-alpha XXX-xxx NE
- - NE
mediated xxx NE
signaling xxx NE
pathways xxx NE
were xxx NE
analyzed xxx NE
in xx NE
primary xxx NE
NK XX NE
cells xxx NE
and xxx NE
in xx NE
the xxx NE
NK3.3 XXd.d NE
cell xxx NE
line xxx NE
. . NE

Gel Xxx Other_B
mobility xxx Other_M
shift xxx Other_E
and xxx NE
immunoprecipitation xxx NE
analyses xxx NE
revealed xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
activating xxx NE
STAT3 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-3 xxx-d NE
) ) NE
and xxx NE
STAT5 XXXXd NE
, , NE
IL-2 XX-d NE
induced xxx NE
tyrosine xxx NE
and xxx NE
serine xxx NE
phosphorylation xxx NE
of xx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
which xxx NE
formed xxx NE
IFN-gamma XXX-xxx NE
-activated -xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
by xx NE
itself xxx NE
and xxx NE
with xxx NE
STAT3 XXXXd NE
. . NE

Although Xxxx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
and xxx NE
STAT5 XXXXd Protein_molecule
, , NE
IL-2 XX-d Protein_molecule
predominantly xxx NE
activated xxx NE
STAT5 XXXXd Protein_molecule
, , NE
while xxx NE
IFN-alpha XXX-xxx Protein_molecule
predominantly xxx NE
activated xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
. . NE

IL-2 XX-d Protein_molecule
induced xxx NE
less xxx NE
STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
induced xxx NE
greater xxx NE
STAT5 XXXXd Other_B
activation xxx Other_E
in xx NE
NK3.3 XXd.d NE
cells xxx NE
compared xxx NE
with xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

In Xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
comparable xxx NE
formation xxx NE
of xx NE
c-fos x-xxx NE
promoter xxx NE
sis-inducible xxx-xxx NE
element xxx NE
IFN-gamma-activated XXX-xxx-xxx NE
sequence xxx NE
-binding -xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
alone xxx NE
with xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
while xxx NE
in xx NE
preactivated xxx Cell_cultured_B
primary xxx Cell_cultured_M
NK XX Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
it xx NE
preferentially xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT3 XXXXd NE
and xxx NE
STAT1 XXXXd NE
alpha xxx NE
. . NE

Thus Xxxx NE
, , NE
signaling xxx NE
in xx NE
NK3.3 XXd.d Cell_cultured_B
cells xxx Cell_cultured_E
is xx NE
not xxx NE
always xxx NE
identical xxx NE
with xxx NE
that xxx NE
in xx NE
primary xxx Cell_natural_B
NK XX Cell_natural_M
cells xxx Cell_natural_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-2 XX-d Protein_molecule
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
induced xxx NE
strong xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
STAT4 XXXXd NE
and xxx NE
variable xxx NE
weak xxx NE
phosphorylation xxx NE
of xx NE
STAT3 XXXXd NE
. . NE

However Xxxx NE
, , NE
supershift xxx NE
analyses xxx NE
using xxx NE
the xxx NE
c-fos x-xxx DNA_molecule_B
promoter xxx DNA_molecule_M
sis-inducible xxx-xxx DNA_molecule_M
element xxx DNA_molecule_M
probe xxx DNA_molecule_E
showed xxx NE
that xxx NE
IL-12 XX-dd NE
activated xxx NE
STAT4 XXXXd NE
, , NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
and xxx NE
STAT3 XXXXd NE
, , NE
and xxx NE
induced xxx NE
complexes xxx NE
containing xxx NE
STAT4 XXXXd NE
only xxx NE
, , NE
STAT4 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
STAT3 XXXXd NE
with xxx NE
STAT1 XXXXd NE
alpha xxx NE
, , NE
or xx NE
STAT1 XXXXd NE
alpha xxx NE
only xxx NE
in xx NE
preactivated xxx NE
primary xxx NE
NK XX NE
cells xxx NE
. . NE

STAT1 XXXXd Protein_molecule_B
alpha xxx Protein_molecule_E
activation xxx NE
by xx NE
IL-12 XX-dd Protein_molecule
correlated xxx NE
with xxx NE
increased xxx NE
phosphorylation xxx NE
of xx NE
serine xxx Amino_acid_monomer
, , NE
but xxx NE
not xxx NE
tyrosine xxx Amino_acid_monomer
. . NE

Finally Xxxx NE
, , NE
IL-2 XX-d Protein_molecule
induced xxx NE
tyrosine xxx Other_B
phosphorylation xxx Other_E
of xx NE
JAK1 XXXd NE
and xxx NE
JAK3 XXXd NE
, , NE
while xxx NE
IL-12 XX-dd NE
induced xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd NE
and xxx NE
TYK2 XXXd NE
in xx NE
both xxx NE
preactivated xxx NE
primary xxx NE
NK XX NE
and xxx NE
NK3.3 XXd.d NE
cells xxx NE
. . NE

Differential Xxxx Other_B
phosphorylation xxx Other_E
and xxx NE
consequent xxx NE
differential xxx Other_B
activation xxx Other_E
of xx NE
both xxx NE
separate xxx NE
and xxx NE
overlapping xxx NE
STAT XXXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
by xx NE
IL-2 XX-d Protein_molecule
, , NE
IL-12 XX-dd Protein_molecule
, , NE
and xxx NE
IFN-alpha XXX-xxx Protein_molecule
may xxx NE
provide xxx NE
a x NE
molecular xxx NE
basis xxx NE
for xxx NE
the xxx NE
similarities xxx NE
and xxx NE
differences xxx NE
in xx NE
the xxx NE
actions xxx NE
of xx NE
these xxx NE
cytokines xxx Protein_family_or_group
on xx NE
NK XX Cell_natural_B
cells xxx Cell_natural_E
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx Cell_natural_B
lymphocytes xxx Cell_natural_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
( ( NE
G0S3 XdXd DNA_domain_or_region
) ) NE
. . NE

G0S3 XdXd DNA_domain_or_region
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_family_or_group_B
G0/G1 Xd/Xd DNA_family_or_group_M
switch xxx DNA_family_or_group_M
regulatory xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
( ( NE
G0S XdX DNA_family_or_group_B
genes xxx DNA_family_or_group_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_domain_or_region_B
FOSB XXXX DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd NE
transcriptional xxx NE
regulator xxx NE
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA_family_or_group
and xxx NE
genomic xxx DNA_domain_or_region_B
sequences xxx DNA_domain_or_region_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_domain_or_region_B
structure xxx DNA_domain_or_region_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_family_or_group_B
family xxx DNA_family_or_group_M
of xx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd NE
and xxx NE
FOS/G0S7 XXX/XdXd NE
mRNAs xXXXx NE
, , NE
which xxx NE
decline xxx NE
rapidly xxx NE
during xxx NE
incubation xxx NE
in xx NE
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx Other_B
expression xxx Other_E
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_molecule_B
mRNA xXXX RNA_molecule_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx Protein_family_or_group
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX NE
and xxx NE
FOSB XXXX NE
mRNAs xXXXx NE
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx Organic_compound_other
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA_domain_or_region
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA_domain_or_region
and xxx NE
FOSB XXXX DNA_domain_or_region
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx Other_B
stability xxx Other_E
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx Other_B
regulation xxx Other_E
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx NE
DNA XXX NE
sequences xxx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX NE
transcripts xxx NE
encoded xxx NE
by xx NE
the xxx NE
murine xxx NE
p105 xddd NE
NF-kappa XX-xxx NE
B X NE
gene xxx NE
generates xxx NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
isoforms xxx NE
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
generates xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd NE
. . NE

One Xxx NE
63-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
termed xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
, , NE
which xxx NE
lacks xxx NE
59 dd Peptide_B
amino xxx Peptide_M
acids xxx Peptide_E
C-terminal X-xxx NE
to xx NE
ankyrin xxx Protein_domain_or_region_B
repeat xxx Protein_domain_or_region_M
7 d Protein_domain_or_region_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx Protein_domain_or_region_B
acid xxx Protein_domain_or_region_M
C X Protein_domain_or_region_M
terminus xxx Protein_domain_or_region_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
the xxx NE
p105 xddd DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

A X NE
55-kDa dd-xXx Protein_molecule_B
isoform xxx Protein_molecule_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
, , NE
lacks xxx NE
the xxx NE
190 ddd Protein_domain_or_region_B
C-terminal X-xxx Protein_domain_or_region_M
amino xxx Protein_domain_or_region_M
acids xxx Protein_domain_or_region_E
of xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx Protein_family_or_group_B
protein xxx Protein_family_or_group_E
, , NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx Cell_component
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibits xxx NE
p50 xdd NE
- - NE
, , NE
p65 xdd NE
- - NE
, , NE
and xxx NE
c-Rel x-Xxx NE
-mediated -xxx NE
transactivation xxx NE
and/or xxx/xx NE
DNA XXX Other_B
binding xxx Other_E
, , NE
both xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd Protein_molecule
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-1 xxx-d Protein_molecule_E
and xxx NE
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma-2 xxx-d Protein_molecule_E
of xx NE
a x NE
protein xxx DNA_domain_or_region_B
kinase xxx DNA_domain_or_region_M
A X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd Protein_molecule
I X Protein_molecule_B
kappa xxx Protein_molecule_M
B X Protein_molecule_M
gamma xxx Protein_molecule_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX Other_B
splicing xxx Other_E
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X Protein_family_or_group_B
kappa xxx Protein_family_or_group_M
B X Protein_family_or_group_M
gamma xxx Protein_family_or_group_M
isoforms xxx Protein_family_or_group_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Ex Xx NE
vivo xxx NE
activation xxx NE
of xx NE
tumor-draining xxx-xxx Cell_natural_B
lymph xxx Cell_natural_M
node xxx Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
reverses xxx NE
defects xxx NE
in xx NE
signal xxx NE
transduction xxx NE
molecules xxx NE
. . NE

The Xxx NE
adoptive xxx NE
transfer xxx NE
of xx NE
tumor-draining xxx-xxx Body_region_B
lymph xxx Body_region_M
node xxx Body_region_E
( ( NE
LN XX Body_region
) ) NE
T X Cell_natural_B
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
with xxx NE
anti-CD3 xxx-XXd Protein_molecule
and xxx NE
interleukin xxx Protein_molecule_B
2 d Protein_molecule_E
( ( NE
IL-2 XX-d Protein_molecule
) ) NE
mediates xxx NE
the xxx NE
regression xxx NE
of xx NE
the xxx NE
poorly xxx Tissue_natural_B
immunogenic xxx Tissue_natural_M
murine xxx Tissue_natural_M
melanoma xxx Tissue_natural_M
D5 Xd Tissue_natural_E
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
the xxx NE
activated xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
is xx NE
augmented xxx NE
when xxx NE
the xxx NE
sensitizing xxx NE
tumor xxx NE
is xx NE
a x NE
genetically xxx Cell_cultured_B
modified xxx Cell_cultured_M
variant xxx Cell_cultured_E
(designated (xxx NE
D5G6 XdXd Cell_cultured
) ) NE
that xxx NE
secretes xxx NE
granulocyte/macrophage-colony-stimulating xxx/xxx-xxx-xxx Protein_molecule_B
factor xxx Protein_molecule_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
anti-CD3 xxx-XXd NE
/ / NE
IL-2 XX-d Protein_molecule
-activated -xxx NE
LN XX Cell_natural_B
cells xxx Cell_natural_E
, , NE
adoptive xxx NE
transfer xxx NE
of xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
has xxx NE
no xx NE
therapeutic xxx Other_B
activity xxx Other_E
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
during xxx NE
ex xx NE
vivo xxx NE
activation xxx NE
is xx NE
associated xxx NE
with xxx NE
modifications xxx NE
in xx NE
signal xxx Other_B
transduction xxx Other_M
capacity xxx Other_E
, , NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinases xxx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
and xxx NE
proteins xxx NE
of xx NE
the xxx NE
NF-kappaB XX-xxxX Protein_family_or_group_B
family xxx Protein_family_or_group_E
were xxx NE
analyzed xxx NE
in xx NE
tumor-draining xxx-xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
. . NE

The Xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
and xxx NE
p59fyn xddxxx Protein_molecule
were xxx NE
lower xxx NE
in xx NE
tumor-draining xxx-xxx NE
than xxx NE
in xx NE
normal xxx Cell_natural_B
LN XX Cell_natural_M
T X Cell_natural_M
cells xxx Cell_natural_E
and xxx NE
production xxx NE
of xx NE
tyrosine xxx NE
-phosphorylated -xxx NE
substrates xxx NE
was xxx NE
markedly xxx NE
depressed xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

After Xxxx NE
5-day d-xxx NE
anti-CD3 xxx-XXd Protein_molecule
/IL-2 /XX-d NE
activation xxx NE
, , NE
levels xxx NE
of xx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
and xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
increased xxx NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
p56lck xddxxx Protein_molecule
, , NE
p59fyn xddxxx Protein_molecule
, , NE
and xxx NE
tyrosine xxx Other_B
kinase xxx Other_M
activity xxx Other_E
were xxx NE
higher xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
derived xxx NE
from xxx NE
LN XX NE
that xxx NE
drained xxx NE
D5G6 XdXd NE
than xxx NE
they xxx NE
were xxx NE
in xx NE
those xxx NE
from xxx NE
D5 Xd NE
tumors xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
cytoplasmic xxx Other_B
levels xxx Other_E
of xx NE
c-Rel x-Xxx Protein_molecule
and xxx NE
Rel Xxx Protein_molecule_B
A X Protein_molecule_E
were xxx NE
normal xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
tumor-draining xxx-xxx Body_region_B
LN XX Body_region_E
, , NE
as xx NE
was xxx NE
nuclear xxx NE
kappaB xxxX NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
induced xxx NE
by xx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
or xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
activated xxx Cell_natural_B
LN XX Cell_natural_M
cells xxx Cell_natural_E
with xxx NE
D5 Xd NE
tumor xxx NE
cells xxx NE
induced xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
the xxx NE
recovery xxx NE
of xx NE
proteins xxx NE
mediating xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
the xxx NE
T X Protein_complex_B
cell xxx Protein_complex_M
receptor/CD3 xxx/XXd Protein_complex_M
complex xxx Protein_complex_E
in xx NE
LN XX Cell_natural_B
T X Cell_natural_M
cells xxx Cell_natural_E
activated xxx NE
ex xx NE
vivo xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
antitumor xxx Other_B
function xxx Other_E
. . NE

Effect Xxxx NE
of xx NE
adenovirus xxx Virus_B
2 d Virus_E
on xx NE
cellular xxx Other_B
gene xxx Other_M
activation xxx Other_E
in xx NE
blood-derived xxx-xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
macrophages xxx Cell_natural
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
adenovirus xxx NE
2 d NE
( ( NE
Ad2 Xxd NE
) ) NE
infection xxx NE
on xx NE
human xxx NE
monocytes xxx NE
and xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx NE
with xxx NE
regard xxx NE
to xx NE
expression xxx NE
of xx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
. . NE

In Xx NE
monocytes xxx NE
, , NE
the xxx NE
virus xxx NE
was xxx NE
bound xxx NE
to xx NE
the xxx NE
surface xxx NE
without xxx NE
being xxx NE
internalized xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
Ad2 Xxd Virus
was xxx NE
internalized xxx NE
by xx NE
macrophages xxx Cell_natural
. . NE

No Xx NE
virus xxx NE
replication xxx NE
and xxx NE
no xx NE
transcription xxx NE
of xx NE
the xxx NE
Ad2 Xxd DNA_family_or_group_B
early xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
was xxx NE
observed xxx NE
in xx NE
either xxx NE
of xx NE
the xxx NE
cells xxx NE
. . NE

Ad2 Xxd Other_B
infection xxx Other_E
induced xxx NE
transient xxx NE
increase xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
for xxx NE
TNF-alpha XXX-xxx NE
and xxx NE
IL-1 XX-d NE
beta xxx NE
in xx NE
both xxx NE
monocytes xxx NE
and xxx NE
in xx NE
macrophages xxx NE
, , NE
although xxx NE
the xxx NE
kinetics xxx NE
of xx NE
the xxx NE
transcription xxx NE
was xxx NE
slightly xxx NE
different xxx NE
. . NE

The Xxx NE
production xxx NE
of xx NE
both xxx NE
cytokines xxx Protein_family_or_group
, , NE
measured xxx NE
by xx NE
ELISA XXXXX Other_B
tests xxx Other_E
, , NE
was xxx NE
enhanced xxx NE
in xx NE
monocytes xxx Cell_natural
. . NE

In Xx NE
macrophages xxx Cell_natural
, , NE
a x NE
slight xxx NE
enhancement xxx NE
of xx NE
TNF-alpha XXX-xxx Other_B
production xxx Other_E
was xxx NE
seen xxx NE
, , NE
whereas xxx NE
IL-1 XX-d NE
beta xxx NE
was xxx NE
not xxx NE
detected xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
cellular xxx DNA_family_or_group_B
genes xxx DNA_family_or_group_E
might xxx NE
be xx NE
activated xxx NE
by xx NE
Ad2 Xxd Other_B
virus xxx Other_M
infection xxx Other_E
in xx NE
nonpermissive xxx NE
cells xxx NE
where xxx NE
no xx NE
viral xxx NE
gene xxx NE
products xxx NE
could xxx NE
be xx NE
detected xxx NE
. . NE

Regulation Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
cytokine xxx NE
gene xxx Other_B
expression xxx Other_E
in xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
by xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
transcription xxx NE
factors xxx NE
. . NE

CD4+ XXd+ Cell_cultured_B
macrophages xxx Cell_cultured_E
in xx NE
tissues xxx NE
such xxx NE
as xx NE
lung xxx Body_region
, , NE
skin xxx Body_region
, , NE
and xxx NE
lymph xxx Body_region_B
nodes xxx Body_region_E
, , NE
promyelocytic xxx Cell_natural_B
cells xxx Cell_natural_E
in xx NE
bone xxx Tissue_natural_B
marrow xxx Tissue_natural_E
, , NE
and xxx NE
peripheral xxx Cell_natural_B
blood xxx Cell_natural_M
monocytes xxx Cell_natural_E
serve xxx NE
as xx NE
important xxx NE
targets xxx NE
and xxx NE
reservoirs xxx NE
for xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

HIV-1 XXX-d Virus
-infected -xxx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
are xxx NE
often xxx NE
diminished xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
participate xxx NE
in xx NE
chemotaxis xxx Other
, , NE
phagocytosis xxx Other
, , NE
and xxx NE
intracellular xxx Other_B
killing xxx Other_E
. . NE

HIV-1 XXX-d Virus
infection xxx NE
of xx NE
myeloid xxx Cell_natural_B
cells xxx Cell_natural_E
can xxx NE
lead xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
surface xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
associated xxx NE
with xxx NE
cellular xxx Other_B
activation xxx Other_E
and/or xxx/xx NE
differentiation xxx Other
that xxx NE
increase xxx NE
the xxx NE
responsiveness xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
cytokines xxx Protein_family_or_group
secreted xxx NE
by xx NE
neighboring xxx NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
to xx NE
bacteria xxx Unicellular_organism
or xx NE
other xxx NE
pathogens xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
is xx NE
related xxx NE
in xx NE
part xxx NE
to xx NE
increased xxx NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
of xx NE
cellular xxx NE
transcription xxx NE
factors xxx NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
binds xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d NE
enhancer xxx NE
region xxx NE
of xx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
and xxx NE
contributes xxx NE
to xx NE
the xxx NE
inducibility xxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
response xxx NE
to xx NE
multiple xxx NE
activating xxx NE
agents xxx NE
. . NE

Phosphorylation Xxxx Other
and xxx NE
degradation xxx Other
of xx NE
the xxx NE
cytoplasmic xxx Protein_family_or_group_B
inhibitor xxx Protein_family_or_group_E
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
crucial xxx NE
regulatory xxx NE
events xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
DNA XXX NE
-binding -xxx NE
activity xxx NE
. . NE

Both Xxxx NE
N- X- NE
and xxx NE
C- X- NE
terminal xxx NE
residues xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
are xxx NE
required xxx NE
for xxx NE
inducer-mediated xxx-xxx NE
degradation xxx NE
. . NE

Chronic Xxxx NE
HIV-1 XXX-d Other_B
infection xxx Other_E
of xx NE
myeloid xxx NE
cells xxx NE
leads xxx NE
to xx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
-binding -xxx NE
activity xxx NE
and xxx NE
provides xxx NE
an xx NE
intranuclear xxx NE
environment xxx NE
capable xxx NE
of xx NE
perpetuating xxx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Increased Xxxx NE
intracellular xxx Other_B
stores xxx Other_E
of xx NE
latent xxx Protein_molecule_B
NF-kappa XX-xxx Protein_molecule_M
B X Protein_molecule_E
may xxx NE
also xxx NE
result xxx NE
in xx NE
rapid xxx NE
inducibility xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
response xxx NE
to xx NE
secondary xxx NE
pathogenic xxx NE
infections xxx NE
or xx NE
antigenic xxx NE
challenge xxx NE
, , NE
cytokine xxx Other_B
gene xxx Other_M
expression xxx Other_E
is xx NE
rapidly xxx NE
induced xxx NE
, , NE
enhanced xxx NE
, , NE
and xxx NE
sustained xxx NE
over xxx NE
prolonged xxx NE
periods xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
myeloid xxx NE
cells xxx NE
compared xxx NE
with xxx NE
uninfected xxx NE
cells xxx NE
. . NE

Elevated Xxxx NE
levels xxx NE
of xx NE
several xxx NE
inflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
have xxx NE
been xxx NE
detected xxx NE
in xx NE
the xxx NE
sera xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
individuals xxx NE
. . NE

Secretion Xxxx NE
of xx NE
myeloid xxx Protein_family_or_group_B
cell-derived xxx-xxx Protein_family_or_group_M
cytokines xxx Protein_family_or_group_E
may xxx NE
both xxx NE
increase xxx NE
virus xxx NE
production xxx NE
and xxx NE
contribute xxx NE
to xx NE
AIDS-associated XXXX-xxx NE
disorders xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx Other_B
bacterial xxx Other_M
infections xxx Other_E
, , NE
lipopolysaccharide xxx Lipid
( ( NE
LPS XXX Lipid
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx Protein_family_or_group_B
mediators xxx Protein_family_or_group_E
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx Other_B
instability xxx Other_E
and xxx NE
shock xxx Other
. . NE

CD14 XXdd Protein_molecule
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx Protein_family_or_group_B
antigen xxx Protein_family_or_group_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX Protein_family_or_group_B
signaling xxx Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd Protein_molecule
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX Lipid
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor xxx NE
-associated -xxx NE
tyrosine xxx NE
kinase xxx NE
( ( NE
TK XX NE
) ) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx Cell_cultured_B
hamster xxx Cell_cultured_M
ovary xxx Cell_cultured_M
(CHO)-K1 (XXX)-Xd Cell_cultured_M
cells xxx Cell_cultured_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx Organic_compound_other
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd Protein_molecule
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx Lipid
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx Organic_compound_other
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx Protein_family_or_group_B
cytokines xxx Protein_family_or_group_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd Protein_molecule
or xx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx Other_B
B X Other_M
translocation xxx Other_E
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX Other_B
activity xxx Other_E
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx Other_B
extracts xxx Other_E
from xxx NE
activated xxx NE
RAW XXX Cell_cultured_B
264.7 ddd.d Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
LPS XXX NE
-induced -xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX Other_B
inhibitors xxx Other_E
herbimycin xxx Organic_compound_other_B
A X Organic_compound_other_E
and xxx NE
genistein xxx Organic_compound_other
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX Other_B
activity xxx Other_E
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Induction Xxxx NE
of xx NE
a x NE
functional xxx NE
vitamin xxx Protein_family_or_group_B
D X Protein_family_or_group_M
receptor xxx Protein_family_or_group_E
in xx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
-induced -xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
of xx NE
M2-type Xd-xxx Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Different Xxxx NE
types xxx NE
of xx NE
acute xxx Cell_natural_B
myeloid xxx Cell_natural_M
leukemia xxx Cell_natural_M
blast xxx Cell_natural_M
cells xxx Cell_natural_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
with xxx NE
all-trans-retinoic xxx-xxx-xxx Organic_compound_other_B
acid xxx Organic_compound_other_E
( ( NE
ATRA XXXX Organic_compound_other
) ) NE
and xxx NE
vitamin xxx Lipid_B
D3 Xd Lipid_E
( ( NE
VD XX Lipid
) ) NE
. . NE

M0/M1 Xd/Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
differentiating xxx Organic_compound_other_B
agents xxx Organic_compound_other_E
, , NE
whereas xxx NE
M3 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
induced xxx NE
to xx NE
undergo xxx NE
granulocytic xxx Other_B
differentiation xxx Other_E
after xxx NE
ATRA XXXX Organic_compound_other
treatment xxx NE
but xxx NE
are xxx NE
not xxx NE
sensitive xxx NE
to xx NE
VD XX Lipid
. . NE

M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
behave xxx NE
differently xxx NE
because xxx NE
they xxx NE
undergo xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
with xxx NE
both xxx NE
the xxx NE
differentiation xxx NE
inducers xxx NE
. . NE

To Xx NE
gain xxx NE
some xxx NE
insight xxx NE
into xxx NE
the xxx NE
maturation xxx NE
of xx NE
M2-type Xd-xxx Cell_natural_B
leukemic xxx Cell_natural_M
cells xxx Cell_natural_E
, , NE
we xx NE
studied xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
underlying xxx NE
monocytic xxx Other_B
differentiation xxx Other_E
induced xxx NE
by xx NE
ATRA XXXX Organic_compound_other
and xxx NE
VD XX Lipid
in xx NE
spontaneous xxx NE
M2 Xd Cell_cultured_B
blast xxx Cell_cultured_M
cells xxx Cell_cultured_E
as xx NE
well xxx NE
as xx NE
in xx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
(an (xx NE
acute xxx Cell_cultured_B
myeloid xxx Cell_cultured_M
leukemia xxx Cell_cultured_M
M2-type Xd-xxx Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
) ) NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
ATRA XXXX Organic_compound_other
as xx NE
well xxx NE
as xx NE
VD XX Lipid
efficiently xxx NE
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
VD XX Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
( ( NE
VDR XXX NE
) ) NE
and xxx NE
promotes xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

VDR XXX Protein_family_or_group
is xx NE
functionally xxx NE
active xxx NE
in xx NE
ATRA XXXX Organic_compound_other
-treated -xxx NE
Kasumi-1 Xxxx-d Cell_cultured_B
cells xxx Cell_cultured_E
because xxx NE
it xx NE
efficiently xxx NE
heterodimerizes xxx NE
with xxx NE
retinoid xxx Protein_molecule_B
X X Protein_molecule_M
receptor xxx Protein_molecule_E
, , NE
binds xxx NE
to xx NE
a x NE
DR3-type XXd-xxx DNA_domain_or_region_B
vitamin xxx DNA_domain_or_region_M
D-responsive X-xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
, , NE
and xxx NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
vitamin xxx DNA_domain_or_region_B
D-responsive X-xxx DNA_domain_or_region_M
element-regulated xxx-xxx DNA_domain_or_region_M
reporter xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
findings xxx NE
, , NE
VD XX NE
-responsive -xxx NE
genes xxx NE
are xxx NE
induced xxx NE
by xx NE
ATRA XXXX NE
treatment xxx NE
of xx NE
Kasumi-1 Xxxx-d NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
genetic xxx NE
program xxx NE
underlying xxx NE
monocytic xxx NE
differentiation xxx NE
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx Other_B
mechanism xxx Other_E
by xx NE
which xxx NE
ATRA XXXX Organic_compound_other
increases xxx NE
the xxx NE
nuclear xxx NE
abundance xxx NE
of xx NE
a x NE
functional xxx NE
VDR XXX Protein_family_or_group
is xx NE
still xxx NE
unknown xxx NE
, , NE
but xxx NE
our xxx NE
data xxx NE
clearly xxx NE
indicate xxx NE
that xxx NE
the xxx NE
M2 Xd Cell_cultured_B
leukemic xxx Cell_cultured_M
cell xxx Cell_cultured_E
context xxx NE
is xx NE
only xxx NE
permissive xxx NE
of xx NE
monocytic xxx Other_B
differentiation xxx Other_E
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- NE
T X NE
lymphocytes xxx NE
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx Cell_cultured_B
(Ipr) (Xxx) Cell_cultured_M
peripheral xxx Cell_cultured_M
CD4-CD8- XXd-XXd- Cell_cultured_M
(CD4-8-) (XXd-d-) Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx Protein_molecule
and xxx NE
CD3 XXd Protein_molecule_B
zeta xxx Protein_molecule_E
tyrosine xxx Other_B
phosphorylation xxx Other_E
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx Protein_family_or_group_B
messengers xxx Protein_family_or_group_E
in xx NE
T X Cell_natural_B
cells xxx Cell_natural_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx Other_B
signaling xxx Other_E
that xxx NE
results xxx NE
in xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
with xxx NE
that xxx NE
of xx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx Polynucleotide
, , NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50-p65 xdd-xdd Protein_molecule_B
heterodimer xxx Protein_molecule_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx Organic_compound_other
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_M
of xx Protein_family_or_group_M
activated xxx Protein_family_or_group_M
T X Protein_family_or_group_M
cells xxx Protein_family_or_group_E
( ( NE
NF-AT XX-XX NE
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX Protein_complex_B
complex xxx Protein_complex_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
from xxx NE
Ipr Xxx Cell_cultured_B
CD4-8- XXd-d- Cell_cultured_M
T X Cell_cultured_M
cells xxx Cell_cultured_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX NE
site xxx NE
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx NE
T X NE
lymphocytes xxx NE
. . NE

Upon Xxxx NE
mitogenic xxx Other_B
stimulation xxx Other_E
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

Evidence Xxxx NE
for xxx NE
suppressed xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
NFAT1 XXXXd Protein_molecule
at xx NE
its xxx NE
proximal xxx DNA_domain_or_region_B
binding xxx DNA_domain_or_region_M
element xxx DNA_domain_or_region_E
P0 Xd DNA_domain_or_region
in xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
promoter xxx DNA_domain_or_region_E
associated xxx NE
with xxx NE
enhanced xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
transcription xxx Other_E
in xx NE
T X NE
cells xxx NE
of xx NE
atopic xxx NE
patients xxx NE
. . NE

Allergen-specific Xxxx-xxx NE
T X Cell_natural_B
cells xxx Cell_natural_E
in xx NE
atopic xxx Multicellular_organism_natural_B
patients xxx Multicellular_organism_natural_E
are xxx NE
polarized xxx NE
IL-4 XX-d NE
-producing -xxx NE
Th2 Xxd NE
cells xxx NE
, , NE
promoting xxx NE
IgE XxX Other_B
synthesis xxx Other_E
by xx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
molecular xxx NE
basis xxx NE
for xxx NE
increased xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
in xx NE
atopy xxx NE
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
regulation xxx NE
in xx NE
general xxx NE
involves xxx NE
the xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NFAT XXXX NE
) ) NE
family xxx NE
of xx NE
transcription xxx NE
factors xxx NE
, , NE
of xx NE
which xxx NE
NFAT1 XXXXd NE
and xxx NE
NFAT2 XXXXd NE
are xxx NE
most xxx NE
prominent xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Recently Xxxx NE
, , NE
a x NE
unique xxx NE
inhibitory xxx NE
role xxx NE
of xx NE
NFAT1 XXXXd Protein_molecule
in xx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
control xxx NE
was xxx NE
shown xxx NE
in xx NE
the xxx NE
mouse xxx Multicellular_organism_natural
. . NE

In Xx NE
a x NE
series xxx NE
of xx NE
electrophoretic xxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
with xxx NE
protein xxx Cell_component_B
extracts xxx Cell_component_E
of xx NE
highly xxx NE
polarized xxx NE
Th2 Xxd NE
clones xxx NE
from xxx NE
atopics xxx Multicellular_organism_natural
and xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
from xxx NE
controls xxx NE
we xx NE
compared xxx NE
DNA-binding XXX-xxx NE
activities xxx NE
at xx NE
the xxx NE
two xxx NE
NFAT XXXX NE
-binding -xxx NE
elements xxx NE
P0 Xd NE
and xxx NE
P1 Xd NE
of xx NE
the xxx NE
crucial xxx NE
proximal xxx NE
human xxx NE
IL-4 XX-d NE
promoter xxx NE
. . NE

At Xx NE
the xxx NE
most xxx NE
proximal xxx NE
P0 Xd DNA_domain_or_region
site xxx NE
, , NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
devoid xxx NE
of xx NE
NFAT2 XXXXd Protein_molecule
were xxx NE
readily xxx NE
inducible xxx NE
in xx NE
the xxx NE
Th1 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
but xxx NE
hardly xxx NE
or xx NE
not xxx NE
in xx NE
the xxx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
. . NE

In Xx NE
contrast xxx NE
, , NE
both xxx NE
in xx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
NFAT XXXX NE
-containing -xxx NE
complexes xxx NE
were xxx NE
strongly xxx NE
inducible xxx NE
at xx NE
the xxx NE
P1 Xd NE
site xxx NE
, , NE
consisting xxx NE
of xx NE
NFAT2 XXXXd NE
and xxx NE
a x NE
P0 Xd NE
-compatible -xxx NE
NFAT XXXX NE
activity xxx NE
, , NE
without xxx NE
apparent xxx NE
differences xxx NE
between xxx NE
Th1 Xxd NE
and xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

Like Xxxx NE
in xx NE
Th2 Xxd Cell_cultured_B
clones xxx Cell_cultured_E
, , NE
suppressed xxx NE
NFAT XXXX NE
- - NE
P0 Xd NE
complex xxx NE
formation xxx NE
was xxx NE
observed xxx NE
also xxx NE
at xx NE
the xxx NE
polyclonal xxx NE
level xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
( ( NE
PBMC XXXX NE
) ) NE
of xx NE
three xxx NE
of xx NE
five xxx NE
severe xxx NE
atopic xxx NE
dermatitis xxx NE
patients xxx NE
with xxx NE
strongly xxx NE
elevated xxx NE
serum xxx NE
IgE XxX NE
levels xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
control xxx NE
PBMC XXXX NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
high-level xxx-xxx Other_B
IL-4 XX-d Other_M
production xxx Other_E
in xx NE
atopic xxx NE
Th2 Xxd NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
selective xxx NE
reduction xxx NE
of xx NE
suppressive xxx NE
NFAT1 XXXXd NE
activity xxx NE
at xx NE
the xxx NE
IL-4 XX-d NE
P0 Xd NE
element xxx NE
and xxx NE
that xxx NE
some xxx NE
patients xxx NE
with xxx NE
this xxx NE
multifactorial xxx NE
disease xxx NE
may xxx NE
have xxx NE
a x NE
putative xxx NE
systemic xxx NE
disorder xxx NE
at xx NE
this xxx NE
level xxx NE
. . NE

Transcription Xxxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
in xx NE
immune-mediated xxx-xxx Other_B
disease xxx Other_E
. . NE

A X NE
large xxx NE
amount xxx NE
of xx NE
detailed xxx NE
information xxx NE
about xxx NE
the xxx NE
intracellular xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
regulating xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
and xxx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
activation xxx NE
has xxx NE
emerged xxx NE
recently xxx NE
. . NE

Several Xxxx NE
small xxx NE
molecules xxx NE
, , NE
an xx NE
antisense xxx Polynucleotide_B
oligonucleotide xxx Polynucleotide_E
, , NE
and xxx NE
gene xxx NE
therapeutic xxx NE
agents xxx NE
that xxx NE
inhibit xxx NE
NF-kappa XX-xxx Other_B
b x Other_M
activation xxx Other_E
have xxx NE
been xxx NE
described xxx NE
. . NE

Despite Xxxx NE
this xxx NE
, , NE
there xxx NE
are xxx NE
still xxx NE
significant xxx NE
gaps xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
this xxx NE
process xxx NE
and xxx NE
its xxx NE
consequences xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
characterization xxx NE
of xx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
selectively xxx NE
regulating xxx NE
cytokine xxx NE
production xxx NE
by xx NE
CD4+ XXd+ Cell_natural_B
T X Cell_natural_M
cell xxx Cell_natural_M
subsets xxx Cell_natural_E
is xx NE
at xx NE
a x NE
very xxx NE
early xxx NE
stage xxx NE
. . NE

Three Xxxx NE
interacting xxx Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
have xxx NE
recently xxx NE
been xxx NE
shown xxx NE
to xx NE
contribute xxx NE
to xx NE
subset-restricted xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
. . NE

There Xxxx NE
are xxx NE
other xxx NE
elements xxx NE
regulating xxx NE
IL-4 XX-d Other_B
gene xxx Other_M
expression xxx Other_E
, , NE
however xxx NE
, , NE
and xxx NE
the xxx NE
relative xxx NE
importance xxx NE
of xx NE
these xxx NE
recently xxx NE
identified xxx NE
proteins xxx NE
has xxx NE
yet xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

Defective Xxxx Other_B
transcription xxx Other_E
of xx NE
the xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
is xx NE
associated xxx NE
with xxx NE
impaired xxx NE
expression xxx NE
of xx NE
c-Fos x-Xxx Protein_molecule
, , NE
FosB XxxX Protein_molecule
, , NE
and xxx NE
JunB XxxX Protein_molecule
in xx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
helper xxx Cell_cultured_M
1 d Cell_cultured_M
cells xxx Cell_cultured_E
. . NE

Anergic Xxxx Cell_cultured_B
CD4+ XXd+ Cell_cultured_M
Th Xx Cell_cultured_M
cells xxx Cell_cultured_E
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d Protein_molecule
when xxx NE
challenged xxx NE
with xxx NE
Ag-pulsed Xx-xxx Cell_cultured_B
accessory xxx Cell_cultured_M
cells xxx Cell_cultured_E
because xxx NE
of xx NE
a x NE
transcriptional xxx Other_B
defect xxx Other_E
. . NE

In Xx NE
this xxx NE
work xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
these xxx NE
anergic xxx Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
are xxx NE
defective xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
up-regulate xx-xxx NE
protein xxx Other_B
binding xxx Other_E
and xxx NE
transactivation xxx NE
at xx NE
two xxx NE
critical xxx NE
IL-2 XX-d DNA_domain_or_region_B
DNA XXX DNA_domain_or_region_M
enhancer xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
: : NE
NF-AT XX-XX NE
( ( NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
; ; NE
a x NE
sequence xxx NE
that xxx NE
binds xxx NE
a x NE
heterotrimeric xxx NE
NFATp XXXXx NE
, , NE
Fos Xxx NE
, , NE
and xxx NE
Jun Xxx NE
protein xxx NE
complex xxx NE
) ) NE
and xxx NE
Activator Xxxx NE
Protein-1 Xxxx-d NE
( ( NE
AP-1 XX-d NE
) ) NE
(that (xxx NE
binds xxx NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
heterodimers xxx NE
) ) NE
. . NE

Western Xxxx Other_B
blot xxx Other_M
analysis xxx Other_E
of xx NE
nuclear xxx Cell_component_B
extracts xxx Cell_component_E
showed xxx NE
that xxx NE
the xxx NE
impaired xxx NE
DNA XXX NE
- - NE
protein xxx NE
interactions xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
were xxx NE
associated xxx NE
with xxx NE
poor xxx NE
expression xxx NE
of xx NE
the xxx NE
inducible xxx NE
AP-1 XX-d NE
family xxx NE
members xxx NE
c-Fos x-Xxx NE
, , NE
FosB XxxX NE
, , NE
and xxx NE
JunB XxxX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
reduced xxx NE
expression xxx NE
of xx NE
these xxx NE
proteins xxx NE
was xxx NE
not xxx NE
the xxx NE
result xxx NE
of xx NE
a x NE
global xxx NE
TCR/CD3 XXX/XXd NE
-signaling -xxx NE
defect xxx NE
because xxx NE
CD3 XXd NE
cross-linking xxx-xxx NE
induced xxx NE
an xx NE
equivalent xxx NE
increase xxx NE
in xx NE
intracellular-free xxx-xxx NE
calcium xxx NE
ions xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
NFATp XXXXx NE
dephosphorylation xxx NE
, , NE
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
and xxx NE
DNA XXX NE
binding xxx NE
in xx NE
both xxx NE
normal xxx NE
and xxx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

Thus Xxxx NE
, , NE
defective xxx NE
IL-2 XX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
transcription xxx NE
appears xxx NE
to xx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
a x NE
selective xxx NE
block xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
Fos Xxx NE
and xxx NE
Jun Xxx NE
family xxx NE
members xxx NE
in xx NE
anergic xxx NE
T X NE
cells xxx NE
. . NE

A X NE
novel xxx NE
mitogen xxx NE
-inducible -xxx NE
gene xxx NE
product xxx NE
related xxx NE
to xx NE
p50/p105-NF-kappa xdd/xddd-XX-xxx NE
B X NE
participates xxx NE
in xx NE
transactivation xxx NE
through xxx NE
a x NE
kappa xxx NE
B X NE
site xxx NE
. . NE

A X NE
Rel-related Xxx-xxx NE
, , NE
mitogen xxx NE
-inducible -xxx NE
, , NE
kappa xxx NE
B X NE
-binding -xxx NE
protein xxx NE
has xxx NE
been xxx NE
cloned xxx NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
activation xxx NE
gene xxx NE
of xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_family_or_group
has xxx NE
an xx NE
open xxx DNA_domain_or_region_B
reading xxx DNA_domain_or_region_M
frame xxx DNA_domain_or_region_E
of xx NE
900 ddd DNA_domain_or_region_B
amino xxx DNA_domain_or_region_M
acids xxx DNA_domain_or_region_E
capable xxx NE
of xx NE
encoding xxx NE
a x NE
97-kDa dd-xXx Protein_molecule_B
protein xxx Protein_molecule_E
. . NE

This Xxxx NE
protein xxx NE
is xx NE
most xxx NE
similar xxx NE
to xx NE
the xxx NE
105-kDa ddd-xXx Peptide_B
precursor xxx Peptide_M
polypeptide xxx Peptide_E
of xx NE
p50-NF-kappa xdd-XX-xxx Protein_molecule_B
B X Protein_molecule_E
. . NE

Like Xxxx NE
the xxx NE
105-kDa ddd-xXx NE
precursor xxx NE
, , NE
it xx NE
contains xxx NE
an xx NE
amino-terminal xxx-xxx Protein_domain_or_region_B
Rel-related Xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
of xx NE
about xxx NE
300 ddd NE
amino xxx NE
acids xxx NE
and xxx NE
a x NE
carboxy-terminal xxx-xxx Protein_domain_or_region_B
domain xxx Protein_domain_or_region_E
containing xxx NE
six xxx NE
full xxx Protein_substructure_B
cell xxx Protein_substructure_M
cycle xxx Protein_substructure_E
or xx NE
ankyrin xxx Protein_substructure_B
repeats xxx Protein_substructure_E
. . NE

In Xx NE
vitro-translated xxx-xxx NE
proteins xxx NE
, , NE
truncated xxx NE
downstream xxx NE
of xx NE
the xxx NE
Rel Xxx NE
domain xxx NE
and xxx NE
excluding xxx NE
the xxx NE
repeats xxx NE
, , NE
bind xxx NE
kappa xxx NE
B X NE
sites xxx NE
. . NE

We Xx NE
refer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
, , NE
truncated xxx NE
protein xxx NE
as xx NE
p50B xddX NE
by xx NE
analogy xxx NE
with xxx NE
p50-NF-kappa xdd-XX-xxx NE
B X NE
and xxx NE
to xx NE
the xxx NE
full-length xxx-xxx NE
protein xxx NE
as xx NE
p97 xdd NE
. . NE

p50B xddX Protein_molecule
is xx NE
able xxx NE
to xx NE
form xxx NE
heteromeric xxx NE
kappa xxx NE
B X NE
-binding -xxx NE
complexes xxx NE
with xxx NE
RelB XxxX NE
, , NE
as xx NE
well xxx NE
as xx NE
with xxx NE
p65 xdd NE
and xxx NE
p50 xdd NE
, , NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Transient-transfection Xxxx-xxx NE
experiments xxx NE
in xx NE
embryonal xxx Cell_cultured_B
carcinoma xxx Cell_cultured_M
cells xxx Cell_cultured_E
demonstrate xxx NE
a x NE
functional xxx NE
cooperation xxx NE
between xxx NE
p50B xddX Protein_molecule
and xxx NE
RelB XxxX Protein_molecule
or xx NE
p65 xdd Protein_molecule
in xx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_molecule_B
plasmid xxx DNA_molecule_E
dependent xxx NE
on xx NE
a x NE
kappa xxx DNA_domain_or_region_B
B X DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
. . NE

The Xxx NE
data xxx NE
imply xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
complex xxx NE
family xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
transcription xxx NE
factors xxx NE
. . NE

A X NE
novel xxx DNA_domain_or_region_B
SP-1 XX-d DNA_domain_or_region_M
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
interleukin-1 xxx-d NE
beta xxx NE
promoter xxx NE
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
of xx NE
interleukin-1beta xxx-dxxx Protein_molecule
( ( NE
IL-1beta XX-dxxx Protein_molecule
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
IL-1beta XX-dxxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx Cell_natural
. . NE

Electrophoretic Xxxx Other_B
mobility xxx Other_M
shift xxx Other_M
assays xxx Other_E
( ( NE
EMSA XXXX Other
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_domain_or_region_B
oligonucleotide xxx DNA_domain_or_region_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_family_or_group_B
factor xxx DNA_family_or_group_M
consensus xxx DNA_family_or_group_M
sequence xxx DNA_family_or_group_M
oligonucleotides xxx DNA_family_or_group_E
and xxx NE
by xx NE
immunosupershift xxx Other
, , NE
transcription xxx Protein_molecule_B
factor xxx Protein_molecule_M
SP-1 XX-d Protein_molecule_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_domain_or_region_B
element xxx DNA_domain_or_region_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_domain_or_region_B
consensus xxx DNA_domain_or_region_M
sequence xxx DNA_domain_or_region_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX NE
motif xxx NE
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx Protein_molecule_B
necrosis xxx Protein_molecule_M
factor-alpha xxx-xxx Protein_molecule_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_domain_or_region_B
site xxx DNA_domain_or_region_E
in xx NE
the xxx NE
human xxx NE
IL-1beta XX-dxxx NE
promoter xxx NE
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_domain_or_region_B
locus xxx DNA_domain_or_region_E
. . NE

Transcription Xxxx NE
of xx NE
the xxx NE
human xxx DNA_domain_or_region_B
beta-globin xxx-xxx DNA_domain_or_region_M
gene xxx DNA_domain_or_region_M
cluster xxx DNA_domain_or_region_E
depends xxx NE
upon xxx NE
upstream xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
sequences xxx DNA_domain_or_region_E
, , NE
which xxx NE
are xxx NE
collectively xxx NE
termed xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
provided xxx NE
new xxx NE
insights xxx NE
into xxx NE
how xxx NE
the xxx NE
individual xxx NE
genes xxx NE
of xx NE
the xxx NE
cluster xxx NE
are xxx NE
regulated xxx NE
through xxx NE
development xxx NE
. . NE

The Xxx NE
crux xxx NE
of xx NE
transcriptional xxx Other_B
activation xxx Other_E
is xx NE
how xxx NE
the xxx NE
locus xxx DNA_domain_or_region_B
control xxx DNA_domain_or_region_M
region xxx DNA_domain_or_region_E
communicates xxx NE
with xxx NE
the xxx NE
gene-proximal xxx-xxx DNA_domain_or_region_B
regulatory xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
. . NE

Inhibition Xxxx NE
of xx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
by xx NE
dehydroepiandrosterone xxx NE
( ( NE
DHEA XXXX NE
) ) NE
and xxx NE
an xx NE
analog xxx NE
of xx NE
DHEA XXXX NE
. . NE

The Xxx NE
initial xxx NE
infection xxx NE
with xxx NE
human xxx Virus_B
immunodeficiency xxx Virus_M
virus xxx Virus_M
type xxx Virus_M
1 d Virus_E
( ( NE
HIV-1 XXX-d Virus
) ) NE
in xx NE
most xxx NE
individuals xxx NE
usually xxx NE
results xxx NE
in xx NE
the xxx NE
establishment xxx NE
of xx NE
a x NE
latent xxx NE
or xx NE
chronic xxx Other_B
infection xxx Other_E
before xxx NE
eventual xxx NE
progression xxx NE
toward xxx NE
acquired xxx Other_B
immunodeficiency xxx Other_M
syndrome xxx Other_E
. . NE

HIV-1 XXX-d Virus
can xxx NE
also xxx NE
establish xxx NE
a x NE
latent xxx NE
or xx NE
persistent xxx NE
infection xxx NE
in xx NE
some xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
that xxx NE
show xxx NE
minimal xxx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

However Xxxx NE
, , NE
activation xxx NE
of xx NE
the xxx NE
T X Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
leading xxx NE
to xx NE
enhanced xxx NE
HIV-1 XXX-d Virus
replication xxx NE
can xxx NE
be xx NE
induced xxx NE
by xx NE
antigens xxx Protein_family_or_group
, , NE
mitogens xxx Other
, , NE
and xxx NE
cytokines xxx Protein_family_or_group
( ( NE
tumor xxx Protein_family_or_group_B
necrosis xxx Protein_family_or_group_M
factor xxx Protein_family_or_group_M
alpha xxx Protein_family_or_group_E
[ [ NE
TNF-alpha XXX-xxx Protein_molecule
] ] NE
, , NE
interleukin xxx Protein_molecule_B
1 d Protein_molecule_E
, , NE
and xxx NE
interleukin-2 xxx-d Protein_molecule
) ) NE
. . NE

Various Xxxx NE
gene xxx NE
products xxx NE
from xxx NE
other xxx NE
viruses xxx NE
( ( NE
HTLV-1 XXXX-d Virus
, , NE
HSV XXX Virus
, , NE
EBV XXX Virus
, , NE
CMV XXX Virus
, , NE
HBV XXX Virus
, , NE
and xxx NE
HHV-6 XXX-d Virus
) ) NE
can xxx NE
also xxx NE
enhance xxx NE
HIV-1 XXX-d NE
long xxx NE
terminal xxx NE
repeat xxx NE
( ( NE
LTR XXX NE
)-driven )-xxx NE
reporter xxx NE
gene xxx NE
activity xxx NE
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
these xxx NE
observations xxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
proposed xxx NE
that xxx NE
reactivation xxx NE
of xx NE
latent xxx NE
HIV-1 XXX-d Virus
harbored xxx NE
in xx NE
chronically xxx Cell_natural_B
infected xxx Cell_natural_M
T X Cell_natural_M
lymphocytes xxx Cell_natural_E
, , NE
monocytes xxx Cell_natural
, , NE
or xx NE
macrophages xxx Cell_natural
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
AIDS XXXX Other
. . NE

So Xx NE
far xxx NE
, , NE
there xxx NE
are xxx NE
no xx NE
drugs xxx NE
or xx NE
therapy xxx NE
available xxx NE
that xxx NE
can xxx NE
provide xxx NE
protection xxx NE
against xxx NE
HIV-1 XXX-d Other_B
latency xxx Other_M
reactivation xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
, , NE
derived xxx NE
from xxx NE
a x NE
human xxx Cell_cultured_B
T X Cell_cultured_M
cell xxx Cell_cultured_M
line xxx Cell_cultured_E
( ( NE
CEM XXX Cell_cultured
) ) NE
, , NE
is xx NE
chronically xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
, , NE
with xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx Other_B
virus xxx Other_M
expression xxx Other_E
. . NE

ACH-2 XXX-d Cell_cultured
can xxx NE
be xx NE
converted xxx NE
to xx NE
productive xxx NE
infection xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx Organic_compound_other
( ( NE
TPA XXX Organic_compound_other
) ) NE
, , NE
mitogen xxx Organic_compound_other
or xx NE
cytokines xxx Protein_family_or_group
( ( NE
TNF-alpha XXX-xxx Protein_molecule
) ) NE
, , NE
or xx NE
infection xxx NE
with xxx NE
HSV XXX Virus
. . NE

Therefore Xxxx NE
the xxx NE
ACH-2 XXX-d Cell_cultured
cell xxx NE
line xxx NE
is xx NE
a x NE
good xxx NE
candidate xxx NE
for xxx NE
studying xxx NE
the xxx NE
effects xxx NE
of xx NE
drugs xxx NE
on xx NE
HIV-1 XXX-d Virus
activation xxx NE
. . NE

Previously Xxxx NE
, , NE
we xx NE
have xxx NE
reported xxx NE
that xxx NE
DHEA XXXX Lipid
and xxx NE
synthetic xxx NE
analogs xxx NE
of xx NE
DHEA XXXX NE
can xxx NE
be xx NE
modest xxx NE
inhibitors xxx NE
of xx NE
HIV-1 XXX-d Other_B
IIIB XXXX Other_M
replication xxx Other_E
in xx NE
phytohemagglutinin xxx NE
-stimulated -xxx NE
peripheral xxx NE
blood xxx NE
lymphocyte xxx NE
cultures xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

C/EBP X/XXX Protein_family_or_group_B
activators xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
HIV-1 XXX-d Other_B
replication xxx Other_E
and xxx NE
proviral xxx NE
induction xxx NE
in xx NE
monocytic xxx NE
cell xxx NE
lines xxx NE
. . NE

Previous Xxxx NE
work xxx NE
has xxx NE
shown xxx NE
that xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
and xxx NE
C/EBP X/XXX Protein_family_or_group_B
transcriptional xxx Protein_family_or_group_M
activators xxx Protein_family_or_group_E
are xxx NE
necessary xxx NE
for xxx NE
HIV-1 XXX-d Other_B
LTR XXX Other_M
activity xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
role xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
play xxx NE
in xx NE
induction xxx NE
and xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d Virus
. . NE

Ectopic Xxxx NE
expression xxx NE
of xx NE
the xxx NE
dominant xxx NE
negative xxx NE
C/EBP X/XXX NE
protein xxx NE
LIP XXX NE
inhibited xxx NE
HIV-1 XXX-d NE
mRNA xXXX NE
and xxx NE
virus xxx NE
production xxx NE
in xx NE
activated xxx NE
U1 Xd NE
cells xxx NE
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX NE
proteins xxx NE
are xxx NE
required xxx NE
for xxx NE
provirus xxx NE
induction xxx NE
. . NE

U1 Xd Cell_cultured_B
lines xxx Cell_cultured_E
overexpressing xxx NE
C/EBP X/XXX Protein_family_or_group_B
activator xxx Protein_family_or_group_E
NF-IL-6 XX-XX-d Protein_molecule
produced xxx NE
more xxx NE
viral xxx RNA_family_or_group_B
mRNA xXXX RNA_family_or_group_E
and xxx NE
virus xxx Virus_B
particles xxx Virus_E
following xxx NE
cellular xxx Other_B
activation xxx Other_E
than xxx NE
control xxx Cell_cultured_B
lines xxx Cell_cultured_E
, , NE
demonstrating xxx NE
that xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
are xxx NE
limiting xxx NE
for xxx NE
virus xxx Other_B
transcription xxx Other_E
. . NE

HIV-1 XXX-d Virus
harboring xxx NE
mutations xxx NE
within xxx NE
two xxx NE
C/EBP X/XXX DNA_domain_or_region_B
sites xxx DNA_domain_or_region_E
were xxx NE
crippled xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
replicate xxx NE
in xx NE
U937 Xddd Cell_cultured_B
promonocytic xxx Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
indicating xxx NE
that xxx NE
these xxx NE
sites xxx NE
are xxx NE
required xxx NE
for xxx NE
replication xxx NE
. . NE

These Xxxx NE
data xxx NE
identify xxx NE
C/EBP X/XXX Protein_family_or_group_B
proteins xxx Protein_family_or_group_E
as xx NE
regulators xxx NE
of xx NE
HIV-1 XXX-d Other_B
expression xxx Other_E
in xx NE
monocytes/macrophages xxx/xxx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibits xxx NE
nuclear xxx Other_B
factor-kappa xxx-xxx Other_M
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
in xx NE
CD3 XXd NE
-stimulated -xxx NE
human xxx NE
peripheral xxx NE
T X NE
lymphocytes xxx NE
. . NE

IL-10 XX-dd Protein_molecule
markedly xxx NE
reduces xxx NE
nuclear xxx NE
factor xxx NE
(NF)-kappa (XX)-xxx Other_B
B/Rel X/Xxx Other_M
nuclear xxx Other_M
activity xxx Other_E
induced xxx NE
in xx NE
PBMC XXXX NE
by xx NE
stimulation xxx NE
with xxx NE
the xxx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
OKT3 XXXd NE
. . NE

The Xxx NE
inhibition xxx NE
is xx NE
exerted xxx NE
specifically xxx NE
on xx NE
the xxx NE
NF-kappa XX-xxx Other_B
B/Rel X/Xxx Other_M
activation xxx Other_E
induced xxx NE
by xx NE
mAb xXx NE
OKT3 XXXd NE
, , NE
and xxx NE
not xxx NE
that xxx NE
produced xxx NE
by xx NE
PMA XXX NE
. . NE

As Xx NE
judged xxx NE
by xx NE
supershifting xxx NE
the xxx NE
DNA-protein XXX-xxx NE
complexes xxx NE
with xxx NE
Abs Xxx NE
recognizing xxx NE
specific xxx NE
components xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B/Rel X/Xxx NE
protein xxx NE
family xxx NE
, , NE
the xxx NE
p50/p65 xdd/xdd NE
( ( NE
Rel Xxx NE
A X NE
) ) NE
heterodimeric xxx NE
form xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
primarily xxx NE
affected xxx NE
. . NE

The Xxx NE
maximal xxx NE
effect xxx NE
is xx NE
observed xxx NE
at xx NE
the xxx NE
IL-10 XX-dd Other_B
concentration xxx Other_E
of xx NE
20 dd NE
U/ml X/xx NE
. . NE

IL-10 XX-dd Protein_molecule
inhibitory xxx NE
activity xxx NE
is xx NE
exerted xxx NE
on xx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
and xxx NE
is xx NE
mediated xxx NE
by xx NE
monocytes xxx Cell_natural
. . NE

Indeed Xxxx NE
, , NE
monocytes xxx Cell_natural
pretreated xxx NE
with xxx NE
IL-10 XX-dd Protein_molecule
are xxx NE
able xxx NE
so xx NE
inhibit xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
purified xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
stimulated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
. . NE

Soluble Xxxx NE
factors xxx NE
do xx NE
not xxx NE
appear xxx NE
to xx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
mechanism xxx NE
of xx NE
inhibition xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
the xxx NE
up-regulation xx-xxx NE
of xx NE
CD80 XXdd Protein_molecule_B
Ag Xx Protein_molecule_E
, , NE
found xxx NE
on xx NE
monocytes xxx Cell_natural
obtained xxx NE
from xxx NE
PBMC XXXX Cell_natural
incubated xxx NE
with xxx NE
OKT3 XXXd Protein_molecule
, , NE
is xx NE
not xxx NE
detected xxx NE
after xxx NE
addition xxx NE
of xx NE
IL-10 XX-dd Protein_molecule
, , NE
and xxx NE
the xxx NE
anti-CD28 xxx-XXdd Protein_family_or_group_B
mAb xXx Protein_family_or_group_E
CLB-CD28/1 XXX-XXdd/d Protein_molecule
restores xxx NE
the xxx NE
NF-kappa XX-xxx Element_B
B/Rel X/Xxx Element_M
nuclear xxx Element_M
activity xxx Element_E
in xx NE
IL-10 XX-dd NE
-inhibited -xxx NE
lymphocytes xxx NE
. . NE

Therefore Xxxx NE
, , NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
inhibition xxx NE
might xxx NE
be xx NE
ascribed xxx NE
to xx NE
a x NE
lack xxx NE
of xx NE
cooperation xxx NE
between xxx NE
accessory xxx NE
cells xxx NE
and xxx NE
T X Cell_natural_B
lymphocytes xxx Cell_natural_E
, , NE
resulting xxx NE
from xxx NE
down-regulation xxx-xxx NE
of xx NE
a x NE
costimulatory xxx NE
molecule xxx NE
, , NE
such xxx NE
as xx NE
CD80 XXdd Protein_molecule
, , NE
produced xxx NE
by xx NE
IL-10 XX-dd Protein_molecule
on xx NE
activated xxx NE
monocytes xxx Cell_natural
. . NE

Our Xxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
IL-10 XX-dd Protein_molecule
can xxx NE
inhibit xxx NE
the xxx NE
induction xxx NE
of xx NE
NF-kappa XX-xxx Protein_complex_B
B/Rel X/Xxx Protein_complex_E
nuclear xxx NE
activity xxx NE
in xx NE
CD3 XXd NE
-stimulated -xxx NE
T X NE
lymphocytes xxx NE
. . NE

Since Xxxx NE
inappropriate xxx NE
activation xxx NE
of xx NE
kappa xxx DNA_family_or_group_B
B-driven X-xxx DNA_family_or_group_M
genes xxx DNA_family_or_group_E
has xxx NE
a x NE
physiopathologic xxx NE
role xxx NE
in xx NE
a x NE
number xxx NE
of xx NE
diseases xxx NE
, , NE
such xxx NE
as xx NE
HIV XXX Other_B
infection xxx Other_E
, , NE
our xxx NE
findings xxx NE
support xxx NE
the xxx NE
possibility xxx NE
of xx NE
using xxx NE
this xxx NE
cytokine xxx NE
to xx NE
suppress xxx NE
an xx NE
undesirable xxx NE
activation xxx NE
of xx NE
these xxx NE
transcription xxx Protein_family_or_group_B
factors xxx Protein_family_or_group_E
. . NE

Multiple Xxxx NE
prolactin xxx NE
-responsive -xxx NE
elements xxx NE
mediate xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
expression xxx NE
of xx NE
the xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
gene xxx NE
. . NE

The Xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
( ( NE
IRF-1 XXX-d NE
) ) NE
gene xxx NE
is xx NE
both xxx NE
an xx NE
immediate-early xxx-xxx NE
G1 Xd NE
phase xxx NE
gene xxx NE
and xxx NE
an xx NE
S X NE
phase xxx NE
gene xxx NE
inducible xxx NE
by xx NE
PRL XXX NE
in xx NE
rat xxx NE
Nb2 Xxd NE
T X NE
lymphocytes xxx NE
. . NE

To Xx NE
understand xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
PRL XXX Protein_molecule
regulates xxx NE
the xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
IRF-1 XXX-d Protein_molecule
, , NE
we xx NE
cloned xxx NE
the xxx NE
rat xxx DNA_domain_or_region_B
IRF-1 XXX-d DNA_domain_or_region_M
gene xxx DNA_domain_or_region_E
and xxx NE
functionally xxx NE
characterized xxx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
. . NE

Upon Xxxx NE
transfection xxx NE
into xxx NE
Nb2 Xxd Cell_cultured_B
T X Cell_cultured_M
cells xxx Cell_cultured_E
, , NE
1.7 d.d NE
kilobases xxx NE
(kb) (xx) NE
of xx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
DNA XXX NE
linked xxx NE
to xx NE
a x NE
chloramphenicol xxx NE
acetyl xxx NE
transferase xxx NE
( ( NE
CAT XXX NE
) ) NE
reporter xxx NE
gene xxx NE
mediated xxx NE
a x NE
30-fold dd-xxx NE
induction xxx NE
of xx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
in xx NE
response xxx NE
to xx NE
24 dd NE
h x NE
of xx NE
PRL XXX NE
stimulation xxx NE
. . NE

Deletion Xxxx NE
mutants xxx NE
containing xxx NE
1.3 d.d NE
, , NE
0.6 d.d NE
, , NE
and xxx NE
0.2 d.d NE
kb xx NE
5'-flanking d'-xxx NE
DNA XXX NE
were xxx NE
incrementally xxx NE
less xxx NE
transcriptionally xxx NE
active xxx NE
, , NE
although xxx NE
0.2 d.d NE
kb xx NE
still xxx NE
mediated xxx NE
a x NE
12-fold dd-xxx NE
induction xxx NE
by xx NE
PRL XXX NE
. . NE

The Xxx NE
sequence xxx NE
between xxx NE
-1.7 -d.d NE
and xxx NE
-0.2 -d.d NE
kb xx NE
linked xxx NE
to xx NE
a x NE
heterologous xxx NE
thymidine xxx NE
kinase xxx NE
promoter xxx NE
failed xxx NE
to xx NE
respond xxx NE
to xx NE
PRL XXX Protein_molecule
stimulation xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
activity xxx NE
of xx NE
upstream xxx DNA_family_or_group_B
PRL XXX DNA_family_or_group_M
response xxx DNA_family_or_group_M
elements xxx DNA_family_or_group_E
may xxx NE
require xxx NE
an xx NE
interaction xxx NE
with xxx NE
promoter-proximal xxx-xxx NE
elements xxx NE
. . NE

By Xx NE
assaying xxx NE
CAT XXX Other_B
enzyme xxx Other_M
activity xxx Other_E
across xxx NE
a x NE
24-h dd-x NE
PRL XXX NE
induction xxx NE
time xxx NE
course xxx NE
, , NE
we xx NE
were xxx NE
able xxx NE
to xx NE
assign xxx NE
G1 Xd NE
vs xx NE
. . NE
S X NE
phase xxx NE
PRL XXX NE
responses xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
gene xxx NE
to xx NE
different xxx NE
regions xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
5'-flanking d'-xxx NE
and xxx NE
promoter xxx NE
DNA XXX NE
. . NE

The Xxx NE
0.2-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
induced xxx NE
by xx NE
PRL XXX NE
stimulation xxx NE
during xxx NE
the xxx NE
G1 Xd NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
1.7-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
inducible xxx NE
by xx NE
PRL XXX Protein_molecule
during xxx NE
both xxx NE
G1 Xd NE
and xxx NE
S X NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

Hence Xxxx NE
, , NE
the xxx NE
PRL XXX Protein_molecule
-induced -xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d DNA_domain_or_region_B
gene xxx DNA_domain_or_region_E
appears xxx NE
to xx NE
be xx NE
controlled xxx NE
by xx NE
separate xxx NE
PRL XXX NE
-responsive -xxx NE
elements xxx NE
: : NE
elements xxx NE
in xx NE
the xxx NE
first xxx NE
0.2 d.d NE
kb xx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
region xxx NE
act xxx NE
during xxx NE
early xxx NE
activation xxx NE
, , NE
and xxx NE
elements xxx NE
between xxx NE
0.2 d.d NE
and xxx NE
1.7 d.d NE
kb xx NE
act xxx NE
in xx NE
concert xxx NE
with xxx NE
the xxx NE
proximal xxx NE
0.2-kb d.d-xx NE
region xxx NE
during xxx NE
S X NE
phase xxx NE
progression xxx NE
. . NE

Triggering Xxxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
CR1 XXd Protein_molecule
( ( NE
CD35 XXdd Protein_molecule
) ) NE
and xxx NE
CR3 XXd Protein_molecule
( ( NE
CD11b/CD18 XXddx/XXdd Protein_molecule
) ) NE
induces xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50/p65 xdd/xdd Protein_molecule
) ) NE
in xx NE
human xxx Cell_natural_B
monocytes xxx Cell_natural_E
and xxx NE
enhances xxx NE
viral xxx Other_B
replication xxx Other_E
in xx NE
HIV XXX NE
-infected -xxx NE
monocytic xxx NE
cells xxx NE
. . NE

Monocyte Xxxx NE
/ / NE
macrophages xxx NE
may xxx NE
harbor xxx NE
HIV XXX NE
in xx NE
a x NE
nonproductive xxx NE
fashion xxx NE
for xxx NE
prolonged xxx NE
periods xxx NE
of xx NE
time xxx NE
. . NE

Viral Xxxx Other_B
gene xxx Other_M
expression xxx Other_E
may xxx NE
be xx NE
reactivated xxx NE
by xx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
LPS XXX Lipid
or xx NE
cytokines xxx Protein_family_or_group
such xxx NE
as xx NE
TNF-alpha XXX-xxx Protein_molecule
in xx NE
vitro xxx NE
. . NE

The Xxx NE
effect xxx NE
of xx NE
LPS XXX Lipid
and xxx NE
TNF-alpha XXX-xxx Protein_molecule
is xx NE
mediated xxx NE
by xx NE
their xxx NE
ability xxx NE
to xx NE
induce xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
the xxx NE
DNA-binding XXX-xxx Protein_family_or_group_B
heterodimer xxx Protein_family_or_group_E
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
( ( NE
p50/p65 xdd/xdd Protein_molecule
) ) NE
, , NE
which xxx NE
binds xxx NE
to xx NE
a x NE
specific xxx NE
sequence xxx NE
in xx NE
the xxx NE
HIV-long XXX-xxx DNA_domain_or_region_B
terminal xxx DNA_domain_or_region_M
repeat xxx DNA_domain_or_region_E
. . NE

The Xxx NE
present xxx NE
study xxx NE
demonstrates xxx NE
that xxx NE
triggering xxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
CR1 XXd Protein_molecule
( ( NE
CD35 XXdd Protein_molecule
) ) NE
and xxx NE
CR3 XXd Protein_molecule
( ( NE
CD11b/CD18 XXddx/XXdd Protein_molecule
) ) NE
enhances xxx NE
viral xxx Other_B
replication xxx Other_E
in xx NE
HIV XXX NE
-infected -xxx NE
human xxx NE
monocytic xxx NE
cells xxx NE
. . NE

Monocytic Xxxx Cell_cultured_B
cell xxx Cell_cultured_M
lines xxx Cell_cultured_E
and xxx NE
normal xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx NE
were xxx NE
infected xxx NE
with xxx NE
HIV-1 XXX-d Virus
in xx NE
vitro xxx NE
and xxx NE
cultured xxx NE
in xx NE
the xxx NE
presence xxx NE
or xx NE
absence xxx NE
of xx NE
F(ab')2 X(xx')d Protein_molecule_B
fragments xxx Protein_molecule_E
of xx NE
monoclonal xxx NE
anti- xxx- NE
CR1 XXd NE
or xx NE
anti- xxx- NE
CR3 XXd NE
Abs Xxx NE
or xx NE
with xxx NE
C3 Xd NE
fragments xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
induces xxx NE
a x NE
two- xxx- NE
to xx NE
fourfold xxx NE
increase xxx NE
in xx NE
the xxx NE
amount xxx NE
of xx NE
cell-associated xxx-xxx NE
and xxx NE
released xxx NE
p24 xdd Protein_molecule_B
Ag Xx Protein_molecule_E
in xx NE
cell xxx Cell_cultured_B
cultures xxx Cell_cultured_E
that xxx NE
was xxx NE
equivalent xxx NE
to xx NE
that xxx NE
observed xxx NE
in xx NE
control xxx Cell_cultured_B
cultures xxx Cell_cultured_E
triggered xxx NE
with xxx NE
LPS XXX Lipid
. . NE

We Xx NE
further xxx NE
observed xxx NE
that xxx NE
stimulation xxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
induces xxx NE
the xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
in xx NE
infected xxx Cell_natural_B
cells xxx Cell_natural_E
. . NE

Translocation Xxxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
was xxx NE
also xxx NE
observed xxx NE
following xxx NE
stimulation xxx NE
of xx NE
CR1 XXd Protein_molecule
or xx NE
CR3 XXd Protein_molecule
of xx NE
uninfected xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx NE
from xxx NE
HIV-seronegative XXX-xxx NE
donors xxx NE
. . NE

The Xxx NE
amount xxx NE
of xx NE
protein xxx NE
translocated xxx NE
was xxx NE
similar xxx NE
to xx NE
that xxx NE
observed xxx NE
when xxx NE
cells xxx NE
were xxx NE
stimulated xxx NE
with xxx NE
rhTNF-alpha xxXXX-xxx Protein_molecule
. . NE

TNF-alpha XXX-xxx Protein_molecule
did xxx NE
not xxx NE
mediate xxx NE
the xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx Protein_molecule_B
B X Protein_molecule_E
p50/p65 xdd/xdd Protein_molecule
induced xxx NE
by xx NE
triggering xxx NE
of xx NE
complement xxx Protein_family_or_group_B
receptors xxx Protein_family_or_group_E
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
observations xxx NE
suggest xxx NE
that xxx NE
HIV XXX Other_B
gene xxx Other_M
expression xxx Other_E
may xxx NE
be xx NE
activated xxx NE
in xx NE
infected xxx Cell_natural_B
monocytes xxx Cell_natural_E
through xxx NE
interaction xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
complement-opsonized xxx-xxx Protein_family_or_group_B
particles xxx Protein_family_or_group_E
and xxx NE
that xxx NE
enhanced xxx NE
viral xxx Other_B
replication xxx Other_E
is xx NE
associated xxx NE
with xxx NE
C3 Xd Protein_family_or_group_B
receptor xxx Protein_family_or_group_E
-mediated -xxx NE
nuclear xxx Other_B
translocation xxx Other_E
of xx NE
the xxx NE
NF-kappa XX-xxx Protein_complex_B
B X Protein_complex_M
complex xxx Protein_complex_E
. . NE

Genes Xxxx NE
encoding xxx NE
general xxx Protein_family_or_group_B
initiation xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
for xxx NE
RNA XXX Protein_molecule_B
polymerase xxx Protein_molecule_M
II XX Protein_molecule_E
transcription xxx NE
are xxx NE
dispersed xxx NE
in xx NE
the xxx NE
human xxx DNA_family_or_group_B
genome xxx DNA_family_or_group_E
. . NE

General Xxxx Protein_family_or_group_B
transcription xxx Protein_family_or_group_M
factors xxx Protein_family_or_group_E
are xxx NE
required xxx NE
for xxx NE
accurate xxx NE
initiation xxx NE
of xx NE
transcription xxx NE
by xx NE
RNA XXX NE
polymerase xxx NE
II XX NE
. . NE

Human Xxxx DNA_family_or_group_B
cDNAs xXXXx DNA_family_or_group_E
encoding xxx NE
subunits xxx NE
of xx NE
these xxx NE
factors xxx NE
have xxx NE
been xxx NE
cloned xxx NE
and xxx NE
sequenced xxx NE
. . NE

Using Xxxx NE
fluorescence xxx Other_B
in xx Other_M
situ xxx Other_M
hybridization xxx Other_E
( ( NE
FISH XXXX Other
) ) NE
, , NE
we xx NE
show xxx NE
here xxx NE
that xxx NE
the xxx NE
genes xxx DNA_family_or_group
encoding xxx NE
the xxx NE
TATA-box XXXX-xxx Protein_family_or_group_B
binding xxx Protein_family_or_group_M
protein xxx Protein_family_or_group_E
( ( NE
TBP XXX Protein_family_or_group
) ) NE
, , NE
TFIIB XXXXX Protein_molecule
, , NE
TFIIE XXXXX Protein_molecule_B
alpha xxx Protein_molecule_E
, , NE
TFIIE XXXXX Protein_molecule_B
beta xxx Protein_molecule_E
, , NE
RAP30 XXXdd Protein_molecule
, , NE
RAP74 XXXdd Protein_molecule
and xxx NE
the xxx NE
62 dd Protein_molecule_B
kDa xXx Protein_molecule_M
subunit xxx Protein_molecule_E
, , NE
of xx NE
TFIIH XXXXX Protein_molecule
are xxx NE
located xxx NE
at xx NE
the xxx NE
human xxx NE
chromosomal xxx NE
bands xxx NE
6q26-27 dxdd-dd NE
, , NE
1p21-22 dxdd-dd NE
, , NE
3q21-24 dxdd-dd NE
, , NE
8p12 dxdd NE
, , NE
13q14 ddxdd NE
, , NE
19p13.3 ddxdd.d NE
and xxx NE
11p14-15.1 ddxdd-dd.d NE
, , NE
respectively xxx NE
. . NE

This Xxxx NE
dispersed xxx NE
localization xxx NE
of xx NE
a x NE
group xxx NE
of xx NE
functionally xxx NE
related xxx NE
gene xxx NE
provides xxx NE
insights xxx NE
into xxx NE
the xxx NE
molecular xxx Other_B
mechanism xxx Other_E
of xx NE
human xxx Other_B
genome xxx Other_M
evolution xxx Other_E
and xxx NE
their xxx NE
possible xxx NE
involvement xxx NE
in xx NE
human xxx NE
diseases xxx NE
. . NE

Cell Xxxx Cell_natural_B
type xxx Cell_natural_M
specificity xxx Cell_natural_E
and xxx NE
activation xxx NE
requirements xxx NE
for xxx NE
NFAT-1 XXXX-d Protein_molecule
( ( NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
of xx NE
activated xxx Cell_natural_B
T-cells X-xxx Cell_natural_E
) ) NE
transcriptional xxx NE
activity xxx NE
determined xxx NE
by xx NE
a x NE
new xxx NE
method xxx NE
using xxx NE
transgenic xxx Multicellular_organism_genetically_modified_B
mice xxx Multicellular_organism_genetically_modified_E
to xx NE
assay xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
an xx NE
individual xxx NE
nuclear xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
. . NE

Nuclear Xxxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
of xx NE
activated xxx Cell_natural_B
T-cells X-xxx Cell_natural_E
( ( NE
NFAT-1 XXXX-d Protein_molecule
) ) NE
is xx NE
a x NE
transcription xxx Protein_family_or_group_B
factor xxx Protein_family_or_group_E
which xxx NE
is xx NE
considered xxx NE
to xx NE
be xx NE
an xx NE
important xxx NE
regulator xxx NE
in xx NE
early xxx NE
T-cell X-xxx Other_B
activation xxx Other_E
. . NE

We Xx NE
have xxx NE
developed xxx NE
a x NE
system xxx NE
to xx NE
monitor xxx NE
the xxx NE
transcriptional xxx Other_B
activity xxx Other_E
of xx NE
NFAT-1 XXXX-d Protein_molecule
at xx NE
the xxx NE
single xxx Cell_natural_B
cell xxx Cell_natural_M
level xxx Cell_natural_E
in xx NE
whole xxx Multicellular_organism_natural_B
animals xxx Multicellular_organism_natural_E
. . NE

The Xxx NE
system xxx NE
is xx NE
based xxx NE
on xx NE
the xxx NE
use xxx NE
of xx NE
an xx NE
oligomerized xxx Polynucleotide_B
NFAT-1 XXXX-d Polynucleotide_M
binding xxx Polynucleotide_M
motif xxx Polynucleotide_E
that xxx NE
directs xxx NE
transcription xxx NE
of xx NE
SV40 XXdd NE
T-antigen X-xxx NE
in xx NE
transgenic xxx NE
mice xxx NE
. . NE

This Xxxx NE
report xxx NE
represents xxx NE
the xxx NE
first xxx NE
demonstration xxx NE
that xxx NE
a x NE
multimerized xxx Polynucleotide_B
short xxx Polynucleotide_M
binding xxx Polynucleotide_M
motif xxx Polynucleotide_E
can xxx NE
function xxx NE
appropriately xxx NE
in xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
mice xxx Multicellular_organism_genetically_modified_E
. . NE

NFAT-1 XXXX-d Protein_molecule
activity xxx NE
had xxx NE
previously xxx NE
been xxx NE
thought xxx NE
to xx NE
be xx NE
confined xxx NE
to xx NE
activated xxx Cell_natural_B
T-lymphocytes X-xxx Cell_natural_E
upon xxx NE
release xxx NE
of xx NE
intracellular xxx NE
calcium xxx NE
. . NE

By Xx NE
targeting xxx NE
NFAT-1 XXXX-d Protein_molecule
-dependent -xxx NE
gene xxx NE
expression xxx NE
in xx NE
transgenic xxx Multicellular_organism_genetically_modified_B
mice xxx Multicellular_organism_genetically_modified_E
we xx NE
discovered xxx NE
new xxx NE
sites xxx NE
of xx NE
NFAT-1 XXXX-d Other_B
activity xxx Other_E
. . NE

Besides Xxxx NE
in xx NE
T-lymphocytes X-xxx Cell_natural
NFAT-1 XXXX-d Other_B
activity xxx Other_E
could xxx NE
also xxx NE
be xx NE
induced xxx NE
in xx NE
T-lymphocyte X-xxx NE
-depleted -xxx NE
spleen xxx NE
cells xxx NE
and xxx NE
purified xxx NE
B-lymphocytes X-xxx NE
and xxx NE
requires xxx NE
agents xxx NE
that xxx NE
both xxx NE
release xxx NE
intracellular xxx NE
calcium xxx NE
and xxx NE
activate xxx NE
protein xxx NE
kinase xxx NE
C X NE
. . NE

A X NE
difference xxx NE
in xx NE
the xxx NE
time xxx NE
course xxx NE
of xx NE
appearance xxx NE
of xx NE
NFAT-1 XXXX-d Other_B
activity xxx Other_E
between xxx NE
T-lymphocytes X-xxx NE
and xxx NE
non-T-lymphocytes xxx-X-xxx NE
was xxx NE
revealed xxx NE
. . NE

Constitutive Xxxx Other_B
expression xxx Other_E
was xxx NE
observed xxx NE
in xx NE
a x NE
small xxx NE
population xxx NE
of xx NE
cells xxx NE
in xx NE
the xxx NE
dermis xxx Tissue_natural
and xxx NE
some xxx NE
mice xxx NE
have xxx NE
developed xxx NE
skin xxx Tissue_natural_B
lesions xxx Tissue_natural_E
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
tissue xxx NE
pattern xxx NE
of xx NE
expression xxx NE
of xx NE
the xxx NE
NFAT-1 XXXX-d Protein_molecule
activity xxx NE
resembles xxx NE
the xxx NE
expression xxx NE
pattern xxx NE
described xxx NE
for xxx NE
HIV-LTR/tat XXX-XXX/xxx Multicellular_organism_natural_B
transgenic xxx Multicellular_organism_natural_M
mice xxx Multicellular_organism_natural_E
(Vogel (Xxxx NE
, , NE
J. X. NE
, , NE
Hinrichs Xxxx NE
, , NE
S X NE
. . NE
H. X. NE
, , NE
Reynolds Xxxx NE
, , NE
R X NE
. . NE
K. X. NE
, , NE
Luciw Xxxx NE
, , NE
P X NE
. . NE
A. X. NE
, , NE
and xxx NE
Jay Xxx NE
, , NE
G X NE
. . NE
(1988) (dddd) NE
Nature Xxxx NE
335 ddd NE
, , NE
606-611) ddd-ddd) NE
. . NE

This Xxxx NE
similarity xxx NE
in xx NE
expression xxx NE
and xxx NE
the xxx NE
fact xxx NE
that xxx NE
NFAT-1 XXXX-d Protein_molecule
has xxx NE
been xxx NE
shown xxx NE
to xx NE
bind xxx NE
functional xxx NE
sequences xxx NE
in xx NE
HIV-LTR XXX-XXX NE
suggest xxx NE
a x NE
role xxx NE
for xxx NE
NFAT-1 XXXX-d Protein_molecule
in xx NE
dermal xxx Other_B
activation xxx Other_E
of xx NE
the xxx NE
HIV-LTR XXX-XXX DNA_domain_or_region
. . NE

Human Xxxx Other_B
MHC XXX Other_M
class xxx Other_M
II XX Other_M
gene xxx Other_M
transcription xxx Other_E
directed xxx NE
by xx NE
the xxx NE
carboxyl xxx NE
terminus xxx NE
of xx NE
CIITA XXXXX NE
, , NE
one xxx NE
of xx NE
the xxx NE
defective xxx NE
genes xxx NE
in xx NE
type xxx NE
II XX NE
MHC XXX NE
combined xxx NE
immune xxx NE
deficiency xxx NE
. . NE

Type Xxxx Other_B
II XX Other_M
major xxx Other_M
histocompatibility xxx Other_M
complex xxx Other_M
combined xxx Other_M
immune xxx Other_M
deficiency xxx Other_E
( ( NE
type xxx NE
II XX NE
MHC XXX NE
CID XXX NE
or xx NE
bare xxx NE
lymphocyte xxx NE
syndrome xxx NE
) ) NE
is xx NE
a x NE
congenital xxx NE
immunodeficiency xxx NE
disease xxx NE
characterized xxx NE
by xx NE
absent xxx NE
MHC XXX NE
class xxx NE
II XX NE
expression xxx NE
. . NE

Four Xxxx NE
distinct xxx NE
complementation xxx NE
groups xxx NE
have xxx NE
been xxx NE
identified xxx NE
. . NE

Recently Xxxx NE
, , NE
the xxx NE
defective xxx DNA_family_or_group_B
gene xxx DNA_family_or_group_E
in xx NE
group xxx Other_B
II XX Other_M
type xxx Other_M
II XX Other_M
MHC XXX Other_M
CID XXX Other_E
has xxx NE
been xxx NE
isolated xxx NE
and xxx NE
termed xxx NE
CIITA XXXXX NE
. . NE

Here Xxxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
CIITA XXXXX DNA_domain_or_region
is xx NE
an xx NE
MHC XXX DNA_family_or_group_B
class xxx DNA_family_or_group_M
II XX DNA_family_or_group_M
gene-specific xxx-xxx DNA_family_or_group_M
transcription xxx DNA_family_or_group_M
activator xxx DNA_family_or_group_E
. . NE

The Xxx NE
transcription xxx Other_B
activation xxx Other_M
function xxx Other_E
is xx NE
provided xxx NE
by xx NE
the xxx NE
N-terminal X-xxx Protein_domain_or_region_B
acidic xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
( ( NE
amino xxx Protein_domain_or_region_B
acids xxx Protein_domain_or_region_M
26-137 dd-ddd Protein_domain_or_region_E
) ) NE
, , NE
which xxx NE
is xx NE
experimentally xxx NE
exchangeable xxx NE
with xxx NE
a x NE
heterologous xxx Protein_domain_or_region_B
viral xxx Protein_domain_or_region_M
transcription-activating xxx-xxx Protein_domain_or_region_M
domain xxx Protein_domain_or_region_E
. . NE

The Xxx NE
specificity xxx NE
of xx NE
CIITA XXXXX Protein_molecule
for xxx NE
three xxx NE
major xxx NE
MHC XXX DNA_domain_or_region_B
class xxx DNA_domain_or_region_M
II XX DNA_domain_or_region_M
genes xxx DNA_domain_or_region_E
, , NE
DR XX NE
, , NE
DQ XX NE
and xxx NE
DP XX NE
, , NE
is xx NE
mediated xxx NE
by xx NE
its xxx NE
remaining xxx NE
C-terminal X-xxx NE
residues xxx NE
( ( NE
amino xxx NE
acids xxx NE
317-1130 ddd-dddd NE
) ) NE
. . NE

The Xxx NE
transactivation xxx NE
of xx NE
multiple xxx DNA_domain_or_region_B
cis xxx DNA_domain_or_region_M
elements xxx DNA_domain_or_region_E
, , NE
especially xxx NE
S X DNA_domain_or_region
and xxx NE
X2 Xd DNA_domain_or_region
, , NE
of xx NE
the xxx NE
DR XX DNA_domain_or_region_B
alpha xxx DNA_domain_or_region_M
proximal xxx DNA_domain_or_region_M
promoter xxx DNA_domain_or_region_E
in xx NE
group xxx NE
II XX NE
CID XXX NE
cells xxx NE
is xx NE
CIITA XXXXX NE
dependent xxx NE
. . NE

Since Xxxx NE
CIITA XXXXX Other_B
overexpression xxx Other_E
in xx NE
normal xxx NE
cells xxx NE
did xxx NE
not xxx NE
increase xxx NE
class xxx NE
II XX NE
expression xxx NE
, , NE
we xx NE
propose xxx NE
that xxx NE
initiation xxx NE
of xx NE
CIITA XXXXX NE
expression xxx NE
serves xxx NE
as xx NE
the xxx NE
on-off xx-xxx NE
switch xxx NE
, , NE
while xxx NE
availability xxx NE
of xx NE
downstream xxx NE
interactor xxx NE
(s) (x) NE
limits xxx NE
transcription xxx NE
. . NE

